var title_f1_7_1136="Drug packet transverse CT image";
var content_f1_7_1136=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F50541&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F50541&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Drug packets on abdominal CT: Transverse image",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 282px; height: 273px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    This transverse image from an abdominal CT performed with water soluble contrast shows the different appearances of drug packets as they align in or opposite to the plane of the image.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Robert Hoffman, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f1_7_1136=[""].join("\n");
var outline_f1_7_1136=null;
var title_f1_7_1137="Jet nebulizer";
var content_f1_7_1137=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F75397&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F75397&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Jet nebulizer",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 370px; height: 372px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    A jet flow of driving gas creates an area of low pressure above the medication reservoir, generating an aerosol. The baffle helps ensure the formation of respirable particles and prevents inhalation of oversized droplets of medication. Most nebulizers require a flow rate of 8 liters per minute for optimum performance.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f1_7_1137=[""].join("\n");
var outline_f1_7_1137=null;
var title_f1_7_1138="Normal human myelocyte";
var content_f1_7_1138=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=HEME%2F54089&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=HEME%2F54089&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Normal human myelocyte",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 433px; height: 288px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Peripheral blood smear shows a normal human myelocyte. As the myelocyte divides and matures, the nucleus becomes smaller and irregularly round, nuclear chromatin becomes coarse and clumped, and nucleoli are sparse to absent. The nuclear to cytoplasmic ratio is reduced compared to promyelocytes. Specific granules are difficult to see on light microscopy.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Robert L Baehner, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f1_7_1138=[""].join("\n");
var outline_f1_7_1138=null;
var title_f1_7_1139="Spina bifida B";
var content_f1_7_1139=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F58063&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F58063&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Spina bifida and hydrocephaly (Arnold-Chiari) at 33 postmenstrual weeks and one day",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 361px; height: 310px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Transverse view showing the U-shaped vertebral body with the neural tissue protruding through.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Ana Monteagudo, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f1_7_1139=[""].join("\n");
var outline_f1_7_1139=null;
var title_f1_7_1140="Colic (excessive crying) in infants";
var content_f1_7_1140=[" <h1 id=\"patTopicTitle\">",
"  Patient information: Colic (excessive crying) in infants (Beyond the Basics)",
" </h1>",
" <div id=\"patTopicContributors\">",
"  <div class=\"rcTop\">",
"   <div>",
"   </div>",
"  </div>",
"  <div class=\"rcContent\">",
"   <table>",
"    <tr>",
"     <td>",
"      <a class=\"contributor contributor_credentials patTopicContributorsType\" href=\"UTD.htm?1/7/1140/contributors\">",
"       Authors",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"UTD.htm?1/7/1140/contributors\" id=\"au4817\">",
"       Teri Lee Turner, MD, MPH, MEd",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"UTD.htm?1/7/1140/contributors\" id=\"au5600\">",
"       Shea Palamountain, MD",
"      </a>",
"     </td>",
"     <td>",
"      <a class=\"contributor contributor_credentials patTopicContributorsType\" href=\"UTD.htm?1/7/1140/contributors\">",
"       Section Editor",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"UTD.htm?1/7/1140/contributors\" id=\"se219\">",
"       Marilyn Augustyn, MD",
"      </a>",
"     </td>",
"     <td>",
"      <a class=\"contributor contributor_credentials patTopicContributorsType\" href=\"UTD.htm?1/7/1140/contributors\">",
"       Deputy Editor",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"UTD.htm?1/7/1140/contributors\" id=\"de5754\">",
"       Mary M Torchia, MD",
"      </a>",
"     </td>",
"    </tr>",
"   </table>",
"  </div>",
"  <div class=\"rcBottom\">",
"   <div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"patTopicTool\" id=\"patTopicToolTop\">",
"  <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"   Find",
"  </a>",
"  <a class=\"toolbutton printicon\" href=\"UTD.htm?1/7/1140?view=print\" title=\"Print This Topic\">",
"   Print",
"  </a>",
"  <script src=\"file://w.sharethis.com/button/sharethis.js#publisher=357881b8-c7e3-4c31-b7d2-242aeb1528e1&amp;type=website&amp;post_services=care2%2Cfacebook%2Ctwitter%2Cmyspace%2Cdigg%2Cdelicious%2Cfaves%2Creddit%2Cxanga%2Cstumbleupon%2Cblinklist%2Csimpy%2Cyigg%2Ctechnorati%2Cmeneame%2Corkut%2Cmixx%2Cfunp%2Cfresqui%2Cmister_wong%2Cfriendster%2Cfriendfeed%2Clinkedin%2Coknotizie%2Cgoogle_bmarks%2Cyahoo_bmarks%2Cfark%2Cnewsvine%2Clivejournal%2Ctypepad%2Cbus_exchange%2Cpropeller%2Cwordpress%2Cblogger%2Cblogmarks%2Cwindows_live%2Cfurl%2Cybuzz%2Cdiigo\" type=\"text/javascript\">",
"  </script>",
" </div>",
" <div id=\"patTopicMiddle\">",
"  <div id=\"topicContent\">",
"   <div id=\"topicText\">",
"    <p class=\"headingAnchor\" id=\"H1\">",
"     <span class=\"h1\">",
"      COLIC OVERVIEW",
"     </span>",
"    </p>",
"    <p>",
"     Colic is the term used to describe infants who cry excessively for no apparent reason during the first three months of life. Colic is one of the most distressing problems of infancy. It is distressing for the infant, the parents, and for the healthcare provider. The cause of colic is not well understood, but it resolves in most infants by three to four months of age. Even though it usually goes away on its own, it can be helpful to learn more about colic in order to gain a better understanding of this difficult stage of your baby&rsquo;s life.",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H2\">",
"     <span class=\"h1\">",
"      COLIC DEFINITIONS",
"     </span>",
"    </p>",
"    <p>",
"     Colic is defined as &ldquo;excessive crying&rdquo;. A child with colic usually cries for more than three hours per day, more than three days per week, for more than three weeks.",
"    </p>",
"    <p>",
"     Colic is extremely common and occurs in up to 40 percent of all infants. It usually starts somewhere between the third and sixth week after birth and ends when a baby is three to four months of age. Colic occurs with equal frequency in the following groups:",
"    </p>",
"    <p>",
"     <ul class=\"bulletCompact-block\">",
"      <li>",
"       Males and females",
"      </li>",
"      <li>",
"       Breast- and bottle-fed infants",
"      </li>",
"      <li>",
"       Full-term and preterm infants",
"      </li>",
"      <li>",
"       The first and second child (and other siblings as well)",
"      </li>",
"     </ul>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H3\">",
"     <span class=\"h2\">",
"      Normal crying patterns",
"     </span>",
"     &nbsp;&mdash;&nbsp;All infants cry more during the first three months of life than during any other time. There is no standard definition for \"excessive\" crying, although it is normal for infants to cry for up to two hours per day. Infants without colic cry, although generally less frequently and for a shorter time than infants with colic.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H4\">",
"     <span class=\"h2\">",
"      Colic",
"     </span>",
"     &nbsp;&mdash;&nbsp;Colic may include more than excessive crying, at least in some infants.",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       Onset &ndash; Each episode of colic has a clear beginning and end, and the onset is unrelated to what was happening before the episode started; the infant may have been happy, fussy, feeding, or even sleeping. The crying episode begins suddenly and often occurs in the evening hours.",
"      </li>",
"      <li>",
"       Differs from normal crying &ndash; Colic episodes are more intense, louder, and higher pitched than \"normal\" crying. Infants with colic may sound as if they are in pain or are screaming.",
"      </li>",
"      <li>",
"       Increased muscle tone &ndash; Infants with colic may have physical symptoms (",
"       <a class=\"graphic graphic_table graphicRef76502 \" href=\"UTD.htm?2/0/2059\">",
"        table 1",
"       </a>",
"       ).",
"      </li>",
"      <li>",
"       Difficult to soothe &ndash; Infants with colic are difficult or impossible to soothe, no matter what the parents do. There may be periods of quiet, but infants often remain fussy. Crying may end after the infant passes gas or a bowel movement.",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     For all infants, colic is a temporary problem. It resolves by three months of age in 60 percent of infants and by four months in 90 percent of infants.",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H5\">",
"     <span class=\"h1\">",
"      OTHER CAUSES OF EXCESSIVE CRYING",
"     </span>",
"    </p>",
"    <p>",
"     There are a number of reasons, other than colic, that an infant may cry excessively; these can range from simple problems such as hunger to more serious problems such as infection.",
"    </p>",
"    <p>",
"     A parent should first check for manageable causes of crying:",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       Hunger &ndash; Try feeding the baby to see whether hunger is the problem. Although most young infants (younger than three months) feed every two to four hours, all babies go through periods when they will want to feed more frequently (usually during growth spurts).",
"      </li>",
"      <li>",
"       Pain &ndash; Check to see if the baby is uncomfortable because of illness or physical injury. Feel the skin to determine if the baby is overheated or too cold. Check to see if the clothing or diaper is too tight or if a hair is wrapped around a finger, toe, or the penis (called a hair tourniquet).",
"      </li>",
"      <li>",
"       Fatigue or overstimulation &ndash; Babies often cry when they become tired or overstimulated from playing or being handled. Swaddling the baby snugly (",
"       <a class=\"graphic graphic_figure graphicRef57880 \" href=\"UTD.htm?8/7/8309\">",
"        figure 1",
"       </a>",
"       ), offering a pacifier, or a change of scenery (such as a stroller or car ride) may help the baby to fall asleep.",
"      </li>",
"      <li>",
"       Food sensitivities &ndash; Infants can have an allergy or sensitivity to foods in their mother's diet or a component of their formula. Foods such as milk, eggs, nuts, and wheat in a mother's diet have a direct effect on the composition of her breast milk; these foods can occasionally cause food reactions and digestive problems such as abdominal pain, cramping, and diarrhea. Formula-fed infants can be sensitive or allergic to a protein in cow's milk-based formulas. Lactose (a type of sugar found in cow's milk) intolerance has little to no effect on the development of colic.",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     Food sensitivities may be suspected if an infant cries or spits up a large amount within an hour of feeding or if a baby has constipation or diarrhea. Symptoms of cow's milk allergy include eczema, wheezing, diarrhea, or vomiting. (See",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?16/16/16643?source=see_link\">",
"      \"Patient information: Acid reflux (gastroesophageal reflux) in infants (Beyond the Basics)\"",
"     </a>",
"     .)",
"    </p>",
"    <p>",
"     If these causes have been eliminated and the baby continues to cry excessively, parents should speak with their healthcare provider. Most infants who cry excessively do not have a serious underlying medical problem; a healthcare provider can help to make this determination. (See",
"     <a class=\"local\" href=\"#H19\">",
"      'When to seek help'",
"     </a>",
"     below.)",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H6\">",
"     <span class=\"h1\">",
"      COLIC DIAGNOSIS",
"     </span>",
"    </p>",
"    <p>",
"     The diagnosis of colic is often made",
"     <strong>",
"      after",
"     </strong>",
"     it has run its typical three- to four-month course. If you are concerned about your infant's crying, call your child's doctor or nurse to discuss your concerns and possible management strategies.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H7\">",
"     <span class=\"h2\">",
"      Home monitoring",
"     </span>",
"     &nbsp;&mdash;&nbsp;You can monitor your infant's crying by keeping a written record of the following information. You can share this information with your child's doctor or nurse to help determine the cause of crying as well as the best ways to manage it.",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       When does crying occur and how long does it last? Crying that occurs directly after feeding may be caused by gastroesophageal reflux (heartburn) or swallowed air. (See",
"       <a class=\"medical medical_patient\" href=\"UTD.htm?16/16/16643?source=see_link\">",
"        \"Patient information: Acid reflux (gastroesophageal reflux) in infants (Beyond the Basics)\"",
"       </a>",
"       .)",
"      </li>",
"      <li>",
"       Does the crying begin at the same time every day? Does the infant cry at other times of the day?",
"      </li>",
"      <li>",
"       What seems to trigger an episode of crying? What helps to stop crying?",
"      </li>",
"      <li>",
"       What do you do when the baby cries? You can hurt your child if you yell, shake, or hit.",
"      </li>",
"      <li>",
"       What does the cry sound like? Infants with colic often have a higher pitched, louder, and more intense sounding cry.",
"      </li>",
"      <li>",
"       How and what do you feed the baby? As mentioned above, overfeeding, underfeeding, and feeding inappropriate foods can cause colic.",
"      </li>",
"      <li>",
"       Is the crying getting better, worse, or is it about the same?",
"      </li>",
"      <li>",
"       How do you feel when the baby cries? Living with a colicky infant is hard; some parents feel overwhelmed and incapable of caring for their infant, while others blame the infant for being difficult.",
"      </li>",
"      <li>",
"       How has colic affected your family? Colic affects all members of a household, and it is important to consider input from everyone.",
"      </li>",
"      <li>",
"       Why do you think the baby cries? Discuss your thoughts and concerns about your infant with your child's doctor or nurse.",
"      </li>",
"     </ul>",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H8\">",
"     <span class=\"h1\">",
"      COLIC MYTHS AND FACTS",
"     </span>",
"    </p>",
"    <p>",
"     There are a number of myths about the causes and treatments of colic. Myths often develop to explain problems that are not well understood. You can learn to separate myths from facts through education and support from respected sources, including healthcare providers.",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       Babies do not cry to manipulate you.",
"      </li>",
"      <li>",
"       It is not possible to spoil a baby by holding or comforting them.",
"      </li>",
"      <li>",
"       Rice cereal does not improve colic. Infants should be given only breast milk or formula until they are four to six months old, unless told otherwise by a healthcare provider. (See",
"       <a class=\"medical medical_patient\" href=\"UTD.htm?40/32/41476?source=see_link\">",
"        \"Patient information: Starting solid foods during infancy (Beyond the Basics)\"",
"       </a>",
"       .)",
"      </li>",
"      <li>",
"       Studies show that simethicone (sample brand name: Mylicon) and lactase (the enzyme that helps to digest lactose, the sugar in milk) do not help with colic. Simethicone may also react with levothyroxine, a drug used to treat congenital hypothyroidism, resulting in inadequate treatment of the hypothyroidism [",
"       <a class=\"abstract\" href=\"UTD.htm?1/7/1140/abstract/1\">",
"        1",
"       </a>",
"       ].",
"      </li>",
"      <li>",
"       Sedatives, antihistamines (diphenhydramine [sample brand name: Benadryl]), and motion-sickness medications (dicyclomine [sample brand name: Bentyl]) are not safe or effective for colic. Dicyclomine can temporarily stop breathing or cause seizures or coma.",
"      </li>",
"     </ul>",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H9\">",
"     <span class=\"h1\">",
"      COLIC MANAGEMENT",
"     </span>",
"    </p>",
"    <p>",
"     The goals of treatment for colic are to decrease the infant's crying, help your family cope, and prevent long-term difficulties in your family's relationships. Many doctors recommend trying several strategies at once (",
"     <a class=\"graphic graphic_table graphicRef69458 \" href=\"UTD.htm?28/63/29691\">",
"      table 2",
"     </a>",
"     ).",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H10\">",
"     <span class=\"h2\">",
"      Parental support",
"     </span>",
"     &nbsp;&mdash;&nbsp;Parents of infants with colic often feel frustrated, angry, exhausted, guilty, and helpless because of their child's crying. These feelings are normal, and do not indicate that you are incapable or unworthy of caring for your child.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H11\">",
"     <span class=\"h3\">",
"      Take a break",
"     </span>",
"     &nbsp;&mdash;&nbsp;It is normal for you to need a break from a child who cries excessively. If you are alone and need a break, leave the infant in a safe place for a few minutes; the infant should be placed on his or her back in a crib or bassinet with side rails. Loose blankets, pillows, and toys that could potentially suffocate the child should be removed.",
"    </p>",
"    <p>",
"     Single parents can get support and information from Parents Without Partners (",
"     <a class=\"external\" href=\"file://www.parentswithoutpartners.org/\">",
"      www.parentswithoutpartners.org",
"     </a>",
"     ).",
"    </p>",
"    <p>",
"     Taking a break allows you to call a friend or relative for help, get away from the crying, and can prevent you from potentially harming your child. Shaking, smothering, or slapping will not stop an infant's crying but can seriously injure or even kill the child. In the United States you can call 24 hours a day, seven days a week and speak with a professional counselor at 1-800-4-A-CHILD (422-4453).",
"    </p>",
"    <p>",
"     Shaken baby syndrome is the term used to describe the injuries suffered by infants who are violently shaken, often by a parent or other adult, who has become overwhelmed by excessive crying. Infants do not have sufficient strength in their neck to limit head movement, and shaking causes the head to move suddenly and uncontrollably. As the head moves backwards and forwards, the brain hits the inside of the skull, causing serious damage and even death. (See",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?13/44/14020?source=see_link\">",
"      \"Patient information: Head injury in children and adolescents (Beyond the Basics)\"",
"     </a>",
"     .)",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H12\">",
"     <span class=\"h2\">",
"      Dietary and feeding technique changes",
"     </span>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H13\">",
"     <span class=\"h3\">",
"      Bottle-fed infants",
"     </span>",
"     &nbsp;&mdash;&nbsp;A number of devices (nipples, bottles) have been designed to decrease the amount of air swallowed during feeding. You may try positioning your infant in a vertical (sitting up) position while feeding. You may also try a curved bottle or collapsible bag, in combination with frequent burping. These techniques can reduce the amount of air swallowed, which may reduce colic in some infants.",
"    </p>",
"    <p>",
"     Some studies suggest that infants with colic improve when their formula is switched to a soy-based or hypoallergenic formula. However, the results of these studies are inconclusive. Consult with your infant's doctor or nurse to determine if a formula change might be helpful.",
"    </p>",
"    <p>",
"     Some doctors suggest a trial of a different formula for one week (for bottle-fed infants). The original formula should be restarted if there is no change; low allergy (hypoallergenic) and soy-based formulas are more expensive than traditional formula and do not need to be continued if crying does not improve after a one-week trial of the new formula.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H14\">",
"     <span class=\"h3\">",
"      Breast-fed infants",
"     </span>",
"     &nbsp;&mdash;&nbsp;Mothers who breastfeed may try consuming a hypoallergenic diet to reduce their infant's colic. A hypoallergenic diet eliminates potentially aggravating food groups, including milk, eggs, nuts, and wheat.",
"    </p>",
"    <p>",
"     To try a hypoallergenic diet, stop eating a single food group for a one-week trial period while you monitor the infant's crying. You can restart the food if you do not see improvement. This type of diet appears to be more effective for infants whose mothers have eczema, asthma, or allergic rhinitis, or if the infant has symptoms of cow's milk allergy (including eczema, wheezing, diarrhea, or vomiting). There is some evidence that having an infant empty one breast completely before switching sides may reduce colic.",
"    </p>",
"    <p>",
"     There is no evidence that stopping breastfeeding and starting formula is of any benefit in babies who have colic. There are a number of benefits to breastfeeding and breast milk that are not available with formula. (See",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?33/63/34805?source=see_link\">",
"      \"Patient information: Deciding to breastfeed (Beyond the Basics)\"",
"     </a>",
"     .)",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H15\">",
"     <span class=\"h2\">",
"      Carrying",
"     </span>",
"     &nbsp;&mdash;&nbsp;Some parents find that carrying their infant in their arms, a sling, or a front carrier can decrease the infant's and parents' anxiety. Although studies have not proven carrying to be effective for all infants, it is worth trying if your infant has not responded to other treatments. Using a sling or front carrier frees your hands and arms and allows you to move around while monitoring your infant.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H16\">",
"     <span class=\"h2\">",
"      Change in environment",
"     </span>",
"     &nbsp;&mdash;&nbsp;There are many other techniques that may help to reduce crying: a pacifier, ride in the car, change of scenery, infant swing, and warm baths have been suggested and may help to soothe an infant with colic.",
"    </p>",
"    <p>",
"     Limiting the infant's movement swaddling (",
"     <a class=\"graphic graphic_figure graphicRef57880 \" href=\"UTD.htm?8/7/8309\">",
"      figure 1",
"     </a>",
"     ) may be soothing. Placing the infant near a white noise machine or clothes drier may soothe an infant who is sensitive to noise.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H110511909\">",
"     <span class=\"h2\">",
"      Probiotics",
"     </span>",
"     &nbsp;&mdash;&nbsp;Probiotics are microorganisms that have beneficial properties for the host (sometimes called &ldquo;good bacteria&rdquo;). Most commercially available probiotics are prepared from food sources like cultured milk (eg, Lactobacillus).",
"    </p>",
"    <p>",
"     Some studies suggest that a particular probiotic, Lactobacillus",
"     <em>",
"      reuteri",
"     </em>",
"     , may be helpful in children with colic. However, additional studies are needed to confirm these results and to determine whether other probiotics may be more helpful.",
"    </p>",
"    <p>",
"     Talk to your doctor or nurse",
"     <strong>",
"      BEFORE",
"     </strong>",
"     giving your infant any probiotic. Probiotics may not be appropriate and could be dangerous in some cases.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H17\">",
"     <span class=\"h2\">",
"      Herbal remedies",
"     </span>",
"     &nbsp;&mdash;&nbsp;Herbs such as chamomile, fennel seed, and balm-mint are thought to have anti-spasmodic properties and have been used in infants with colic. Although a few studies have shown improvement in infants given a tea made with a specific mix of herbs, parents should be cautious about trying this type of treatment.",
"    </p>",
"    <p>",
"     Gripe water is a mixture of herbs, primarily dill, and water that has been promoted for its ability to cure colic. However, various types of gripe water have been found to contain dangerous ingredients, including glass particles and alcohol. A homeopathic remedy, colocynthis (found in cocyntal and Hyland colic tablets) was also found to contain dangerous ingredients (including alcohol) [",
"     <a class=\"abstract\" href=\"UTD.htm?1/7/1140/abstract/2\">",
"      2",
"     </a>",
"     ].",
"    </p>",
"    <p>",
"     Talk to your doctor or nurse",
"     <strong>",
"      BEFORE",
"     </strong>",
"     giving your infant any herbal remedy; herbal remedies may not be appropriate and could be dangerous in some cases.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H18\">",
"     <span class=\"h2\">",
"      Infant massage",
"     </span>",
"     &nbsp;&mdash;&nbsp;Infant massage has been recommended to parents of infants with colic, although no studies have proven it to be of clear benefit. A full description of infant massage can be found at the La Leche League Web site,",
"     <a class=\"external\" href=\"file://www.lalecheleague.org/\">",
"      www.lalecheleague.org",
"     </a>",
"     (search for \"massage for colic\").",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H19\">",
"     <span class=\"h1\">",
"      WHEN TO SEEK HELP",
"     </span>",
"    </p>",
"    <p>",
"     Call your child's doctor or nurse during the day or night if any of the following occur:",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       The baby has cried for more than two hours.",
"      </li>",
"      <li>",
"       The parent is afraid he or she may hurt the baby, or if the parent has shaken the baby.",
"      </li>",
"      <li>",
"       If crying could be the result of an injury or fall.",
"      </li>",
"      <li>",
"       The baby has a fever of &ge;100.4&ordm;F (38&ordm;C). Parents should call their infant's healthcare provider or go to an emergency department immediately. This Table describes how to take a child's temperature (",
"       <a class=\"graphic graphic_table graphicRef57109 \" href=\"UTD.htm?7/6/7277\">",
"        table 3",
"       </a>",
"       ). (See",
"       <a class=\"medical medical_patient\" href=\"UTD.htm?36/23/37235?source=see_link\">",
"        \"Patient information: Fever in children (Beyond the Basics)\"",
"       </a>",
"       .)",
"      </li>",
"      <li>",
"       The infant refuses to eat or drink anything for more than a few hours, vomits excessively, has bloody stools, or has a change in behavior, including lethargy or decreased responsiveness.",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     A parent should call their child's healthcare provider's office during normal office hours if any of the following occur:",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       You cannot soothe your baby's crying or you have questions or concerns about how to manage your crying baby",
"      </li>",
"      <li>",
"       Excessive crying continues after the infant is older than four months",
"      </li>",
"      <li>",
"       The infant fails to gain weight",
"      </li>",
"     </ul>",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H20\">",
"     <span class=\"h1\">",
"      LONG-TERM OUTCOMES OF COLIC",
"     </span>",
"    </p>",
"    <p>",
"     Colic can take a toll on families. Some researchers have suggested that colic interferes with child-parent interactions and can have a long-term effect on the family and child.",
"    </p>",
"    <p>",
"     Long-term studies have examined the possible relationships between colic and later childhood, including temperament, sleep patterns, family functioning, asthma, and cognitive development. However, no significant relationship between colic and these features of later childhood have been proven.",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H21\">",
"     <span class=\"h1\">",
"      WHERE TO GET MORE INFORMATION",
"     </span>",
"    </p>",
"    <p>",
"     Your child's healthcare provider is the best source of information for questions and concerns related to your child's medical problem.",
"    </p>",
"    <p>",
"     This article will be updated as needed on our web site (",
"     <a class=\"external\" href=\"file://www.uptodate.com/\">",
"      www.uptodate.com",
"     </a>",
"     ). Related topics for patients, as well as selected articles written for healthcare professionals, are also available. Some of the most relevant are listed below.",
"     <br/>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H27018397\">",
"     <span class=\"h2\">",
"      Patient level information",
"     </span>",
"     &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H27018382\">",
"     <span class=\"h3\">",
"      The Basics",
"     </span>",
"     &nbsp;&mdash;&nbsp;The Basics patient education pieces answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials.",
"    </p>",
"    <p>",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?37/53/38738?source=see_link\">",
"      Patient information: Colic (The Basics)",
"     </a>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H27018367\">",
"     <span class=\"h3\">",
"      Beyond the Basics",
"     </span>",
"     &nbsp;&mdash;&nbsp;Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are best for patients who want in-depth information and are comfortable with some medical jargon.",
"    </p>",
"    <p>",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?16/16/16643?source=see_link\">",
"      Patient information: Acid reflux (gastroesophageal reflux) in infants (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?40/32/41476?source=see_link\">",
"      Patient information: Starting solid foods during infancy (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?13/44/14020?source=see_link\">",
"      Patient information: Head injury in children and adolescents (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?33/63/34805?source=see_link\">",
"      Patient information: Deciding to breastfeed (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?36/23/37235?source=see_link\">",
"      Patient information: Fever in children (Beyond the Basics)",
"     </a>",
"     <br/>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H27018404\">",
"     <span class=\"h2\">",
"      Professional level information",
"     </span>",
"     &nbsp;&mdash;&nbsp;Professional level articles are designed to keep doctors and other health professionals up-to-date on the latest medical findings. These articles are thorough, long, and complex, and they contain multiple references to the research on which they are based. Professional level articles are best for people who are comfortable with a lot of medical terminology and who want to read the same materials their doctors are reading.",
"    </p>",
"    <p>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/27/10680?source=see_link\">",
"      Clinical features and etiology of colic",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?14/52/15177?source=see_link\">",
"      Evaluation and management of colic",
"     </a>",
"     <br/>",
"     <br/>",
"     The following organizations also provide reliable health information.",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       National Library of Medicine",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp;(",
"     <a class=\"external\" href=\"file://www.nlm.nih.gov/medlineplus/healthtopics.html\">",
"      www.nlm.nih.gov/medlineplus/healthtopics.html",
"     </a>",
"     )",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       American Academy of Pediatrics",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp;(",
"     <a class=\"external\" href=\"file://www.aap.org\">",
"      www.aap.org",
"     </a>",
"     )",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       American Academy of Family Physicians",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp; (",
"     <a class=\"external\" href=\"file://www.familydoctor.org/\">",
"      www.familydoctor.org",
"     </a>",
"     )",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       The Nemours Foundation",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; (",
"     <a class=\"external\" href=\"file://kidshealth.org/parent/growth/growing/colic.html\">",
"      file://kidshealth.org/parent/growth/growing/colic.html",
"     </a>",
"     )",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       The Mayo Clinic",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; (",
"     <a class=\"external\" href=\"file://www.mayoclinic.com/\">",
"      www.mayoclinic.com",
"     </a>",
"     )",
"    </p>",
"    <p>",
"     [",
"     <a class=\"abstract\" href=\"UTD.htm?1/7/1140/abstract/3-10\">",
"      3-10",
"     </a>",
"     ]",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Apr 1, 2013.",
"  </div>",
"  <div class=\"patTopicTool\" id=\"patTopicToolBottom\">",
"   <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"    Find",
"   </a>",
"   <a class=\"toolbutton printicon\" href=\"UTD.htm?1/7/1140?view=print\" title=\"Print This Topic\">",
"    Print",
"   </a>",
"  </div>",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <div id=\"patTopicRefHeader\">",
"    <div id=\"patTopicRefHeaderHeader\">",
"     References",
"    </div>",
"    <div id=\"patTopicRefHeaderTop\">",
"     <a href=\"#top\">",
"      <img alt=\"\" src=\"./../images/top_arrow.myextg\">",
"       Top",
"      </img>",
"     </a>",
"    </div>",
"   </div>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/7/1140/abstract/1\">",
"      Balapatabendi M, Harris D, Shenoy SD. Drug interaction of levothyroxine with infant colic drops. Arch Dis Child 2011; 96:888.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/7/1140/abstract/2\">",
"      Aviner S, Berkovitch M, Dalkian H, et al. Use of a homeopathic preparation for \"infantile colic\" and an apparent life-threatening event. Pediatrics 2010; 125:e318.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/7/1140/abstract/3\">",
"      Lehtonen LA, Rautava PT. Infantile colic: natural history and treatment. Curr Probl Pediatr 1996; 26:79.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/7/1140/abstract/4\">",
"      Geertsma MA, Hyams JS. Colic--a pain syndrome of infancy? Pediatr Clin North Am 1989; 36:905.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/7/1140/abstract/5\">",
"      Barr RG, Rotman A, Yaremko J, et al. The crying of infants with colic: a controlled empirical description. Pediatrics 1992; 90:14.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/7/1140/abstract/6\">",
"      St James-Roberts I, Halil T. Infant crying patterns in the first year: normal community and clinical findings. J Child Psychol Psychiatry 1991; 32:951.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/7/1140/abstract/7\">",
"      Garrison MM, Christakis DA. A systematic review of treatments for infant colic. Pediatrics 2000; 106:184.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/7/1140/abstract/8\">",
"      Reijneveld SA, van der Wal MF, Brugman E, et al. Infant crying and abuse. Lancet 2004; 364:1340.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/7/1140/abstract/9\">",
"      Lucassen PL, Assendelft WJ, Gubbels JW, et al. Effectiveness of treatments for infantile colic: systematic review. BMJ 1998; 316:1563.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/7/1140/abstract/10\">",
"      Rautava P, Lehtonen L, Helenius H, Sillanp&auml;&auml; M. Infantile colic: child and family three years later. Pediatrics 1995; 96:43.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
" </div>",
" <!-- patTopicMiddle -->",
"</div>"].join("\n");
var script_f1_7_1140=[""].join("\n");
var outline_f1_7_1140=[" <div class=\"patTopicFancyTop\">",
"  <div class=\"rcTop\">",
"   <div>",
"   </div>",
"  </div>",
"  <div class=\"rcContent\">",
"   <p>",
"    Contents of this article",
"   </p>",
"  </div>",
" </div>",
" <div class=\"patTopicFancySpacer\">",
" </div>",
" <div class=\"patTopicOutline\">",
"  <div class=\"rcbBottom\">",
"   <div class=\"rcbLeft\">",
"    <div class=\"rcbRight\">",
"     <div class=\"rcbBottomLeft\">",
"      <div class=\"rcbBottomRight rcbBottomRightBottomOnly\">",
"       <div id=\"outline\">",
"        <ul>",
"         <li class=\"plainItem\">",
"          <a href=\"#H1\">",
"           COLIC OVERVIEW",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H2\">",
"           COLIC DEFINITIONS",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H5\">",
"           OTHER CAUSES OF EXCESSIVE CRYING",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H6\">",
"           COLIC DIAGNOSIS",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H8\">",
"           COLIC MYTHS AND FACTS",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H9\">",
"           COLIC MANAGEMENT",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H19\">",
"           WHEN TO SEEK HELP",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H20\">",
"           LONG-TERM OUTCOMES OF COLIC",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H21\">",
"           WHERE TO GET MORE INFORMATION",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#references\">",
"           REFERENCES",
"          </a>",
"         </li>",
"        </ul>",
"       </div>",
"       <h1>",
"        GRAPHICS",
"       </h1>",
"       <div id=\"relatedGraphics\">",
"        <ul>",
"         <li class=\"plainItem\">",
"          FIGURES",
"         </li>",
"         <li class=\"bulletItem\">",
"          <a class=\"graphic graphic_figure\" href=\"UTD.htm?8/7/8309\" title=\"figure 1\">",
"           How to swaddle PI",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          TABLES",
"         </li>",
"         <li class=\"bulletItem\">",
"          <a class=\"graphic graphic_table\" href=\"UTD.htm?2/0/2059\" title=\"table 1\">",
"           Muscle tone in colic PI",
"          </a>",
"         </li>",
"         <li class=\"bulletItem\">",
"          <a class=\"graphic graphic_table\" href=\"UTD.htm?28/63/29691\" title=\"table 2\">",
"           Colic management PI",
"          </a>",
"         </li>",
"         <li class=\"bulletItem\">",
"          <a class=\"graphic graphic_table\" href=\"UTD.htm?7/6/7277\" title=\"table 3\">",
"           Measuring temperature PI",
"          </a>",
"         </li>",
"        </ul>",
"       </div>",
"      </div>",
"     </div>",
"    </div>",
"   </div>",
"  </div>",
" </div>"].join("\n");
var title_f1_7_1141="Theophylline: Patient drug information";
var content_f1_7_1141=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Theophylline: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"UTD.htm?29/31/30200?source=see_link\">",
"     see \"Theophylline: Drug information\"",
"    </a>",
"    and",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?23/49/24344?source=see_link\">",
"     see \"Theophylline: Pediatric drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F226552\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Elixophyllin&reg; Elixir;",
"     </li>",
"     <li>",
"      Theo-24&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F226553\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Apo-Theo LA&reg;;",
"     </li>",
"     <li>",
"      Novo-Theophyl SR;",
"     </li>",
"     <li>",
"      PMS-Theophylline;",
"     </li>",
"     <li>",
"      Pulmophylline;",
"     </li>",
"     <li>",
"      ratio-Theo-Bronc;",
"     </li>",
"     <li>",
"      Teva-Theophylline SR;",
"     </li>",
"     <li>",
"      Theo ER;",
"     </li>",
"     <li>",
"      Theolair;",
"     </li>",
"     <li>",
"      Uniphyl",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt war-os drugH1Div\" id=\"F12784524\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warning",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700602",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Sometimes drugs are not safe when you take them with certain other drugs. Taking them together can cause bad side effects. This is one of those drugs. Be sure to talk to your doctor about all the drugs you take.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10022063\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691768",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat breathing problems.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10022062\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2703015",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to theophylline or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"link\">",
"        urn:lims:b498:s2705429",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       <b>",
"        <span style=\"text-decoration: underline\">",
"         Shot:",
"        </span>",
"       </b>",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s4021542",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to corn or corn products.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10022067\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697780",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Wear disease medical alert ID (identification).",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698463",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Have your blood work checked often. Talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697564",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Limit your use of caffeine (for example, tea, coffee, cola) and chocolate. Use with this drug may cause nervousness, shakiness, and a fast heartbeat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697357",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you stop smoking, talk with your doctor. How much drug you take may need to be changed.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s4128402",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you drink grapefruit juice or eat grapefruit often, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697641",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are pregnant or plan on getting pregnant. You will need to talk about the benefits and risks of using this drug while you are pregnant.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697636",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are breast-feeding. You will need to talk about any risks to your baby.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10022068\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698279",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Nervous and excitable.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698272",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Upset stomach or throwing up. Many small meals, good mouth care, sucking hard, sugar-free candy, or chewing sugar-free gum may help.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10022070\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698655",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       A fast heartbeat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699023",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad dizziness or passing out.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699112",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very nervous and excitable.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699042",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very upset stomach or throwing up.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698996",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Peak flow measurement low.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10022065\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695887",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take on an empty stomach. Take 1 hour before or 2 hours after meals.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695701",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Swallow enteric-coated and long-acting products whole. Do not chew, break, or crush.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"link\">",
"        urn:lims:b498:s2696421",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       <b>",
"        <span style=\"text-decoration: underline\">",
"         Liquid:",
"        </span>",
"       </b>",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696107",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Those who have feeding tubes may also use the liquid. Flush the feeding tube before and after this drug is given.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"link\">",
"        urn:lims:b498:s2705429",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       <b>",
"        <span style=\"text-decoration: underline\">",
"         Shot:",
"        </span>",
"       </b>",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696019",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is given into a vein for a period of time.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyd-os drugH1Div\" id=\"F10022066\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I do if I miss a dose?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"link\">",
"        urn:lims:b498:s2705490",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       <b>",
"        <span style=\"text-decoration: underline\">",
"         Oral:",
"        </span>",
"       </b>",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696563",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take a missed dose as soon as you think about it.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696496",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If it is close to the time for your next dose, skip the missed dose and go back to your normal time.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696475",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not take 2 doses at the same time or extra doses.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696457",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not change the dose or stop this drug. Talk with the doctor.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F10022071\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"link\">",
"        urn:lims:b498:s2705490",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       <b>",
"        <span style=\"text-decoration: underline\">",
"         Oral:",
"        </span>",
"       </b>",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699336",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store at room temperature.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699266",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store in a dry place. Do not store in a bathroom.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10022072\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 11085 Version 37.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0602-201.77.166.39-DF771C1915-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f1_7_1141=[""].join("\n");
var outline_f1_7_1141=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F226552\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F226553\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F12784524\">",
"      Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10022063\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10022062\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10022067\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10022068\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10022070\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10022065\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10022066\">",
"      What do I do if I miss a dose?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10022071\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10022072\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?29/31/30200?source=related_link\">",
"      Theophylline: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?23/49/24344?source=related_link\">",
"      Theophylline: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f1_7_1142="Special situations in children and adolescents with type 1 diabetes mellitus";
var content_f1_7_1142=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"0\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Special situations in children and adolescents with type 1 diabetes mellitus",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?1/7/1142/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?1/7/1142/contributors\">",
"     Lynne L Levitsky, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?1/7/1142/contributors\">",
"     Madhusmita Misra, MD, MPH",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?1/7/1142/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?1/7/1142/contributors\">",
"     Joseph I Wolfsdorf, MB, BCh",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?1/7/1142/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?1/7/1142/contributors\">",
"     Alison G Hoppin, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?1/7/1142/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Apr 8, 2009.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Type 1 diabetes mellitus, one of the most common chronic diseases in childhood, is caused by insulin deficiency resulting from the destruction of insulin-producing pancreatic beta cells. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/42/23210?source=see_link\">",
"     \"Pathogenesis of type 1 diabetes mellitus\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In children and adolescents with type 1 diabetes, there are circumstances, such as acute illnesses, when glucose metabolism is significantly altered, requiring additional monitoring of blood glucose",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    adjustment of the child's daily insulin dose. The school or daycare setting also presents challenges in the management of the insulin-dependent child.",
"   </p>",
"   <p>",
"    Managing the child or adolescent with type 1 diabetes in settings with altered insulin requirements and at school or daycare is reviewed here. The diagnosis, management, and complications of type 1 diabetes mellitus in children and adolescents are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/59/40889?source=see_link\">",
"     \"Epidemiology, presentation, and diagnosis of type 1 diabetes mellitus in children and adolescents\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/9/40090?source=see_link\">",
"     \"Management of type 1 diabetes mellitus in children and adolescents\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/29/40410?source=see_link\">",
"     \"Complications and screening in children and adolescents with type 1 diabetes mellitus\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     SICK-DAY MANAGEMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;In diabetic children and adolescents with type 1 diabetes, acute illness complicates diabetes management because of its varying effects upon insulin requirements.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Increased insulin requirements are due to an increase in counter-regulatory hormones released in response to stress. These hormones, which include epinephrine and cortisol, raise peripheral insulin resistance, thereby increasing insulin requirements. Increased insulin resistance may persist for a few days after recovery from the acute illness.",
"     </li>",
"     <li>",
"      Decreased insulin requirements are due to reduced oral intake of carbohydrates because of decreased appetite, nausea, or vomiting.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Thus, a child with type 1 diabetes during an acute illness can develop:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Hypoglycemia",
"     </li>",
"     <li>",
"      Significant hyperglycemia",
"     </li>",
"     <li>",
"      Diabetic ketoacidosis (DKA) due to inadequate insulin supplementation",
"     </li>",
"     <li>",
"      Ketosis, independent of hyperglycemia",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Sick-day management is directed towards prevention of the above complications and should not be left solely in the hands of the child or adolescent. Parental involvement is imperative to avoid these diabetic complications. Telephone management with the diabetes care team is helpful in the care of these patients.",
"   </p>",
"   <p>",
"    Management includes the following [",
"    <a class=\"abstract\" href=\"UTD.htm?1/7/1142/abstract/1\">",
"     1",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Increased frequency of blood glucose monitoring (eg, every two to three hours; this may be increased to every one to two hours if necessary).",
"     </li>",
"     <li>",
"      Checking for urinary ketones with each void, regardless of blood glucose concentration. Ketone formation can occur without hyperglycemia, especially if oral intake is poor.",
"     </li>",
"     <li>",
"      Home testing of blood for beta-hydroxybutyrate may permit earlier detection of ketosis than use of urinary strips (which measure acetone and acetoacetate). Blood testing for beta-hydroxybutyrate is particularly useful for early detection of ketoacidosis in children on a continuous subcutaneous insulin infusion, where only ultra-short acting insulin is used. The blood testing strips may be more effective because they are used by families more readily than the urine testing strips.",
"     </li>",
"     <li>",
"      Additional doses of rapid- or very-rapid-acting insulin for elevated blood glucose or urine ketones (if blood glucose is not low) (",
"      <a class=\"graphic graphic_table graphicRef73676 \" href=\"UTD.htm?1/62/2028\">",
"       table 1",
"      </a>",
"      ). We suggest administering insulin at a dose of 0.05 to 0.1",
"      <span class=\"nowrap\">",
"       units/kg",
"      </span>",
"      (5 to 10 percent of the total daily dose), given every two to four hours as needed based upon blood glucose. We suggest administering insulin at a dose of 0.1",
"      <span class=\"nowrap\">",
"       unit/kg",
"      </span>",
"      for moderate to large urinary ketones. Because blood beta-hydroxybutyrate converts to acetoacetate during recovery and may therefore decrease more quickly than acetoacetate measured in urine, checking blood rather than urine for ketones could theoretically prevent overtreatment with insulin and subsequent hypoglycemia as the child recovers. This has not been shown to be important clinically.",
"     </li>",
"     <li>",
"      Reduction of insulin dose to avoid hypoglycemia, if the child is unable to ingest the required amount of carbohydrates and blood glucose concentration is not high. Management is dependent on the insulin regimen used by the patient. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?39/9/40090?source=see_link&amp;anchor=H17#H17\">",
"       \"Management of type 1 diabetes mellitus in children and adolescents\", section on 'Insulin'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      In children treated conventionally with a fixed schedule that includes intermediate acting-insulin (NPH), the daily dose(s) of the intermediate-acting insulin can be reduced by 30 to 50 percent.",
"     </li>",
"     <li>",
"      For children on intensive therapy that includes a basal dose (eg,",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?16/50/17190?source=see_link\">",
"       insulin glargine",
"      </a>",
"      or insulin pump), the basal dose can be continued at the usual rate or slightly decreased by 10 to 20 percent. In these children, insulin should not be discontinued as this may lead to DKA, because insulin requirements, although decreased, are not completely eliminated. If the usual dose of basal insulin proves too high, then the dosing has been incorrect for the child and has been used to compensate for food intake without bolus dosing.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    With either regimen, increased blood glucose can be treated with rapid or very-rapid-acting insulin (",
"    <a class=\"graphic graphic_table graphicRef73676 \" href=\"UTD.htm?1/62/2028\">",
"     table 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Ketonuria with hypoglycemia is not uncommon if oral intake has been deficient. These patients should be treated with an increased intake of carbohydrate-containing fluids and insulin as necessary.",
"     </li>",
"     <li>",
"      Ice cold, sugar-containing liquids",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?37/0/37891?source=see_link\">",
"       glucagon",
"      </a>",
"      in very low doses (0.1-0.2 mg subcutaneously every hour for up to two hours) should be given to patients who are unable to eat and have hypoglycemia. However, if vomiting persists or home therapy cannot correct hypoglycemia, the patient should be evaluated and treated at an appropriate medical facility. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?39/29/40410?source=see_link&amp;anchor=H2#H2\">",
"       \"Complications and screening in children and adolescents with type 1 diabetes mellitus\", section on 'Hypoglycemia'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Oral hydration should be maintained with fluids that contain both carbohydrates and electrolytes. However, if adequate oral hydration cannot be maintained, especially if ketosis is present, the patient should be evaluated and treated at an appropriate medical facility. These patients may require intravenous fluids and additional insulin. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?7/28/7626?source=see_link\">",
"       \"Treatment and complications of diabetic ketoacidosis in children\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     MEDICAL PROCEDURES",
"    </span>",
"    &nbsp;&mdash;&nbsp;In patients with diabetes who require medical, dental, and surgical procedures, glycemic management can be complicated by factors that affect insulin requirements, such as a period of medically mandated fasting (NPO), anesthesia, and stress. Withholding oral intake will decrease insulin requirements, while stress may increase insulin needs because of increased peripheral insulin resistance. (See",
"    <a class=\"local\" href=\"#H2\">",
"     'Sick-day management'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    If the procedure requires a period of fasting, it is preferable to have the patient scheduled as the first case to minimize the duration of fasting.",
"   </p>",
"   <p>",
"    Insulin management is dependent on the insulin regimen used by the patient. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/9/40090?source=see_link&amp;anchor=H17#H17\">",
"     \"Management of type 1 diabetes mellitus in children and adolescents\", section on 'Insulin'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In children using an intensive insulin regimen with a basal insulin (eg,",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?16/50/17190?source=see_link\">",
"       insulin glargine",
"      </a>",
"      or insulin pump), the normal basal rate should be maintained. During and after the procedure, rapid- or very-rapid-acting insulin can be used to cover additional insulin needs as determined by blood glucose concentrations (",
"      <a class=\"graphic graphic_table graphicRef73676 \" href=\"UTD.htm?1/62/2028\">",
"       table 1",
"      </a>",
"      ). Intravenous dextrose should be administered if blood glucose decreases.",
"     </li>",
"     <li>",
"      In children using a conventional insulin regimen with a fixed schedule of an intermediate acting-insulin (eg, NPH), patients should receive two-thirds of their normal intermediate acting-insulin dose and no very-rapid or rapid-acting insulin before the procedure. During and after the procedure, very-rapid or rapid-acting insulin can be used to cover additional insulin needs as determined by blood glucose concentrations (",
"      <a class=\"graphic graphic_table graphicRef73676 \" href=\"UTD.htm?1/62/2028\">",
"       table 1",
"      </a>",
"      ).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    During long procedures, switching from the usual conventional regimen to infusions of intravenous insulin administrated at a rate of 0.02 to 0.03",
"    <span class=\"nowrap\">",
"     units/kg",
"    </span>",
"    per hour and 5 percent dextrose with electrolytes has been used successfully to maintain glycemic control [",
"    <a class=\"abstract\" href=\"UTD.htm?1/7/1142/abstract/2\">",
"     2",
"    </a>",
"    ]. Ongoing blood glucose monitoring permits adjustment of the insulin infusion rate to avoid hypo- or hyperglycemia.",
"   </p>",
"   <p>",
"    (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/63/29688?source=see_link\">",
"     \"Perioperative management of diabetes mellitus\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     TRAVEL",
"    </span>",
"    &nbsp;&mdash;&nbsp;In children who travel large distances and cross multiple time zones, an intensive insulin",
"    <span class=\"nowrap\">",
"     basal/bolus",
"    </span>",
"    regimen (eg,",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?16/50/17190?source=see_link\">",
"     insulin glargine",
"    </a>",
"    with",
"    <span class=\"nowrap\">",
"     lispro/aspart",
"    </span>",
"    or the insulin pump) simplifies care.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Multiple dose injections &mdash; The long-acting insulin (eg,",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?16/50/17190?source=see_link\">",
"       insulin glargine",
"      </a>",
"      ) that provides the basal insulin dose should continue to be administered at the time that the child would have received this injection in",
"      <span class=\"nowrap\">",
"       his/her",
"      </span>",
"      home time zone. If the child is advancing time zones by more than two hours for an extended time period, the family can adjust the time of insulin glargine injections by an hour a day to a time that is more appropriate for the new time zone. Very-rapid and rapid-acting insulin should continue to be administered before meals and snacks.",
"     </li>",
"     <li>",
"      Management is more complicated in children on conventional regimens. The child can receive additional doses of very-rapid and rapid-acting insulin if the last dose of NPH insulin does not cover the child's insulin requirements before the next scheduled administered NPH dose, usually at the child's next breakfast or dinner. The next dose of NPH should be held until before this meal, when it should be administered with very-rapid and rapid-acting insulin at the dose the child would have received before the meal in question while at home.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    During air travel, insulin supplies should be transported as carry-on luggage. Insulin should be protected (but not frozen) in a cooler during long trips where heat exposure is likely. The newer insulins are particularly heat sensitive.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     SCHOOL AND DAYCARE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Children can spend up to 8 to 10 hours a day at school or extended daycare. The overall goals for children in these settings are to maintain excellent glycemic control, minimize interruptions of their daily learning, prevent complications, and prevent or eliminate any stigmatization related to their disease. Children must be allowed to check blood glucose levels, give insulin injections under the supervision of a knowledgeable adult, and be treated for hypoglycemia in close proximity to the school classroom [",
"    <a class=\"abstract\" href=\"UTD.htm?1/7/1142/abstract/3\">",
"     3",
"    </a>",
"    ]. In one study of 58 children and their parents, better glycemic control was demonstrated in children who had greater flexibility in performing diabetes care at school and who attended schools where school personnel received diabetes training [",
"    <a class=\"abstract\" href=\"UTD.htm?1/7/1142/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A school staff member, preferably a school nurse if available, needs to be identified and appropriately trained. The adult supervisor is responsible for successful implementation of daily care including insulin administration, timing and content of meals, physical education classes, and any additional sport activities. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/9/40090?source=see_link\">",
"     \"Management of type 1 diabetes mellitus in children and adolescents\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Teachers need to be able to identify and treat hypoglycemia. Oral rapidly absorbed simple carbohydrates should be available in the classroom setting. A",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?37/0/37891?source=see_link\">",
"     glucagon",
"    </a>",
"    emergency kit should be kept at the school. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/29/40410?source=see_link&amp;anchor=H2#H2\">",
"     \"Complications and screening in children and adolescents with type 1 diabetes mellitus\", section on 'Hypoglycemia'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     INFORMATION RESOURCES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Useful resources for patient, families and school personnel include the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Children with diabetes &mdash; Internet community and resource, including guidance for completing 504 plans for school. Available at:",
"      <a class=\"external\" href=\"file://www.childrenwithdiabetes.com/\">",
"       www.childrenwithdiabetes.com",
"      </a>",
"      .",
"     </li>",
"     <li>",
"      Juvenile diabetes research foundation &mdash; Internet resource for management of many special situations, including school and travel. Available at:",
"      <a class=\"external\" href=\"file://www.jdrf.org/\">",
"       www.jdrf.org",
"      </a>",
"      .",
"     </li>",
"     <li>",
"      American Diabetes Association (ADA) &mdash; Internet resource for patients, families, and providers, available at:",
"      <a class=\"external\" href=\"file://www.diabetes.org/\">",
"       www.diabetes.org",
"      </a>",
"      .",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    ADA resources for school personnel Include the ADA position statement \"Care of Children with Diabetes in the School and Day Care Setting\" [",
"    <a class=\"abstract\" href=\"UTD.htm?1/7/1142/abstract/5\">",
"     5",
"    </a>",
"    ] and \"Helping the Student with Diabetes Succeed: A Guide for School Personnel\" [",
"    <a class=\"abstract\" href=\"UTD.htm?1/7/1142/abstract/6\">",
"     6",
"    </a>",
"    ], as well as sample 504 plans.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?17/48/18179?source=see_link\">",
"       \"Patient information: My child has diabetes: How will we manage? (The Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?35/25/36243?source=see_link\">",
"       \"Patient information: Keeping your child&rsquo;s blood sugar under control (The Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?36/52/37699?source=see_link\">",
"       \"Patient information: Carb counting and your child&rsquo;s diet (The Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?37/11/38066?source=see_link\">",
"       \"Patient information: Managing diabetes in school (The Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?5/33/5651?source=see_link\">",
"       \"Patient information: Giving your child insulin (The Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?38/26/39331?source=see_link\">",
"       \"Patient information: Checking your child&rsquo;s blood sugar level (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    In children and adolescents with type 1 diabetes, there are circumstances when insulin requirements are significantly altered, resulting in a need for additional monitoring of blood glucose",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    adjustment of the child's daily insulin dose. These include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Acute illness &mdash; Children with diabetes who are acutely ill can develop hypoglycemia, or hyperglycemia and ketosis because of changing insulin requirements. Because of the inability to predict the ill child's insulin requirement, the frequency of blood glucose monitoring should be increased and urinary ketones measured with each void. Adjustments of insulin therapy and dietary manipulations are dependent on blood glucose concentrations, the presence of ketones, and the ability of the child to consume adequate carbohydrates and fluids. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Sick-day management'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Medical procedures &mdash; In diabetic patients requiring medical, dental, and surgical procedures, glycemic management can be complicated by factors that affect insulin requirements, such as the duration for which oral intake is curtailed, the use of anesthesia, and presence of stress. Adjustments of insulin therapy are dependent on the insulin regimen used by the patient (intensive with a",
"      <span class=\"nowrap\">",
"       basal/bolus",
"      </span>",
"      insulin rate versus conventional with a fixed insulin daily schedule). (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Medical procedures'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Travel &mdash; Travel across multiple time zones can require readjustment of insulin therapy and is dependent on the child's insulin regimen. During air travel, insulin supplies should be transported as carry-on luggage. Insulin should be protected (but not frozen) in a cooler during long trips where heat exposure is likely, because insulin preparations are heat sensitive. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Travel'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The care of diabetic children in school or daycare requires the following: (see",
"    <a class=\"local\" href=\"#H5\">",
"     'School and daycare'",
"    </a>",
"    above and",
"    <a class=\"local\" href=\"#H6\">",
"     'Information resources'",
"    </a>",
"    above).",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      An adult staff person, preferably a nurse, should be identified and trained to provide care and supervision to the diabetic child.",
"     </li>",
"     <li>",
"      A daily schedule should be established that includes insulin administration, meals, physical education class, and other physical activities.",
"     </li>",
"     <li>",
"      Teachers and school nurses should be trained to identify and treat hypoglycemia.",
"     </li>",
"     <li>",
"      Oral rapidly absorbed simple carbohydrates and",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?37/0/37891?source=see_link\">",
"       glucagon",
"      </a>",
"      should be readily available to treat a hypoglycemic episode.",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/7/1142/abstract/1\">",
"      Silverstein J, Klingensmith G, Copeland K, et al. Care of children and adolescents with type 1 diabetes: a statement of the American Diabetes Association. Diabetes Care 2005; 28:186.",
"     </a>",
"    </li>",
"    <li>",
"     Plotnick, LP, Klingensmith, GJ, Silverstein, J, Rosenbloom, AL. Diabetes Mellitus. In: Principles and Practice of Pediatric Endocrinology, Kappy, MS, Allen, DB, Geffner, ME (Eds), Charles C Thomas, Springfield, 2005. p. 635.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/7/1142/abstract/3\">",
"      Klingensmith G, Kaufman F, Schatz D, et al. Diabetes care in the school and day care setting. Diabetes Care 2004; 27 Suppl 1:S122.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/7/1142/abstract/4\">",
"      Wagner J, Heapy A, James A, Abbott G. Brief report: glycemic control, quality of life, and school experiences among students with diabetes. J Pediatr Psychol 2006; 31:764.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/7/1142/abstract/5\">",
"      Klingensmith G, Kaufman F, Schatz D, et al. Care of children with diabetes in the school and day care setting. Diabetes Care 2003; 26 Suppl 1:S131.",
"     </a>",
"    </li>",
"    <li>",
"     National Diabetes Education Program (NDEP). \"Helping the Student with Diabetes Succeed: A Guide for School Personnel. Available at: ndep.nih.gov/resources/school.htm (Accessed April 8, 2009).",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 5819 Version 6.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0505-197.136.42.3-0322F712F2-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f1_7_1142=[""].join("\n");
var outline_f1_7_1142=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H7\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      SICK-DAY MANAGEMENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      MEDICAL PROCEDURES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      TRAVEL",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      SCHOOL AND DAYCARE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      INFORMATION RESOURCES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PEDS/5819\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PEDS/5819|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?1/62/2028\" title=\"table 1\">",
"      Insulin pharmacokinetics",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/29/40410?source=related_link\">",
"      Complications and screening in children and adolescents with type 1 diabetes mellitus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/59/40889?source=related_link\">",
"      Epidemiology, presentation, and diagnosis of type 1 diabetes mellitus in children and adolescents",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/9/40090?source=related_link\">",
"      Management of type 1 diabetes mellitus in children and adolescents",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/42/23210?source=related_link\">",
"      Pathogenesis of type 1 diabetes mellitus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?36/52/37699?source=related_link\">",
"      Patient information: Carb counting and your child&rsquo;s diet (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?38/26/39331?source=related_link\">",
"      Patient information: Checking your child&rsquo;s blood sugar level (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?5/33/5651?source=related_link\">",
"      Patient information: Giving your child insulin (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?35/25/36243?source=related_link\">",
"      Patient information: Keeping your child&rsquo;s blood sugar under control (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?37/11/38066?source=related_link\">",
"      Patient information: Managing diabetes in school (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?17/48/18179?source=related_link\">",
"      Patient information: My child has diabetes: How will we manage? (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/63/29688?source=related_link\">",
"      Perioperative management of diabetes mellitus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/28/7626?source=related_link\">",
"      Treatment and complications of diabetic ketoacidosis in children",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f1_7_1143="Methylene blue: Drug information";
var content_f1_7_1143=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Methylene blue: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?38/6/39012?source=see_link\">",
"    see \"Methylene blue: Patient drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_pediatric\" href=\"UTD.htm?19/61/20438?source=see_link\">",
"    see \"Methylene blue: Pediatric drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F195174\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Antidote",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F195166\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Methemoglobinemia:",
"     </b>",
"     I.V.: 1-2 mg/kg or 25-50 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     over 5-10 minutes; may be repeated in 1 hour if necessary",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Ifosfamide-induced encephalopathy (unlabeled use):",
"     </b>",
"     I.V.:",
"     <b>",
"      Note:",
"     </b>",
"     Treatment may not be necessary; encephalopathy may improve spontaneously:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Prevention: 50 mg every 6-8 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Treatment: 50 mg as a single dose or every 4-8 hours until symptoms resolve",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Vasoplegia syndrome associated with cardiac surgery (unlabeled use):",
"     </b>",
"     I.V.: 1.5-2 mg/kg over 20-60 minutes administered once (Levin, 2004; Leyh, 2003).",
"     <b>",
"      Note:",
"     </b>",
"     Improvement of vasoplegia (eg, increased systemic vascular resistance, reduced vasopressor dosage) has been in observed 1-2 hours following methylene blue administration.",
"    </p>",
"   </div>",
"   <div class=\"block dop drugH1Div\" id=\"F195170\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Pediatric",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?19/61/20438?source=see_link\">",
"      see \"Methylene blue: Pediatric drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Methemoglobinemia:",
"     </b>",
"     Children: Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F195167\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block dor drugH1Div\" id=\"F9953972\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Renal Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No dosage adjustment recommendations available; however, caution should be used in severe renal impairment.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F195153\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Injection, solution: 10 mg/mL (1 mL, 10 mL)",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F195142\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F195155\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     I.V.: Administer undiluted by direct I.V. injection over 5-10 minutes. For the treatment of ifosfamide-induced encephalopathy, methylene blue may be administered either undiluted as a slow I.V. push over at least 5 minutes or diluted and infused over at least 5 minutes. Consider concomitant dextrose administration, especially in patients who are hypoglycemic, to ensure efficacy of methylene blue.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F195154\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Antidote for cyanide poisoning and drug-induced methemoglobinemia, indicator dye",
"    </p>",
"   </div>",
"   <div class=\"block usu drugH1Div\" id=\"F195171\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use - Unlabeled",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Treatment/prevention of ifosfamide-induced encephalopathy; topically, in conjunction with polychromatic light to photoinactivate viruses such as herpes simplex; alone or in combination with vitamin C for the management of chronic urolithiasis; vasoplegia syndrome associated with  cardiac surgery",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F195181\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Other safety concerns:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Due to the potential for dosing errors between mg and mL of methylene blue, prescribing and dosing should only be expressed in terms of mg of methylene blue (and not as mL)",
"      </p>",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Due to potential toxicity (hemolytic anemia), do not use methylene blue to color enteral feedings to detect aspiration.",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F195172\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Frequency not defined.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Cardiovascular: Angina, arrhythmia, hypertension, precordial pain",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Central nervous system: Dizziness, headache, fever, mental confusion",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Dermatologic: Staining of skin",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Gastrointestinal: Abdominal pain, fecal discoloration (blue-green), nausea, vomiting",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Genitourinary: Bladder irritation, discoloration of urine (blue-green)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Hematologic: Anemia, transient reduction in oxygen saturation as read by pulse oximetry",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Miscellaneous: Diaphoresis",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Postmarketing and/or case reports: Serotonin syndrome",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F195158\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to methylene blue or any component of the formulation; intraspinal injection; renal insufficiency; pregnancy",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F195146\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Anemia: Continued use can cause profound anemia.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Methemoglobinemia: At high doses or in patients with G6PD-deficiency and infants, methylene blue may catalyze the oxidation of ferrous iron in hemoglobin to ferric iron causing paradoxical methemoglobinemia. Monitor methemoglobin concentrations regularly during administration.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Renal impairment: Use with caution in patients with severe impairment.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concurrent drug therapy issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Serotonin modulators: Serotonin syndrome has been reported with concomitant administration of methylene blue and serotonin reuptake inhibitors  (eg, SSRIs, SNRIs, tricyclic antidepressants); avoid concomitant use and allow a washout period of at least 4-5 half-lives of the serotonin reuptake inhibitor prior to intravenous methylene blue use.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Special populations:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; G6PD deficiency: Use with caution in patients with G6PD deficiency.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Young patients: Use with caution in young patients.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Other warnings/precautions:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Administration: Do not inject SubQ or intrathecally.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Enteral feedings: Methylene blue should not be added to enteral feeding products (Durfee, 2006; Wessel, 2005). Safety and efficacy have not been established.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13299700\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Inhibits",
"     </b>",
"     Monoamine Oxidase",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F6221635\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alpha-/Beta-Agonists (Direct-Acting): MAO Inhibitors may enhance the vasopressor effect of Alpha-/Beta-Agonists (Direct-Acting). Primarily with oral administration of phenylephrine.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Dipivefrin.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alpha-/Beta-Agonists (Indirect-Acting): MAO Inhibitors may enhance the hypertensive effect of Alpha-/Beta-Agonists (Indirect-Acting).",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alpha1-Agonists: MAO Inhibitors may enhance the hypertensive effect of Alpha1-Agonists.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alpha2-Agonists (Ophthalmic): MAO Inhibitors may enhance the hypertensive effect of Alpha2-Agonists (Ophthalmic).",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Altretamine: May enhance the orthostatic hypotensive effect of MAO Inhibitors.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Amphetamines: MAO Inhibitors may enhance the hypertensive effect of Amphetamines.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Anilidopiperidine Opioids: May enhance the serotonergic effect of MAO Inhibitors. This could result in serotonin syndrome. Management: Avoid use of fentanyl (and other anilidopiperidine opioids when possible) in patients who have used a monoamine oxidase inhibitor within the past 14 days due to reports of unpredictable but severe adverse effects.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antihypertensives: MAO Inhibitors may enhance the hypotensive effect of Antihypertensives. MAO Inhibitors may enhance the orthostatic hypotensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antipsychotics: May enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     AtoMOXetine: MAO Inhibitors may enhance the neurotoxic (central) effect of AtoMOXetine.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Beta2-Agonists: MAO Inhibitors may enhance the adverse/toxic effect of Beta2-Agonists.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bezafibrate: MAO Inhibitors may enhance the adverse/toxic effect of Bezafibrate.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Buprenorphine: May enhance the adverse/toxic effect of MAO Inhibitors.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     BuPROPion: May enhance the serotonergic effect of Methylene Blue. This could result in serotonin syndrome.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     BusPIRone: May enhance the serotonergic effect of Methylene Blue. This could result in serotonin syndrome.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CarBAMazepine: May enhance the adverse/toxic effect of MAO Inhibitors. Management: Avoid concurrent use of carbamazepine during, or within 14 days of discontinuing, treatment with a monoamine oxidase inhibitor.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     COMT Inhibitors: May enhance the adverse/toxic effect of MAO Inhibitors.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cyclobenzaprine: May enhance the serotonergic effect of MAO Inhibitors. This could result in serotonin syndrome.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dexmethylphenidate: MAO Inhibitors may enhance the hypertensive effect of Dexmethylphenidate.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dextromethorphan: MAO Inhibitors may enhance the serotonergic effect of Dextromethorphan. This may cause serotonin syndrome.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Diethylpropion: MAO Inhibitors may enhance the hypertensive effect of Diethylpropion.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Doxapram: MAO Inhibitors may enhance the hypertensive effect of Doxapram.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     HYDROmorphone: MAO Inhibitors may enhance the adverse/toxic effect of HYDROmorphone.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Hypoglycemic Agents: MAO Inhibitors may enhance the hypoglycemic effect of Hypoglycemic Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Levodopa: May enhance the adverse/toxic effect of MAO Inhibitors. Of particular concern is the development of hypertensive reactions when levodopa is used with nonselective MAOI.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Linezolid: MAO Inhibitors may enhance the adverse/toxic effect of Linezolid.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lithium: MAO Inhibitors may enhance the adverse/toxic effect of Lithium.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     MAO Inhibitors: May enhance the serotonergic effect of Methylene Blue. This could result in serotonin syndrome.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Maprotiline: May enhance the serotonergic effect of Methylene Blue. This could result in serotonin syndrome.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Meperidine: MAO Inhibitors may enhance the serotonergic effect of Meperidine. This may cause serotonin syndrome.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Methadone: MAO Inhibitors may enhance the adverse/toxic effect of Methadone.  Management: Initial safety testing, where small incremental doses of methadone are given with the patient closely monitored (including vitals, etc.), is recommended if methadone is to be used with (or within 14 days of) an MAO inhibitor. Avoid transdermal selegiline.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Methyldopa: MAO Inhibitors may enhance the adverse/toxic effect of Methyldopa.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Methylphenidate: MAO Inhibitors may enhance the hypertensive effect of Methylphenidate.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Metoclopramide: Serotonin Modulators may enhance the adverse/toxic effect of Metoclopramide. This may be manifest as symptoms consistent with serotonin syndrome or neuroleptic malignant syndrome.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mirtazapine: May enhance the serotonergic effect of Methylene Blue. This could result in serotonin syndrome.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Nefazodone: May enhance the serotonergic effect of Methylene Blue. This could result in serotonin syndrome.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Orthostatic Hypotension Producing Agents: MAO Inhibitors may enhance the orthostatic hypotensive effect of Orthostatic Hypotension Producing Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Oxymorphone: May enhance the adverse/toxic effect of MAO Inhibitors.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pizotifen: MAO Inhibitors may enhance the anticholinergic effect of Pizotifen.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Reserpine: MAO Inhibitors may enhance the adverse/toxic effect of Reserpine. Existing MAOI therapy can result in paradoxical effects of added reserpine (e.g., excitation, hypertension).  Management: Monoamine oxidase inhibitors (MAOIs) should be avoided or used with great caution in patients who are also receiving reserpine.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Selective Serotonin Reuptake Inhibitors: MAO Inhibitors may enhance the serotonergic effect of Selective Serotonin Reuptake Inhibitors. This may cause serotonin syndrome.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Selective Serotonin Reuptake Inhibitors: May enhance the serotonergic effect of Methylene Blue. This could result in serotonin syndrome.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Serotonin 5-HT1D Receptor Agonists: MAO Inhibitors may decrease the metabolism of Serotonin 5-HT1D Receptor Agonists.  Management: If MAO inhibitor therapy is required, naratriptan, eletriptan or frovatriptan may be a suitable 5-HT1D agonist to employ.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Eletriptan; Frovatriptan; Naratriptan.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Serotonin Modulators: May enhance the adverse/toxic effect of other Serotonin Modulators. The development of serotonin syndrome may occur.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Serotonin/Norepinephrine Reuptake Inhibitors: MAO Inhibitors may enhance the serotonergic effect of Serotonin/Norepinephrine Reuptake Inhibitors. This may cause serotonin syndrome.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Serotonin/Norepinephrine Reuptake Inhibitors: May enhance the serotonergic effect of Methylene Blue. This could result in serotonin syndrome.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tapentadol: May enhance the adverse/toxic effect of MAO Inhibitors.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tetrabenazine: May enhance the adverse/toxic effect of MAO Inhibitors.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tetrahydrozoline (Nasal): MAO Inhibitors may enhance the hypertensive effect of Tetrahydrozoline (Nasal).",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     TraMADol: May enhance the neuroexcitatory and/or seizure-potentiating effect of MAO Inhibitors. TraMADol may enhance the serotonergic effect of MAO Inhibitors. Management: Consider alternatives to combined treatment with tramadol and monoamine oxidase inhibitors due to an increased risk of serotonin syndrome and seizures. Avoid transdermal selegiline.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     TraZODone: May enhance the serotonergic effect of Methylene Blue. This could result in serotonin syndrome.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tricyclic Antidepressants: MAO Inhibitors may enhance the serotonergic effect of Tricyclic Antidepressants. This may cause serotonin syndrome.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tricyclic Antidepressants: May enhance the serotonergic effect of Methylene Blue. This could result in serotonin syndrome.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tryptophan: May enhance the adverse/toxic effect of MAO Inhibitors.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F195150\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     X (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F14079758\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Use during amniocentesis has shown evidence of fetal abnormalities (atresia of the ileum and jejunum, ileal occlusions, and other adverse effects); has been used orally without similar adverse events; use, however, is contraindicated in women who are or may become pregnant. In general, medications used as antidotes should take into consideration the health and prognosis of the mother.",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F5210341\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Arterial blood gases; cardiac monitoring (patients with pre-existing pulmonary and/or cardiac disease); CBC; methemoglobin levels (co-oximetry yields a direct and accurate measure of methemoglobin levels); pulse oximeter (will not provide accurate measurement of oxygenation when methemoglobin levels are &gt;35% or following methylene blue administration); renal function; signs and symptoms of methemoglobinemia such as pallor, cyanosis, nausea, muscle weakness, dizziness, confusion, agitation, dyspnea, and tachycardia; transcutaneous O",
"     <sub>",
"      2",
"     </sub>",
"     saturation",
"    </p>",
"   </div>",
"   <div class=\"block rer drugH1Div\" id=\"F5210339\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Reference Range",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Methemoglobin levels:",
"     <b>",
"      Note:",
"     </b>",
"     The level of methemoglobin is expressed as a percent of total hemoglobin affected.",
"    </p>",
"    <p style=\"text-indent:-4em;margin-left:4em;\">",
"     10% to 25%: Cyanosis",
"    </p>",
"    <p style=\"text-indent:-4em;margin-left:4em;\">",
"     35% to 40%: Fatigue, dizziness, dyspnea, headache, tachycardia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     60%: Lethargy, stupor",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     &gt;70%: Death (adults)",
"    </p>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F195145\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Weak germicide in low concentrations, hastens the conversion of methemoglobin to hemoglobin; has opposite effect at high concentrations by converting ferrous ion of reduced hemoglobin to ferric ion to form methemoglobin; in cyanide toxicity, it combines with cyanide to form cyanmethemoglobin preventing the interference of cyanide with the cytochrome system",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F195157\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Onset of action: Reduction of methemoglobin: I.V.: 30-60 minutes",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Absorption: Oral: 53% to 97%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Metabolism: Peripheral reduction to leukomethylene blue",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Excretion: In bile, feces, and urine as leukomethylene blue",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Albert M, Lessin MS, and Gilchrist BF, &ldquo;Methylene Blue: Dangerous Dye for Neonates,&rdquo; J Pediatr Surg, 2003, 38(8):1244-5.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?1/7/1143/abstract-text/12891503/pubmed\" id=\"12891503\" target=\"_blank\">",
"        12891503",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Bailey B, \"Are There Teratogenic Risks Associated With Antidotes Used in the Acute Management of Poisoned Pregnant Women?\"",
"      <i>",
"       Birth Defects Res A Clin Mol Teratol",
"      </i>",
"      , 2003, 67(2):133-40.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?1/7/1143/abstract-text/12769509/pubmed\" id=\"12769509\" target=\"_blank\">",
"        12769509",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Burnakis TG, &ldquo;Inadvertent Substitution of Methylene Blue for Indigo Carmine to Detect Premature Rupture of Membranes,&rdquo;",
"      <i>",
"       Hosp Pharm",
"      </i>",
"      , 1995, 30(4):336-8.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Clifton J 2nd and Leikin JB, &ldquo;Methylene Blue,&rdquo;",
"      <i>",
"       Am J Ther",
"      </i>",
"      , 2003, 10(4):289-91.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?1/7/1143/abstract-text/12845393/pubmed\" id=\"12845393\" target=\"_blank\">",
"        12845393",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      David KA and Picus J, &ldquo;Evaluating Risk Factors for the Development of Ifosfamide Encephalopathy,&rdquo;",
"      <i>",
"       Am J Clin Oncol",
"      </i>",
"      , 2005, 28(3):277-80.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?1/7/1143/abstract-text/15923801/pubmed\" id=\"15923801\" target=\"_blank\">",
"        15923801",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Dawson AH and Whyte IM, &ldquo;Management of Dapsone Poisoning Complicated by Methaemoglobinaemia,&rdquo;",
"      <i>",
"       Med Toxicol Adverse Drug Exp",
"      </i>",
"      , 1989, 4(5):387-92.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?1/7/1143/abstract-text/2811676/pubmed\" id=\"2811676\" target=\"_blank\">",
"        2811676",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      DiSanto AR and Wagner JG, &ldquo;Pharmacokinetics of Highly Ionized Drugs II: Methylene Blue - Absorption, Metabolism, and Excretion in Man and Dog After Oral Administration,&rdquo;",
"      <i>",
"       J Pharm Sci",
"      </i>",
"      , 1972, 61(7):1086-90.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?1/7/1143/abstract-text/5044807/pubmed\" id=\"5044807\" target=\"_blank\">",
"        5044807",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Durfee SM, Gallagher-Allred C, Pasquale JA, &ldquo;Standards for Specialized Nutrition Support for Adult Residents of Long-Term Care Facilities,&rdquo;",
"      <i>",
"       Nutr Clin Pract",
"      </i>",
"      , 2006, 21(1):96-104.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?1/7/1143/abstract-text/16439775/pubmed\" id=\"16439775\" target=\"_blank\">",
"        16439775",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Harvey JW and Keitt AS, &ldquo;Studies of the Efficacy and Potential Hazards of Methylene Blue Therapy in Aniline-Induced Methaemoglobinaemia,&rdquo;",
"      <i>",
"       Br J Haematol",
"      </i>",
"      , 1983, 54(1):29-41.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?1/7/1143/abstract-text/6849836/pubmed\" id=\"6849836\" target=\"_blank\">",
"        6849836",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Jahns BE, Rynn KO, and Paloucek FP, &ldquo;Interference of Methylene Blue (MthB) in the Determination of Whole Blood Methemoglobin (MtHgb) Concentrations,&rdquo;",
"      <i>",
"       Vet Hum Toxicol",
"      </i>",
"      , 1994, 36:342.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Levin RL, Degrange MA, Bruno GF, et al, &ldquo;Methylene Blue Reduces Mortality and Morbidity in Vasoplegic Patients After Cardiac Surgery,&rdquo;",
"      <i>",
"       Ann Thorac Surg",
"      </i>",
"      , 2004, 77(2):496-9.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?1/7/1143/abstract-text/14759425/pubmed\" id=\"14759425\" target=\"_blank\">",
"        14759425",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Leyh RG, Kofidis T, Str&uuml;ber M, et al, &ldquo;Methylene Blue: The Drug of Choice for Catecholamine-Refractory Vasoplegia After Cardiopulmonary Bypass?&rdquo;",
"      <i>",
"       J Thorac Cardiovasc Surg",
"      </i>",
"      , 2003, 125(6):1426-31.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?1/7/1143/abstract-text/12830064/pubmed\" id=\"12830064\" target=\"_blank\">",
"        12830064",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Maloney JP, Ryan TA, Brasel KJ, et al, &ldquo;Food Dye Use in Enteral Feedings: A Review and a Call for a Moratorium,&rdquo;",
"      <i>",
"       Nutr Clin Pract",
"      </i>",
"      , 2002, 17(3):169-81.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?1/7/1143/abstract-text/16214982/pubmed\" id=\"16214982\" target=\"_blank\">",
"        16214982",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Mokhlesi B, Leikin JB, Murray P, et al, &ldquo;Adult Toxicology in Critical Care: Part II: Specific Poisonings,&rdquo;",
"      <i>",
"       Chest",
"      </i>",
"      , 2003, 123(3):897-922.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?1/7/1143/abstract-text/12628894/pubmed\" id=\"12628894\" target=\"_blank\">",
"        12628894",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Patel PN, &ldquo;Methylene Blue for Management of Ifosfamide-Induced Encephalopathy,&rdquo;",
"      <i>",
"       Ann Pharmacother",
"      </i>",
"      , 2006, 40(2):299-303.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?1/7/1143/abstract-text/16391008/pubmed\" id=\"16391008\" target=\"_blank\">",
"        16391008",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Pelgrims J, DeVos F, Van den Brande J, et al, &ldquo;Methylene Blue in the Treatment and Prevention of Ifosfamide-Induced Encephalopathy: Report of 12 Cases and a Review of the Literature,&rdquo;",
"      <i>",
"       Br J Cancer",
"      </i>",
"      , 2000, 82(2) 291-4.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?1/7/1143/abstract-text/10646879/pubmed\" id=\"10646879\" target=\"_blank\">",
"        10646879",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Preiser JC, Lejeune P, Roman A, et al, &ldquo;Methylene Blue Administration in Septic Shock: A Clinical Trial,&rdquo;",
"      <i>",
"       Crit Care Med",
"      </i>",
"      , 1995, 23(2):259-64.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?1/7/1143/abstract-text/7532559/pubmed\" id=\"7532559\" target=\"_blank\">",
"        7532559",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Shanmugam G, \"Vasoplegic Syndrome -- the Role of Methylene Blue,\"",
"      <i>",
"       Eur J Cardiothorac Surg",
"      </i>",
"      , 2005, 28(5):705-10.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?1/7/1143/abstract-text/16143539/pubmed\" id=\"16143539\" target=\"_blank\">",
"        16143539",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Sills M and Zinkham W, &ldquo;Methylene Blue-Induced Heinz Body Hemolytic Anemia,&rdquo;",
"      <i>",
"       Arch Pediatr Adolesc Med",
"      </i>",
"      , 1994, 148(3):306-10.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?1/7/1143/abstract-text/8130867/pubmed\" id=\"8130867\" target=\"_blank\">",
"        8130867",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Turner AR, Duong CD, and Good DJ, &ldquo;Methylene Blue for the Treatment and Prophylaxis of Ifosfamide-Induced Encephalopathy,&rdquo;",
"      <i>",
"       Clin Oncol (R Coll Radiol)",
"      </i>",
"      , 2003, 15(7):435-9.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?1/7/1143/abstract-text/14570094/pubmed\" id=\"14570094\" target=\"_blank\">",
"        14570094",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Wessel J, Balint J, Crill C, et al, &ldquo;Standards for Specialized Nutrition Support: Hospitalized Pediatric Patients,&rdquo;",
"      <i>",
"       Nutr Clin Pract",
"      </i>",
"      , 2005, 20(1):103-116.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?1/7/1143/abstract-text/16207652/pubmed\" id=\"16207652\" target=\"_blank\">",
"        16207652",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Wright RO, Lewander WJ, and Woolf AD, &ldquo;Methemoglobinemia: Etiology, Pharmacology, and Clinical Management,&rdquo;",
"      <i>",
"       Ann Emerg Med",
"      </i>",
"      , 1999, 34(5):646-56.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?1/7/1143/abstract-text/10533013/pubmed\" id=\"10533013\" target=\"_blank\">",
"        10533013",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Zulian GB, Tullen E, and Maton B, &ldquo;Methylene Blue for Ifosfamide-Associated Encephalopathy,&rdquo;",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 1995, 332(18):1239-40.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?1/7/1143/abstract-text/7700329/pubmed\" id=\"7700329\" target=\"_blank\">",
"        7700329",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 9636 Version 36.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0502-61.234.146.186-FE4A772EBF-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f1_7_1143=[""].join("\n");
var outline_f1_7_1143=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F195174\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F195166\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F195170\">",
"      Dosing: Pediatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F195167\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9953972\">",
"      Dosing: Renal Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F195153\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F195142\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F195155\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F195154\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F195171\">",
"      Use - Unlabeled",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F195181\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F195172\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F195158\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F195146\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13299700\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6221635\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F195150\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14079758\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5210341\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5210339\">",
"      Reference Range",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F195145\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F195157\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9636\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9636|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?38/6/39012?source=related_link\">",
"      Methylene blue: Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?19/61/20438?source=related_link\">",
"      Methylene blue: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f1_7_1144="Prescribed versus delivered dialysis: Importance of dialysis time";
var content_f1_7_1144=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Prescribed versus delivered dialysis: Importance of dialysis time",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?1/7/1144/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?1/7/1144/contributors\">",
"     Robert Hootkins, MD, PhD, FACP, FAHA, FASN",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?1/7/1144/contributors\">",
"     William L Henrich, MD, MACP",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?1/7/1144/contributors\">",
"     Richard A Sherman, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?1/7/1144/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?1/7/1144/contributors\">",
"     Steve J Schwab, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?1/7/1144/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?1/7/1144/contributors\">",
"     Alice M Sheridan, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?1/7/1144/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Feb 27, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Adequacy of hemodialysis is an important issue, since it appears to be an important determinant of patient survival. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/13/37082?source=see_link\">",
"     \"Patient survival and maintenance dialysis\"",
"    </a>",
"    .) One method of assessing the amount of dialysis prescribed is to assess urea removal normalized for a measure of body size, the",
"    <span class=\"nowrap\">",
"     Kt/V.",
"    </span>",
"    This parameter can be estimated from the dialyzer urea clearance data supplied by the manufacturer (",
"    <strong>",
"     K",
"    </strong>",
"    ), the duration of dialysis in minutes (",
"    <strong>",
"     t",
"    </strong>",
"    ), and the patient's urea space (",
"    <strong>",
"     V",
"    </strong>",
"    ) as derived from a standard",
"    <span class=\"nowrap\">",
"     height/weight",
"    </span>",
"    nomogram.",
"   </p>",
"   <p>",
"    A number of the major factors contributing to K are:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The size of the dialysis membrane, since larger surface area membranes can remove more urea per unit time.",
"     </li>",
"     <li>",
"      The blood flow rate to the dialyzer (Qb), since presenting new plasma with a high urea concentration maintains the favorable gradient for urea removal (",
"      <a class=\"graphic graphic_figure graphicRef55473 \" href=\"UTD.htm?13/17/13597\">",
"       figure 1",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      The dialysate flow rate (Qd), since delivering new fluid containing no urea also maintains the urea concentration gradient.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Ultrafiltration, which removes urea by convection in a concentration similar to that in the plasma, also plays a contributory role. Convective loss of small solutes is of minor importance with standard dialysis, but is the primary route of urea removal with continuous dialytic therapies for acute renal failure. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/25/33174?source=see_link\">",
"     \"Renal replacement therapy (dialysis) in acute kidney injury (acute renal failure): Metabolic and hemodynamic considerations\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    As will be seen below, increasing surface area, Qb, or Qd above a certain level is associated with little further increase in urea removal. Thus, once these three parameters are maximized (often with Qb as the limiting factor), the most important determinant affecting the dose of dialysis is its duration (Td). It was previously assumed that the decrease in time could be counterbalanced by increasing the efficiency of dialysis per unit time. However, this hypothesis has not been validated and is erroneous because the delivered dialytic solute removal falls increasingly short of the prescribed amount as Td declines [",
"    <a class=\"abstract\" href=\"UTD.htm?1/7/1144/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. Thus, pressures to shorten Td in an effort to reduce cost and enhance patient and staff convenience generally should be resisted.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     HISTORICAL BACKGROUND",
"    </span>",
"    &nbsp;&mdash;&nbsp;Early studies found that increasing blood or dialysate flow rates did not improve patient well-being. The latter could be achieved only by increasing the dialysis surface area or duration of dialysis. These observations suggested that larger \"middle molecules\" might be of primary importance as uremic toxins. Middle molecules diffuse across the dialysis membrane more slowly; as a result, a large concentration gradient between blood and dialysate is maintained at relatively low blood and dialysate flow rates. Thus, any benefit from increasing these rates is minimal. Clearance can be enhanced by increasing the duration of dialysis or the permeability of the dialyzer.",
"   </p>",
"   <p>",
"    The National Cooperative Dialysis Study (NCDS) in 1981 was designed to test the relative importance of small and middle molecules as uremic toxins [",
"    <a class=\"abstract\" href=\"UTD.htm?1/7/1144/abstract/2\">",
"     2",
"    </a>",
"    ]. The NCDS clearly demonstrated that the clearance of small molecules (such as urea) and the closely associated time-averaged blood concentration of urea correlated best with patient outcome. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/14/6378?source=see_link\">",
"     \"Kt/V and the adequacy of hemodialysis\"",
"    </a>",
"    .) However, the surrogates for middle molecule removal almost reached statistical significance. Their failure to do so may be due to the study having been underpowered.",
"   </p>",
"   <p>",
"    Although most nephrologists now estimate the adequacy of dialysis by measuring urea removal via calculation of",
"    <span class=\"nowrap\">",
"     Kt/V,",
"    </span>",
"    it is important to appreciate the presence of complicating factors that lower the effective urea clearance below that which is prescribed [",
"    <a class=\"abstract\" href=\"UTD.htm?1/7/1144/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. It is these factors, discussed below, that invalidate the assumption that lowering the duration of dialysis can be compensated for by a proportionate enhancement of dialysis efficiency (ie, solute removal per unit time).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     DETERMINANTS OF DIALYTIC SOLUTE CLEARANCE",
"    </span>",
"    &nbsp;&mdash;&nbsp;The dialytic clearance of any solute includes both diffusive (concentration gradient) and convective (pressure gradient) removal. Diffusion of a solute is a function of the area-permeability product of the dialyzer (KoA) for that solute as well as the Qb and Qd [",
"    <a class=\"abstract\" href=\"UTD.htm?1/7/1144/abstract/3\">",
"     3",
"    </a>",
"    ]. Convective loss is primarily determined by the ultrafiltration rate (Quf), as the solute is lost in the same concentration as that in the plasma. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/25/33174?source=see_link\">",
"     \"Renal replacement therapy (dialysis) in acute kidney injury (acute renal failure): Metabolic and hemodynamic considerations\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The first figure shows the delivered dialyzer clearance (Kd) over a range of Qb for a dialyzer with a KoA of 961",
"    <span class=\"nowrap\">",
"     mL/min",
"    </span>",
"    and a Qd of 500",
"    <span class=\"nowrap\">",
"     mL/min",
"    </span>",
"    (",
"    <a class=\"graphic graphic_figure graphicRef55473 \" href=\"UTD.htm?13/17/13597\">",
"     figure 1",
"    </a>",
"    ). The relationship between Kd and Qb is linear when Qb is low, since the delivery of new blood containing a high urea concentration maintains a high rate of diffusion. At high levels of Qb, further increases in Kd are minimized due to the diffusion limits of the membrane. This curve represents the best clearance that can be achieved at a given Qb in the absence of the complicating factors discussed below.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     DIMINISHED UREA CLEARANCE DUE TO THE PARALLEL NATURE OF HEMODIALYSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;When hemodialysis is performed with the dialyzer in series with the central venous and systemic compartments, as with a central venous catheter, urea removal is efficient and most closely approximates that shown in the figure above. With the dialyzer in series, the entire systemic compartment is available for urea extraction (",
"    <a class=\"graphic graphic_figure graphicRef75734 \" href=\"UTD.htm?38/19/39229\">",
"     figure 2",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    In comparison, hemodialysis using a standard arteriovenous access more closely approximates a parallel procedure [",
"    <a class=\"abstract\" href=\"UTD.htm?1/7/1144/abstract/4\">",
"     4",
"    </a>",
"    ]. In this setting, flow through the peripheral access (Qac) occurs in parallel to the systemic and central venous compartments and flow through the dialyzer is in parallel to that in the access (",
"    <a class=\"graphic graphic_figure graphicRef63939 \" href=\"UTD.htm?14/61/15326\">",
"     figure 3",
"    </a>",
"    ). These parallel circuits reduce extraction of urea to levels below the theoretical clearance from the dialyzer (",
"    <a class=\"graphic graphic_figure graphicRef55473 \" href=\"UTD.htm?13/17/13597\">",
"     figure 1",
"    </a>",
"    ). This occurs because dialyzed blood leaving the access short circuits the systemic compartment (ie, the capillaries where this blood refills with urea).",
"   </p>",
"   <p>",
"    Blood leaving the dialyzer has a BUN 60 to 70 percent lower than blood entering the dialyzer. This blood enters the venous system and reduces the BUN of central venous, cardiac, and arterial blood by 5 to 15 percent, compared with the average BUN in other (peripheral) veins; the reduction depends on dialyzer blood flow and efficiency as well as cardiac output [",
"    <a class=\"abstract\" href=\"UTD.htm?1/7/1144/abstract/5\">",
"     5",
"    </a>",
"    ]. As a result, blood leaving the heart and returning to the access has a lower urea concentration than if there had been complete equilibration with the systemic, circulation. Originally termed arteriovenous disequilibrium [",
"    <a class=\"abstract\" href=\"UTD.htm?1/7/1144/abstract/5\">",
"     5",
"    </a>",
"    ], this phenomenon is now termed cardiopulmonary recirculation [",
"    <a class=\"abstract\" href=\"UTD.htm?1/7/1144/abstract/4,6\">",
"     4,6",
"    </a>",
"    ]. The net effect of cardiopulmonary recirculation is that the urea concentration of blood returning to the access is not as high as it would be if equilibration occurred, thereby limiting total urea removal.",
"   </p>",
"   <p>",
"    Access flow itself has a small (about two percent) adverse impact on urea clearance from the body. This is apparent from consideration of a patient with an arteriovenous access (unused) who is receiving dialysis via a central venous catheter. Since the blood traversing the arteriovenous access short circuits the capillaries, it does not contribute to urea clearance.",
"   </p>",
"   <p>",
"    There is a surprising finding if one measures the BUN in a peripheral vein later in dialysis. In one study, the venous BUN in the arm opposite the fistula exceeded that in the arterial line of the access arm (after access recirculation was excluded) by 36 percent after two hours of dialysis [",
"    <a class=\"abstract\" href=\"UTD.htm?1/7/1144/abstract/7\">",
"     7",
"    </a>",
"    ]. This phenomenon is best explained by considering the ratio of blood flow to organ and tissue volume. When a relatively low rate of perfusion is present, urea is removed from the tissues slowly. The urea concentration in the poorly perfused compartment (eg, the muscles of the arm) and its equilibrated venous drainage remains closer to the high value present at the start of dialysis compared with that in the veins draining well-perfused tissues in which the BUN declines rapidly as treatment progresses. Originally termed venovenous disequilibrium (since veins may differ in their BUN), this phenomenon is usually presented as evidence for the regional blood flow model.",
"   </p>",
"   <p>",
"    Both cardiopulmonary recirculation and the regional differences in BUN contribute to the rebound elevation in BUN that occurs shortly after stopping hemodialysis. The BUN promptly rebounds in the central veins and arteries (including the AV access) as cardiopulmonary recirculation dissipates with a further rebound from late urea movement out of the poorly perfused tissues (see below).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Vascular access recirculation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Access recirculation is another factor that can impair urea elimination and reduce delivered dialysis dose below that prescribed. Access recirculation occurs when dialyzed blood exiting the dialyzer reverses flow after it reenters the arteriovenous fistula and is taken up by the dialyzer inlet. Thus, the dialyzer is \"seeing\" blood from the systemic circuit that has been \"diluted\" with blood that has just been dialyzed.",
"   </p>",
"   <p>",
"    Access recirculation occurs when the Qb entering the dialyzer approaches or exceeds blood flow through the access (Qac). This most often occurs when there is venous stenosis in the access. In this setting, the Qb can be maintained at prescribed levels by the blood pump in the dialyzer only by creation of a suction effect in the access, causing some of the blood returning to the access from the dialyzer to be pulled back toward the dialysis inlet and redialyzed. A discussion on how to estimate and treat access recirculation is presented elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/15/3318?source=see_link\">",
"     \"Arteriovenous fistula recirculation in hemodialysis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Thus, it is apparent that, in addition to the theoretic clearance of the dialyzer (Kd), the extraction of urea is dependent upon the relationship between cardiac output, Qb, and (to a lesser extent) Qac, as well as the relationship between Qac and Qb (which determines the degree of access recirculation). The following figure shows the degree of impairment of Kd induced by lowering the cardiac output (which increases cardiopulmonary recirculation by diminishing mixing between dialyzed blood and that in the systemic tissue compartment), raising Qb in the setting of a high Qac (which will have the same effect), and increasing access recirculation from two to 15 percent of Qb (",
"    <a class=\"graphic graphic_figure graphicRef66749 \" href=\"UTD.htm?14/48/15118\">",
"     figure 4",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Thus, for a given Qb, the total body effective solute clearance (Ktb) may be markedly lower than the theoretical clearance provided by the dialyzer alone. Paying attention only to the latter will result in an unanticipated shortfall in the amount of dialysis actually delivered to the patient.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     DIMINISHED UREA CLEARANCE DUE TO DIMINISHED EQUILIBRATION WITH INTRACELLULAR STORES",
"    </span>",
"    &nbsp;&mdash;&nbsp;The above discussion has emphasized that maximally efficient dialysis requires the delivery of blood with a high BUN to the dialyzer. As urea is removed from the extracellular fluid by dialysis, urea moves out of the cells to replete extracellular stores (",
"    <a class=\"graphic graphic_figure graphicRef68212 \" href=\"UTD.htm?23/12/23758\">",
"     figure 5",
"    </a>",
"    ). This process is not instantaneous but follows two-pool kinetics with an average urea mass transfer coefficient (MTCurea) of 800",
"    <span class=\"nowrap\">",
"     mL/min",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?1/7/1144/abstract/8,9\">",
"     8,9",
"    </a>",
"    ]. An MTCurea below 400",
"    <span class=\"nowrap\">",
"     mL/min",
"    </span>",
"    puts the patient at risk for underdialysis, since less urea is delivered to the dialyzer to be removed [",
"    <a class=\"abstract\" href=\"UTD.htm?1/7/1144/abstract/8\">",
"     8",
"    </a>",
"    ]. This problem can occur if urea is trapped in compartments with reduced flow (due to vascular disease); there may also be a genetic variation in the rate at which the cell membranes permit urea to leave the cells.",
"   </p>",
"   <p>",
"    It is important to appreciate the seemingly paradoxical effect of a reduced MTCurea. There will be a low intra- and postdialysis BUN (a misleading indicator of adequate dialysis) that leads to a low overall rate of urea removal. The higher the MTCurea, the more net urea removal will occur because there will be a higher intra- and postdialysis BUN (which might suggest inadequate dialysis) (",
"    <a class=\"graphic graphic_figure graphicRef80093 \" href=\"UTD.htm?35/23/36221\">",
"     figure 6",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    The inclusion of the effect of a low MTCurea on Kd is shown in the following figure (",
"    <a class=\"graphic graphic_figure graphicRef78452 \" href=\"UTD.htm?22/44/23246\">",
"     figure 7",
"    </a>",
"    ). The net effect of the inclusion of both technical and physiologic limitations inherent in performing hemodialysis can result in a substantial reduction in Ktb of as much as 20 to 50 percent from the predicted Kd.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Regional blood flow model",
"    </span>",
"    &nbsp;&mdash;&nbsp;An alternative model that has now gained substantial support is the regional blood flow model; this assumes that urea is sequestered within cells of some organs during dialysis because those organs have a low ratio of blood flow to urea content, and not as a result of cell membrane limited diffusion. (",
"    <a class=\"graphic graphic_figure graphicRef58368 \" href=\"UTD.htm?19/43/20145\">",
"     figure 8",
"    </a>",
"    ). The major organ responsible for this urea sequestration is skeletal muscle which receives only 15 to 20 percent of the cardiac outflow but may sequester up to 80 percent of the total body urea. This model predicts that postdialysis urea rebound is dependent upon cardiac output (cardiac index) and the amount of muscle mass in a particular individual; it has now been validated in a number of studies [",
"    <a class=\"abstract\" href=\"UTD.htm?1/7/1144/abstract/10-14\">",
"     10-14",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A more detailed description of this model is also worth considering [",
"    <a class=\"abstract\" href=\"UTD.htm?1/7/1144/abstract/15\">",
"     15",
"    </a>",
"    ]. Urea is generated by the liver and then distributed to various tissue compartments. These various tissue compartments have different rates of blood perfusion and the amount of potential urea \"trapping\" is a function of both the perfusion and the size of the compartment (",
"    <a class=\"graphic graphic_figure graphicRef58368 \" href=\"UTD.htm?19/43/20145\">",
"     figure 8",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Although most compartments with poor perfusion have the highest potential risk of urea sequestration, they are generally small. In contrast, the skeletal compartment is so large it acts as the dominant tissue \"holding\" urea. In terms of dialysis efficiency, the limiting factor in urea removal from the body may be more related to the urea trapping in this tissue rather than the dialyzer KoA parameter particularly in the latter stages of the dialysis treatment.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     OTHER LIMITING FACTORS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several additional factors can also contribute to a decrease in dialysis delivery. These include:",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Inaccurate manufacturer's specifications",
"    </span>",
"    &nbsp;&mdash;&nbsp;In vivo clearances are often as much as 20 percent lower than manufacturer's in vitro clearances. For this reason, it is desirable to evaluate specific dialyzer clearances in vivo in the dialysis unit using the formula:",
"   </p>",
"   <p>",
"    &nbsp;C(x) &nbsp; = &nbsp; Qb &nbsp;x &nbsp;([Ax &nbsp;- &nbsp;",
"    <span class=\"nowrap\">",
"     Vx]/Ax)",
"    </span>",
"   </p>",
"   <p>",
"    where C(x) refers to the clearance of solute x (urea, creatinine, phosphate, and vitamin B12 are most often used) and Ax and Vx refer to the concentration of x in the arterial and venous lines, respectively.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Inaccurate and decreased blood flow rates",
"    </span>",
"    &nbsp;&mdash;&nbsp;The rate of blood flow through the dialyzer may be overestimated if there is a problem with the dialyzer pump or the blood line, such as the use of 6 mm tubing with a high blood flow setting or decreased compliance of the plastic tubing. Both of these blood line problems prevent full refill of the tubing after compression by the roller pump, resulting in undetected shortfalls in delivered blood flow.",
"   </p>",
"   <p>",
"    In general, higher blood flow rates are observed with AV accesses versus that obtained with central venous catheters [",
"    <a class=\"abstract\" href=\"UTD.htm?1/7/1144/abstract/16\">",
"     16",
"    </a>",
"    ]. The blood flow rate will also be diminished with hemodialysis catheter dysfunction, including reversal of the access lines.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Reduced fiber bundle volume from clotting",
"    </span>",
"    &nbsp;&mdash;&nbsp;Clotting within the dialyzer can reduce the surface area available for effective dialysis. Standard dialyzer reuse criteria rejects dialyzers in which the fiber bundle volume falls below 80 percent. It has been suggested that careful attention to maintaining an adequate",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    anticoagulation of the fibers can minimize the degree of clotting and significantly improve polysulfone dialyzer clearances [",
"    <a class=\"abstract\" href=\"UTD.htm?1/7/1144/abstract/17\">",
"     17",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Inefficient dialysis",
"    </span>",
"    &nbsp;&mdash;&nbsp;The &ldquo;clock time&rdquo; for dialysis duration often does not reflect good dialysis time with optimal blood flows, since it does not include corrections for periods of low blood flow or blood pump cutoff during alarms. Nursing personnel and patients must be counseled that delivery of the proper dialysis prescription requires strict adherence to the prescribed time on dialysis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Errors in measurement of BUN",
"    </span>",
"    &nbsp;&mdash;&nbsp;Predialysis and postdialysis blood for measurement of the urea nitrogen concentration must always be drawn from the dialyzer blood inflow line when blood flow is greatly reduced (&lt;50",
"    <span class=\"nowrap\">",
"     mL/min)",
"    </span>",
"    to minimize any effect of recirculation of dialyzed venous blood. Drawing the postdialysis blood sample within about 20 seconds is common practice. The resulting single pool (unequilibrated)",
"    <span class=\"nowrap\">",
"     Kt/V",
"    </span>",
"    estimate has a predictable relationship with the two pool (equilibrated)",
"    <span class=\"nowrap\">",
"     Kt/V.",
"    </span>",
"    However, this relationship is altered when the dialysis time is unusually short, the patient unusually small, or dialysis efficiency particularly high (ie, situations of high",
"    <span class=\"nowrap\">",
"     K/V).",
"    </span>",
"    If so, the estimated dialysis dose may be substantially less than the actual, equilibrated value (",
"    <a class=\"graphic graphic_figure graphicRef57290 \" href=\"UTD.htm?25/7/25725\">",
"     figure 9",
"    </a>",
"    ). Two accepted methods of post-BUN draws include the \"stop\" flow and the \"slow\" flow to minimize the effects of recirculation and non-equilibration via tissue compartments.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Residual urea clearance",
"    </span>",
"    &nbsp;&mdash;&nbsp;Some patients with residual renal function may have significant urea loss from the native kidneys. This can be measured and included with the \"extracorporeal\" dialysis",
"    <span class=\"nowrap\">",
"     Kt/V",
"    </span>",
"    to generate a composite",
"    <span class=\"nowrap\">",
"     Kt/V;",
"    </span>",
"    however, assuming that the native clearance is zero may help minimize underdialysis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h1\">",
"     TOTAL BODY EFFECTIVE CLEARANCE AND TIME ON DIALYSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The calculated dialysis delivered to the patient is usually estimated by calculating the",
"    <span class=\"nowrap\">",
"     Kt/V",
"    </span>",
"    or the urea reduction ratio (the [pre-dialysis BUN &ndash; post-dialysis BUN]",
"    <span class=\"nowrap\">",
"     /",
"    </span>",
"    [pre-dialysis BUN]). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/14/6378?source=see_link\">",
"     \"Kt/V and the adequacy of hemodialysis\"",
"    </a>",
"    .) A urea reduction ratio (URR) of 0.6 is usually indicative of adequate dialysis. However, the URR uses an immediate post-dialysis BUN which is unequilibrated [",
"    <a class=\"abstract\" href=\"UTD.htm?1/7/1144/abstract/4\">",
"     4",
"    </a>",
"    ]. (",
"    <a class=\"graphic graphic_figure graphicRef57290 \" href=\"UTD.htm?25/7/25725\">",
"     figure 9",
"    </a>",
"    ). While a late (30 minute) post-dialysis BUN is not routinely measured, mathematical modeling allows this value and the equilibrated",
"    <span class=\"nowrap\">",
"     Kt/V",
"    </span>",
"    to be obtained using the routine post-dialysis BUN. This equilibrated",
"    <span class=\"nowrap\">",
"     Kt/V",
"    </span>",
"    is now commonly provided by dialysis laboratories and offers a more accurate assessment of dialysis dose than does the URR.",
"   </p>",
"   <p>",
"    <br/>",
"    An important question is how to correct a low",
"    <span class=\"nowrap\">",
"     Kt/V",
"    </span>",
"    or URR. The optimal approach requires a knowledge of the frequency with which various limiting factors contribute to the low",
"    <span class=\"nowrap\">",
"     Kt/V.",
"    </span>",
"    These issues were addressed in a study of 146 stable dialysis patients in whom measurements of",
"    <span class=\"nowrap\">",
"     Kt/V",
"    </span>",
"    and access recirculation were obtained every month for three successive months [",
"    <a class=\"abstract\" href=\"UTD.htm?1/7/1144/abstract/18\">",
"     18",
"    </a>",
"    ]. An abnormal",
"    <span class=\"nowrap\">",
"     Kt/V",
"    </span>",
"    value was defined as a decline of &ge;0.2 or &ge; 0.1 if the baseline",
"    <span class=\"nowrap\">",
"     Kt/V",
"    </span>",
"    was &ge;1.2 or &lt;1.2, respectively. The following results were reported:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Approximately 40 percent of low",
"      <span class=\"nowrap\">",
"       Kt/V",
"      </span>",
"      values were due to a lower than prescribed blood flow or time of dialysis, which resulted largely from inadequate needle placement and patient initiated time constraints, respectively.",
"     </li>",
"     <li>",
"      25 percent of abnormal values resulted from significant access recirculation.",
"     </li>",
"     <li>",
"      A cause was not uncovered in the remaining patients; however, subsequent",
"      <span class=\"nowrap\">",
"       Kt/V",
"      </span>",
"      values rapidly returned to baseline values without any intervention.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Our approach to correcting a low",
"    <span class=\"nowrap\">",
"     Kt/V",
"    </span>",
"    or URR therefore begins by assessing whether there is noncompliance with the dialysis prescription. If found, further evaluation is usually unnecessary, and patient and staff education concerning the importance of the dialysis prescription is undertaken. Among those in whom dialysis is being properly administered, we estimate the degree of access recirculation and, if elevated, correct any venous stenosis that may be present.",
"   </p>",
"   <p>",
"    When the primary problem is cardiopulmonary recirculation or delayed transfer out of the cells, the equilibrated",
"    <span class=\"nowrap\">",
"     Kt/V",
"    </span>",
"    but not the URR will be lowered. Under these circumstances urea clearance of the blood delivered to the dialyzer will not be substantially improved by dialyzer size, Qb, or Qd. The only way to compensate for the reduced efficiency of urea removal is to increase the time on dialysis (Td).",
"   </p>",
"   <p>",
"    Suppose, for example:",
"   </p>",
"   <p>",
"    &nbsp;Kd &nbsp; = &nbsp; 270",
"    <span class=\"nowrap\">",
"     mL/min",
"    </span>",
"    (where Kd is derived from the manufacturer's data and is theoretical, eg, the best possible without considering various degrading factors).",
"    <br/>",
"    &nbsp;Td &nbsp; = &nbsp; 180 min",
"    <br/>",
"    &nbsp;Vd &nbsp; = &nbsp; 40,000 mL (40 liters)",
"   </p>",
"   <p>",
"    The calculated",
"    <span class=\"nowrap\">",
"     Kt/V",
"    </span>",
"    will equal 1.2:",
"   </p>",
"   <p>",
"    &nbsp;",
"    <span class=\"nowrap\">",
"     Kt/V",
"    </span>",
"    &nbsp; = &nbsp; 270 &nbsp;x &nbsp;180 &nbsp;&divide; &nbsp;40,000 &nbsp; = &nbsp; 1.2",
"   </p>",
"   <p>",
"    If, however, Ktb is 70 percent of Kd or 189",
"    <span class=\"nowrap\">",
"     mL/min,",
"    </span>",
"    then to achieve the same",
"    <span class=\"nowrap\">",
"     Kt/V",
"    </span>",
"    of 1.2, requires an increase in Td to 260 min.",
"   </p>",
"   <p>",
"    This example demonstrates that short Td hemodialysis may be limited by decreased total body solute clearance as well as symptomatic intolerance of high ultrafiltration rates. Current recommendations for a target delivered",
"    <span class=\"nowrap\">",
"     Kt/V",
"    </span>",
"    (single pool or unequilibrated) is approximately 1.4, with a minimum level of at least 1.2. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/14/6378?source=see_link\">",
"     \"Kt/V and the adequacy of hemodialysis\"",
"    </a>",
"    .) Even with the use of large dialyzers and high blood and dialysate flow rates, attainment of this degree of hemodialysis will require a minimum treatment duration of four hours in many patients.",
"   </p>",
"   <p>",
"    To further improve clearance, another option is to enhance the duration",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    the frequency of dialysis, even in combination with slower blood and dialysate flow rates. This regimen may also provide higher clearance of solutes larger than urea, since their removal is hampered during conventional dialysis by slow intercompartmental transfer. Using a two body-compartment mathematical model, one report calculated the removal of urea and creatinine (low molecular weight surrogates),",
"    <a class=\"drug drug_general\" href=\"UTD.htm?41/41/42649?source=see_link\">",
"     vancomycin",
"    </a>",
"    and inulin (middle molecule surrogates), and beta-2 microglobulin (high molecular weight surrogate) using the following five different hemodialysis regimens [",
"    <a class=\"abstract\" href=\"UTD.htm?1/7/1144/abstract/19\">",
"     19",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The prescription for regimen A (standard therapy) was three times per week, 240",
"      <span class=\"nowrap\">",
"       minutes/session",
"      </span>",
"      (720",
"      <span class=\"nowrap\">",
"       minutes/week),",
"      </span>",
"      and blood and dialysate flow rates of 350 and 600",
"      <span class=\"nowrap\">",
"       mL/min,",
"      </span>",
"      respectively.",
"     </li>",
"     <li>",
"      Regimen B (daily, short-time therapy) was seven times per week, 100",
"      <span class=\"nowrap\">",
"       minutes/session",
"      </span>",
"      (700",
"      <span class=\"nowrap\">",
"       minutes/week),",
"      </span>",
"      and blood and dialysate flow of 350 and 600",
"      <span class=\"nowrap\">",
"       mL/min,",
"      </span>",
"      respectively.",
"     </li>",
"     <li>",
"      Regimens C, D, and E (low-flow, long-time therapies) were three, five, and seven times per week, respectively, with each session lasting 8 hours, and blood and dialysate flow rates of 300 and 100",
"      <span class=\"nowrap\">",
"       mL/min,",
"      </span>",
"      respectively. Regimens C, D, and E therefore consisted of 1440, 2400, and 3360 minutes of dialysis, respectively.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    When compared with the clearance of solute resulting from standard therapy (regimen A), the following conclusions were drawn concerning regimens B, C, D, and E:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Despite an equivalent time of dialysis, daily short-time therapy (regimen B) resulted in a mild increase in urea and middle molecule clearance (3 to 6 percent).",
"     </li>",
"     <li>",
"      The three times per week low-flow, long-time regimen (C) had an equivalent clearance of urea but increased clearance of middle and large molecules.",
"     </li>",
"     <li>",
"      The daily low-flow, long-time regimen (E), resulted in markedly higher clearances of all solutes (eg, 2.2, 3.6, and 2.2 times higher clearances for urea, inulin, and beta-2 microglobulin, respectively).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    This study highlights the potential pitfalls of relying too heavily on use of urea as a surrogate marker to assess dialysis dose. Urea clearance is readily dissociated from middle and large molecule clearance when treatment time and frequency are modified. Peritoneal and hemodialysis are roughly equivalent despite striking differences in urea clearance. Even consideration of solute size may be inadequate. Intracellular solutes that can move readily across a dialysis membrane may be rate limited by cellular membranes making their removal more treatment frequency dependent rather than treatment time or blood flow dependent.",
"   </p>",
"   <p>",
"    Nocturnal hemodialysis, a regimen in which dialysis is performed overnight for at least eight hours six to seven times per week using low blood and dialysate flows, replicates regimen E and has therefore been advocated as an alternative and perhaps preferable hemodialysis regimen. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/16/264?source=see_link\">",
"     \"Technical aspects of nocturnal hemodialysis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/44/19144?source=see_link\">",
"     \"Home hemodialysis\"",
"    </a>",
"    .) Whether this or similar regimens are associated with improved outcomes compared with conventional hemodialysis is currently under investigation.",
"   </p>",
"   <p>",
"    The advisability of reducing dialysis dose (generally by reducing Td) frequently arises, particularly in small women in whom routine treatment parameters result in a delivered dialysis dose substantially above the usual target levels. Such reductions may not be wise, since women may be particularly likely to benefit from more dialysis. In the HEMO study, women randomized to the high dose group (equilibrated",
"    <span class=\"nowrap\">",
"     Kt/V",
"    </span>",
"    1.45) had a 19 percent lower mortality rate than those in the standard dose group (equilibrated",
"    <span class=\"nowrap\">",
"     Kt/V",
"    </span>",
"    1.05) [",
"    <a class=\"abstract\" href=\"UTD.htm?1/7/1144/abstract/20\">",
"     20",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/13/37082?source=see_link&amp;anchor=H15#H15\">",
"     \"Patient survival and maintenance dialysis\", section on 'HEMO study'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/13/37082?source=see_link&amp;anchor=H18#H18\">",
"     \"Patient survival and maintenance dialysis\", section on 'Hemodialysis session length'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?9/26/9635?source=see_link\">",
"       \"Patient information: Dialysis or kidney transplantation &mdash; which is right for me? (Beyond the Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?39/57/40852?source=see_link\">",
"       \"Patient information: Hemodialysis (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H835989860\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Adequacy of hemodialysis is an important determinant of patient survival. One method of assessing the amount of dialysis prescribed is to assess urea removal normalized for a measure of body size, the",
"      <span class=\"nowrap\">",
"       Kt/V.",
"      </span>",
"      This parameter is calculated from the dialyzer urea clearance data supplied by the manufacturer (",
"      <strong>",
"       K",
"      </strong>",
"      ), the duration of dialysis in minutes (",
"      <strong>",
"       t",
"      </strong>",
"      ), and the patient's urea space (",
"      <strong>",
"       V",
"      </strong>",
"      ) as derived from a standard",
"      <span class=\"nowrap\">",
"       height/weight",
"      </span>",
"      nomogram. However, a number of factors may cause this approach to overestimate the delivered dialysis dose. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H2\">",
"       'Historical background'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Factors that contribute to K include the size of the dialysis membrane, the blood flow rate to the dialyzer, and the dialysate flow rate. Increasing surface area above a certain level is associated with little further increase in urea removal. Thus, once these three parameters are maximized, the most important determinant affecting the dose of dialysis is its duration. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Complicating factors may lower the effective urea clearance below that which is prescribed. These factors include cardiopulmonary recirculation and vascular access recirculation. Decreased urea equilibration between intracellular and extracellular compartments and urea sequestration may also contribute. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Diminished urea clearance due to diminished equilibration with intracellular stores'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Additional factors that can also contribute to a decrease in dialysis delivery include inaccurate manufacturer&rsquo;s specified clearances, inaccurate and decreased blood flow rates, clotting within the dialyzer which reduces the available surface area, inaccurate time on dialysis due to lack of correction for periods of low blood flow, errors in measurement of BUN. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Other limiting factors'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Correcting a low",
"      <span class=\"nowrap\">",
"       Kt/V",
"      </span>",
"      requires a knowledge of the frequency with which various limiting factors contribute to the low",
"      <span class=\"nowrap\">",
"       Kt/V.",
"      </span>",
"      Our approach to correcting a low",
"      <span class=\"nowrap\">",
"       Kt/V",
"      </span>",
"      begins by assessing whether there is noncompliance with the dialysis prescription. Among those in whom dialysis is being properly administered, we estimate the degree of access recirculation and, if elevated, correct any venous stenosis that may be present. If the primary problem is cardiopulmonary recirculation or delayed transfer out of the cells, then urea clearance of the blood delivered to the dialyzer is already at near maximal levels. The only way to compensate for the reduced efficiency of urea removal is to increase the time on dialysis. (See",
"      <a class=\"local\" href=\"#H16\">",
"       'Total body effective clearance and time on dialysis'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/7/1144/abstract/1\">",
"      Parker, TF, Husni, L. Delivering the prescribed dialysis. Semin Dial 1993; 6:13.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/7/1144/abstract/2\">",
"      Sargent JA. Shortfalls in the delivery of dialysis. Am J Kidney Dis 1990; 15:500.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/7/1144/abstract/3\">",
"      Hootkins R, Bourgeois B. The effect of ultrafiltration on dialysance. Mathematical theory and experimental verification. ASAIO Trans 1991; 37:M375.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/7/1144/abstract/4\">",
"      Depner TA. Assessing adequacy of hemodialysis: urea modeling. Kidney Int 1994; 45:1522.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/7/1144/abstract/5\">",
"      Sherman, RA. Recirculation revisited. Semin Dial 1991; 4:221.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/7/1144/abstract/6\">",
"      Schneditz D, Kaufman AM, Polaschegg HD, et al. Cardiopulmonary recirculation during hemodialysis. Kidney Int 1992; 42:1450.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/7/1144/abstract/7\">",
"      Depner TA, Rizwan S, Cheer AY, et al. High venous urea concentrations in the opposite arm. A consequence of hemodialysis-induced compartment disequilibrium. ASAIO Trans 1991; 37:M141.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/7/1144/abstract/8\">",
"      Star, RA, Hootkins, R, Thompson, JR, et al. Variability and stability of two pool urea mass transfer coefficient (abstract). J Am Soc Nephrol 1992; 3:395.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/7/1144/abstract/9\">",
"      Gabriel JP, Fellay G, Descombes E. Urea kinetic modeling: an in vitro and in vivo comparative study. Kidney Int 1994; 46:789.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/7/1144/abstract/10\">",
"      Schneditz D, Van Stone JC, Daugirdas JT. A regional blood circulation alternative to in-series two compartment urea kinetic modeling. ASAIO J 1993; 39:M573.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/7/1144/abstract/11\">",
"      Schneditz D, Daugirdas JT. Formal analytical solution to a regional blood flow and diffusion based urea kinetic model. ASAIO J 1994; 40:M667.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/7/1144/abstract/12\">",
"      Daugirdas JT, Schneditz D. Overestimation of hemodialysis dose depends on dialysis efficiency by regional blood flow but not by conventional two pool urea kinetic analysis. ASAIO J 1995; 41:M719.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/7/1144/abstract/13\">",
"      George TO, Priester-Coary A, Dunea G, et al. Cardiac output and urea kinetics in dialysis patients: evidence supporting the regional blood flow model. Kidney Int 1996; 50:1273.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/7/1144/abstract/14\">",
"      George, TO, Prifster-Coary, A, Dunea, G, et al. Cardiac output and urea kinetics in dialysis patients: Evidence supporting the regional blood flow model and the concept of cardiopulmonary recirculation (abstract). Blood Purif 1997; 15:3.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/7/1144/abstract/15\">",
"      Smye, SW, Hootkins, RE, Will, EJ. Solute clearance and tissue clearance times. Semin Dial 1998; 11:185.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/7/1144/abstract/16\">",
"      Cortez AJ, Paulson WD, Schwab SJ. Vascular access as a determinant of adequacy of dialysis. Semin Nephrol 2005; 25:96.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/7/1144/abstract/17\">",
"      Wei SS, Ellis PW, Magnusson MO, Paganini EP. Effect of heparin modeling on delivered hemodialysis therapy. Am J Kidney Dis 1994; 23:389.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/7/1144/abstract/18\">",
"      Coyne DW, Delmez J, Spence G, Windus DW. Impaired delivery of hemodialysis prescriptions: an analysis of causes and an approach to evaluation. J Am Soc Nephrol 1997; 8:1315.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/7/1144/abstract/19\">",
"      Clark WR, Leypoldt JK, Henderson LW, et al. Quantifying the effect of changes in the hemodialysis prescription on effective solute removal with a mathematical model. J Am Soc Nephrol 1999; 10:601.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/7/1144/abstract/20\">",
"      Depner T, Daugirdas J, Greene T, et al. Dialysis dose and the effect of gender and body size on outcome in the HEMO Study. Kidney Int 2004; 65:1386.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 1986 Version 10.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1103-122.72.76.133-B89E15691A-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f1_7_1144=[""].join("\n");
var outline_f1_7_1144=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H835989860\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      HISTORICAL BACKGROUND",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      DETERMINANTS OF DIALYTIC SOLUTE CLEARANCE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      DIMINISHED UREA CLEARANCE DUE TO THE PARALLEL NATURE OF HEMODIALYSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Vascular access recirculation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      DIMINISHED UREA CLEARANCE DUE TO DIMINISHED EQUILIBRATION WITH INTRACELLULAR STORES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Regional blood flow model",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      OTHER LIMITING FACTORS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Inaccurate manufacturer's specifications",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Inaccurate and decreased blood flow rates",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Reduced fiber bundle volume from clotting",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Inefficient dialysis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Errors in measurement of BUN",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Residual urea clearance",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      TOTAL BODY EFFECTIVE CLEARANCE AND TIME ON DIALYSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H835989860\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"NEPH/1986\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"NEPH/1986|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?13/17/13597\" title=\"figure 1\">",
"      Effect of blood flow on urea clearance during hemodialysis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?38/19/39229\" title=\"figure 2\">",
"      Schematic figure demonstrating hd access in series with circulat",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?14/61/15326\" title=\"figure 3\">",
"      Schematic figure demonstrating hd access in parallel with circ",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?14/48/15118\" title=\"figure 4\">",
"      Recirculation and HD delivery",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?23/12/23758\" title=\"figure 5\">",
"      Urea equilibration in HD",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?35/23/36221\" title=\"figure 6\">",
"      Urea mass transfer coefficient",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?22/44/23246\" title=\"figure 7\">",
"      Reduced dialysis delivery",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?19/43/20145\" title=\"figure 8\">",
"      Organ reservoirs of urea",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?25/7/25725\" title=\"figure 9\">",
"      Changes in BUN",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/15/3318?source=related_link\">",
"      Arteriovenous fistula recirculation in hemodialysis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/44/19144?source=related_link\">",
"      Home hemodialysis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/14/6378?source=related_link\">",
"      Kt/V and the adequacy of hemodialysis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?9/26/9635?source=related_link\">",
"      Patient information: Dialysis or kidney transplantation &mdash; which is right for me? (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?39/57/40852?source=related_link\">",
"      Patient information: Hemodialysis (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/13/37082?source=related_link\">",
"      Patient survival and maintenance dialysis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/25/33174?source=related_link\">",
"      Renal replacement therapy (dialysis) in acute kidney injury (acute renal failure): Metabolic and hemodynamic considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?0/16/264?source=related_link\">",
"      Technical aspects of nocturnal hemodialysis",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f1_7_1145="Nefazodone: Pediatric drug information";
var content_f1_7_1145=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Nefazodone: Pediatric drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_general\" href=\"UTD.htm?2/0/2057?source=see_link\">",
"    see \"Nefazodone: Drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?41/61/42965?source=see_link\">",
"    see \"Nefazodone: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"block black-box-warn drugH1Div\" id=\"F5709167\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     ALERT: U.S. Boxed Warning",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     The FDA-approved labeling includes a boxed warning. See Warnings/Precautions section for a concise summary of this information.  For verbatim wording of the boxed warning, consult the product labeling or",
"     <a href=\"file://www.fda.gov\" target=\"_blank\">",
"      www.fda.gov",
"     </a>",
"     .",
"    </p>",
"   </div>",
"   <div class=\"list_set htclist drugH1Div drugBrandNames\" id=\"F1027088\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Therapeutic Category",
"    </span>",
"    <ul>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Antidepressant, Serotonin Reuptake Inhibitor/Antagonist",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block dos drugH1Div\" id=\"F1027122\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Usual",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_general\" href=\"UTD.htm?2/0/2057?source=see_link\">",
"      see \"Nefazodone: Drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Oral: Depression:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Children and Adolescents:",
"     <b>",
"      Note:",
"     </b>",
"     Not FDA approved. Limited information is available: Based on primary outcome measures, no randomized, placebo-controlled trial has shown nefazodone to be effective for the treatment of depression in pediatric patients (Findling, 2006; Laughren, 2004; Wagner, 2005); one study showed a positive trend toward efficacy (Emslie, 2000); two open-label trials [(n=28; age range: 7-17 years) and (n=10; adolescents)] showed nefazodone improved depressive symptom severity scores in children and adolescents (Findling, 2000; Goodnick, 2000); a small case series (n=7; age range: 9-17 years) showed improvement in depression severity scores in treatment refractory children and adolescents with multiple comorbid conditions (Wilens, 1997). Because efficacy has not been established in controlled clinical trials and due to the risk of hepatotoxicity, nefazodone is seldom prescribed in children and adolescents (Dopheide, 2006). If use is indicated, some experts recommend the following doses: Initial: 50 mg twice daily (100 mg/day) for at least 7 days; then increase to 100 mg twice daily (200 mg/day) for at least 7 days; then titrate at weekly intervals using 50 mg/day increments in children and 100 mg/day increments in adolescents; usual target range: 300-400 mg/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Adults: Initial: 200 mg/day given in 2 divided doses; titrate in 100-200 mg/day increments at &ge;1 week intervals; effective dosage: 300-600 mg/day in 2 divided doses",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F200284\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, oral, as hydrochloride: 50 mg, 100 mg, 150 mg, 200 mg, 250 mg",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F200268\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes",
"    </p>",
"   </div>",
"   <div class=\"block meg drugH1Div\" id=\"F7874745\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Guide",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     An FDA-approved patient medication guide, which is available with the product information and at",
"     <a href=\"file://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?id=4522\" target=\"_blank\">",
"      file://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?id=4522",
"     </a>",
"     , must be dispensed with this medication.",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F1027126\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     May be administered with or without food",
"    </p>",
"   </div>",
"   <div class=\"block sta drugH1Div\" id=\"F1027110\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Stability",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Store at controlled room temperature at 20&deg;C to 25&deg;C (68&deg;F to 77&deg;F); dispense in a tightly-closed, light-resistant container.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F1027089\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Treatment of depression (FDA approved in adults)",
"     <b>",
"      Note:",
"     </b>",
"     Due to the risk of hepatic failure, other antidepressant agents are generally tried first",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F200348\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Serzone&reg; may be confused with selegiline, SEROquel&reg;, sertraline",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block arm drugH1Div\" id=\"F200345\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Cardiovascular: Bradycardia, hypotension, orthostatic hypotension, peripheral edema, vasodilation",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Central nervous system: Abnormal dreams, agitation, ataxia, chills, confusion, decreased concentration, dizziness, drowsiness, fever, headache, incoordination, insomnia, lightheadedness, memory impairment, psychomotor retardation, tremor",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Dermatologic: Pruritus, rash",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Endocrine &amp; metabolic: Breast pain, decreased libido, impotence",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Gastrointestinal: Constipation, diarrhea, dyspepsia, gastroenteritis, increased appetite, nausea, taste perversion, thirst, vomiting, xerostomia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Genitourinary: Urinary frequency, urinary retention",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Hematologic: Decreased hematocrit",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Arthralgia, hypertonia, neck rigidity, paresthesia, tremor, weakness",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Ocular: Abnormal vision, blurred vision, eye pain, visual field defect",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Otic: Tinnitus",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Respiratory: Bronchitis, cough, dyspnea, pharyngitis",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Miscellaneous: Flu syndrome, infection",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Rare but important or life-threatening: Allergic reaction, angioedema, AV block, galactorrhea, gynecomastia, hallucinations, hepatic failure, hepatic necrosis, hepatitis, hyponatremia, impotence, increased prolactin, leukopenia, liver function tests (abnormal), photosensitivity, priapism, rhabdomyolysis (with lovastatin/simvastatin), seizure, serotonin syndrome, Stevens-Johnson syndrome, thrombocytopenia",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F1027094\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to nefazodone, related compounds (phenylpiperazine antidepressants), or any component; liver injury due to previous nefazodone treatment; concurrent use with astemizole, carbamazepine, cisapride, pimozide, or terfenadine; concurrent therapy with triazolam",
"    </p>",
"   </div>",
"   <div class=\"block pre drugH1Div\" id=\"F7710964\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Precautions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Use with caution in patients with a history of seizures; seizures have been reported with nefazodone use. May cause orthostatic or postural hypotension; use with caution in patients with known cardiovascular or cerebrovascular disease or predisposing hypotensive conditions like dehydration, hypovolemia, or concurrent antihypertensive therapy. Priapism has been reported (rarely) during postmarketing surveillance; if condition occurs, therapy should be discontinued and physician contacted. Use with caution in patients with recent history of MI or unstable heart disease; nefazodone has not been studied in these patients; sinus bradycardia may occur with nefazodone use. Use with caution and decrease the dose in debilitated patients. May impair physical or mental abilities; patients must be cautioned about performing tasks which require mental alertness (eg, operating machinery or driving) until certain nefazodone does not adversely affect abilities. Visual disturbances, including blurred vision, scotoma, and visual trials have been reported. No clinical studies have assessed the combined use of nefazodone and electroconvulsive therapy; however, similar drugs may increase the risks associated with electroconvulsive therapy; consider discontinuing, when possible, prior to ECT treatment. Discontinue use prior to elective surgery (unknown interactions with general anesthetics may exist).",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F1027095\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Nefazodone is not approved for use in pediatric patients. Clinical worsening of depression or suicidal ideation and behavior may occur in children and adults with major depressive disorder",
"     <b>",
"      [U.S. Boxed Warning]",
"     </b>",
"     . In clinical trials, antidepressants increased the risk of suicidal thinking and behavior (suicidality) in children, adolescents, and young adults (18-24 years of age) with major depressive disorder and other psychiatric disorders. This risk must be considered before prescribing antidepressants for any clinical use. Short-term studies did not show an increased risk of suicidality with antidepressant use in patients &gt;24 years of age and showed a decreased risk in patients &ge;65 years.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Patients of all ages who are treated with antidepressants for any indication require appropriate monitoring and close observation for clinical worsening of depression, suicidality, and unusual changes in behavior, especially during the first few months after antidepressant initiation or when the dose is adjusted. Family members and caregivers should be instructed to closely observe the patient (ie, daily) and communicate condition with healthcare provider. Patients should also be monitored for associated behaviors (eg, anxiety, agitation, panic attacks, insomnia, irritability, hostility, aggressiveness, impulsivity, akathisia, hypomania, mania) which may increase the risk for worsening depression or suicidality. Worsening depression or emergence of suicidality (or associated behaviors listed above) that is abrupt in onset, severe, or not part of the presenting symptoms, may require discontinuation or modification of drug therapy. If intolerable symptoms occur following a decrease in dosage or upon discontinuation of therapy, consider resuming the previous dose with a more gradual taper. Therapy should not be abruptly discontinued in patients receiving high doses for prolonged periods. To reduce risk of intentional overdose, write prescriptions for the smallest quantity consistent with good patient care.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Life-threatening hepatic failure has been reported in patients treated with nefazodone",
"     <b>",
"      [U.S. Boxed Warning]",
"     </b>",
"     . The estimated rate is 1 case of liver failure (resulting in liver transplant or death) per 250,000-300,000 patient-years of nefazodone treatment (3-4 times the background rate of liver failure); actual incidence may be higher due to under-reporting. Onset of liver injury has generally occurred between 2 weeks to 6 months of nefazodone therapy. Nefazodone should not routinely be started in patients with active liver disease or elevated baseline serum transaminases (baseline abnormalities may complicate patient monitoring). Nefazodone should be discontinued if clinical signs or symptoms suggestive of liver failure occur or if serum AST or ALT levels increase to &ge;3 times the upper limit of normal. Do not reinitiate nefazodone in these patients.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Concurrent use with triazolam is contraindicated; nefazodone significantly increases triazolam serum concentrations; initial triazolam dosage must be reduced by 75% if drugs are used concomitantly; such reductions may not be possible with available dosage forms; thus, use with triazolam is contraindicated. Nefazodone significantly increases alprazolam serum concentrations; initial alprazolam dosage should be reduced by 50% if drugs are used concomitantly. Concurrent use of MAO inhibitors, use of MAO inhibitors within previous 14 days, and use of MAO inhibitors within 1 week of stopping nefazodone is not recommended; serious, potentially fatal reactions may occur. Nefazodone may potentially significantly increase plasma concentrations of astemizole, cisapride, pimozide, and terfenadine, resulting in QT prolongation and serious cardiovascular adverse events; concurrent use with any of these drugs is contraindicated. Carbamazepine will significantly decrease nefazodone serum concentrations; concurrent use is contraindicated.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     May precipitate a shift to mania or hypomania in patients with bipolar disorder. Monotherapy in patients with bipolar disorder should be avoided. Patients presenting with depressive symptoms should be screened for bipolar disorder. Use with caution in patients with a history of mania. Nefazodone is not FDA approved for the treatment of bipolar depression.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F200333\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Substrate",
"     </b>",
"     of CYP2D6 (major), CYP3A4 (major);",
"     <b>",
"      Note:",
"     </b>",
"     Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential;",
"     <b>",
"      Inhibits",
"     </b>",
"     CYP1A2 (weak), CYP2B6 (weak), CYP2C8 (weak), CYP2D6 (weak), CYP3A4 (strong);",
"     <b>",
"      Induces",
"     </b>",
"     P-glycoprotein",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F200277\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Abiraterone Acetate: May increase the serum concentration of CYP2D6 Substrates. Management: Avoid concurrent use of abiraterone with CYP2D6 substrates that have a narrow therapeutic index whenever possible.  When concurrent use is not avoidable, monitor patients closely for signs/symptoms of toxicity.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ado-Trastuzumab Emtansine: CYP3A4 Inhibitors (Strong) may increase serum concentrations of the active metabolite(s) of Ado-Trastuzumab Emtansine. Specifically, strong CYP3A4 inhibitors may increase concentrations of the cytotoxic DM1 component.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alfuzosin: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Alfuzosin.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Almotriptan: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Almotriptan.  Management: Limit initial almotriptan adult dose to 6.25 mg and maximum adult dose to 12.5 mg/24-hrs when used with a strong CYP3A4 inhibitor. Avoid concurrent use in patients with impaired hepatic or renal function.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alosetron: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Alosetron.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antipsychotic Agents (Phenothiazines): May enhance the adverse/toxic effect of Antidepressants (Serotonin Reuptake Inhibitor/Antagonist). Specifically, this may be manifest as symptoms consistent with serotonin syndrome or neuroleptic malignant syndrome. Antidepressants (Serotonin Reuptake Inhibitor/Antagonist) may enhance the hypotensive effect of Antipsychotic Agents (Phenothiazines).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antipsychotics: May enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Apixaban: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Apixaban.  Management: Apixaban U.S. prescribing information states dose reduction criteria that may be applied under some circumstances. The apixaban Canadian product monograph suggests that any combined use is contraindicated. See full interaction monograph for details.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     ARIPiprazole: CYP3A4 Inhibitors (Strong) may increase the serum concentration of ARIPiprazole.  Management: See full interaction monograph for details.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Avanafil: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Avanafil.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Axitinib: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Axitinib.  Management: Avoid concurrent use of axitinib with any strong CYP3A inhibitor whenever possible.  If a strong CYP3A inhibitor must be used with axitinib, a 50% axitinib dose reduction is recommended.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bedaquiline: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Bedaquiline.  Management: Limit the duration of concomitant administration of bedaquiline with CYP3A4 inhibitors to no more than 14 days, unless the benefit of continued administration is judged to outweigh the possible risks. Monitor for toxic effects of bedaquiline.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bortezomib: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Bortezomib.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bosutinib: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Bosutinib.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Brentuximab Vedotin: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Brentuximab Vedotin. Specifically, concentrations of the active monomethyl auristatin E (MMAE) component may be increased.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Brinzolamide: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Brinzolamide.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Budesonide (Nasal): CYP3A4 Inhibitors (Strong) may increase the serum concentration of Budesonide (Nasal).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Budesonide (Systemic, Oral Inhalation): CYP3A4 Inhibitors (Strong) may increase the serum concentration of Budesonide (Systemic, Oral Inhalation).  Management: Consider reducing the oral budesonide dose when used together with a CYP3A4 inhibitor.  This interaction is likely less severe with orally inhaled budesonide.  Monitor patients closely for signs/symptoms of corticosteroid excess.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     BusPIRone: May enhance the serotonergic effect of Antidepressants (Serotonin Reuptake Inhibitor/Antagonist).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cabozantinib: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Cabozantinib.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CarBAMazepine: May decrease the serum concentration of Nefazodone. Concentrations of active Nefazodone metabolites may also be reduced. Nefazodone may increase the serum concentration of CarBAMazepine. Also, concentrations of the active CarBAMazepine epoxide metabolite may be reduced.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cardiac Glycosides: Nefazodone may increase the serum concentration of Cardiac Glycosides.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cisapride: Nefazodone may increase the serum concentration of Cisapride.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CloZAPine: Nefazodone may decrease the metabolism of CloZAPine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Colchicine: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Colchicine.  Management: Colchicine is contraindicated in patients with impaired renal or hepatic function who are also receiving a strong CYP3A4 inhibitor.  In those with normal renal and hepatic function, reduce colchicine dose as directed.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Conivaptan: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Conivaptan.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Corticosteroids (Orally Inhaled): CYP3A4 Inhibitors (Strong) may increase the serum concentration of Corticosteroids (Orally Inhaled).  Management: Monitor for signs and symptoms of adrenal suppression if inhaled budesonide or mometasone are coadministered with a strong CYP3A4 inhibitor.  Avoid combining inhaled fluticasone with any strong CYP3A4 inhibitor.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Beclomethasone (Oral Inhalation); Triamcinolone (Systemic).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Crizotinib: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Crizotinib.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP2D6 Inhibitors (Moderate): May decrease the metabolism of CYP2D6 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP2D6 Inhibitors (Strong): May decrease the metabolism of CYP2D6 Substrates.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP3A4 Inducers (Strong): May increase the metabolism of CYP3A4 Substrates. Management: Consider an alternative for one of the interacting drugs. Some combinations may be specifically contraindicated. Consult appropriate manufacturer labeling.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP3A4 Inhibitors (Moderate): May decrease the metabolism of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP3A4 Inhibitors (Strong): May decrease the metabolism of CYP3A4 Substrates.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP3A4 Substrates: CYP3A4 Inhibitors (Strong) may decrease the metabolism of CYP3A4 Substrates.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dabigatran Etexilate: P-glycoprotein/ABCB1 Inducers may decrease the serum concentration of Dabigatran Etexilate.  Management: Avoid concurrent use of dabigatran with p-glycoprotein inducers when possible.  Closely monitor for decreased levels/effects of dabigatran if concomitantly administering  p-glycoprotein inducers, particularly strong inducers.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dasatinib: May increase the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Deferasirox: May decrease the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dienogest: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Dienogest.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dronedarone: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Dronedarone.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dutasteride: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Dutasteride.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Enzalutamide: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Enzalutamide.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Eplerenone: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Eplerenone.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Everolimus: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Everolimus.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     FentaNYL: CYP3A4 Inhibitors (Strong) may increase the serum concentration of FentaNYL.  Management: Monitor patients extra closely for several days following initiation of the combination, and fentanyl dosage reductions should be made as appropriate.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Fesoterodine: CYP3A4 Inhibitors (Strong) may increase serum concentrations of the active metabolite(s) of Fesoterodine.  Management: Avoid fesoterodine doses greater than 4 mg daily in adult patients who are also receiving strong CYP3A4 inhibitors.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Fluticasone (Nasal): CYP3A4 Inhibitors (Strong) may increase the serum concentration of Fluticasone (Nasal).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Fluticasone (Oral Inhalation): CYP3A4 Inhibitors (Strong) may increase the serum concentration of Fluticasone (Oral Inhalation).",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     GuanFACINE: CYP3A4 Inhibitors (Strong) may increase the serum concentration of GuanFACINE.  Management: Reduce the guanfacine dose by 50% when adding a strong CYP3A4 inhibitor.  Limit the guanfacine dose to 2 mg/day when starting guanfacine in a patient who is taking a strong CYP3A4 inhibitor.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Halofantrine: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Halofantrine.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ifosfamide: CYP3A4 Inhibitors (Strong) may decrease serum concentrations of the active metabolite(s) of Ifosfamide.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Iloperidone: CYP3A4 Inhibitors (Strong) may increase serum concentrations of the active metabolite(s) of Iloperidone. Specifically, concentrations of the metabolites P88 and P95 may be increased. CYP3A4 Inhibitors (Strong) may increase the serum concentration of Iloperidone.  Management: Reduce iloperidone dose by half when administered with a strong CYP3A4 inhibitor.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ivabradine: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Ivabradine.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ivacaftor: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Ivacaftor.  Management: Decrease ivacaftor dose to 150 mg twice a week in patients also receiving strong CYP3A4 inhibitors.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ixabepilone: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Ixabepilone.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lapatinib: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Lapatinib.  Management: If an overlap in therapy cannot be avoided, consider reducing lapatinib dose to 500 mg/day during, and within 1 week of completing, treatment with the strong CYP3A4 inhibitor.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Linagliptin: P-glycoprotein/ABCB1 Inducers may decrease the serum concentration of Linagliptin.  Management: Strongly consider using an alternative to any strong P-glycoprotein inducer in patients who are being treated with linagliptin. If this combination is used, monitor patients closely for evidence of reduced linagliptin effectiveness.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lomitapide: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Lomitapide.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lovastatin: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Lovastatin.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lumefantrine: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Lumefantrine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lurasidone: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Lurasidone.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     MAO Inhibitors: May enhance the adverse/toxic effect of Antidepressants (Serotonin Reuptake Inhibitor/Antagonist).",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     MAO Inhibitors: May enhance the orthostatic hypotensive effect of Orthostatic Hypotension Producing Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Maraviroc: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Maraviroc.  Management: Reduce the adult dose of maraviroc to 150 mg twice daily when used with a strong CYP3A4 inhibitor.  Do not use maraviroc with strong CYP3A4 inhibitors in patients with Clcr less than 30 mL/min.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Methylene Blue: Nefazodone may enhance the serotonergic effect of Methylene Blue. This could result in serotonin syndrome.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     MethylPREDNISolone: CYP3A4 Inhibitors (Strong) may increase the serum concentration of MethylPREDNISolone.  Management: Consider methylprednisolone dose titration and/or adjustments in patients receiving strong CYP3A4 inhibitors (eg, azole antifungals, protease inhibitors) and monitor for  increased steroid related adverse effects.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Metoclopramide: Serotonin Modulators may enhance the adverse/toxic effect of Metoclopramide. This may be manifest as symptoms consistent with serotonin syndrome or neuroleptic malignant syndrome.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mifepristone: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Mifepristone.  Management: Limit mifepristone adult dose, when used for treatment of hyperglycemia in Cushing's syndrome, to a maximum of 300 mg/day when combined with a strong CYP3A4 inhibitor. Monitor for increased mifepristone toxicity regardless of dose or indication.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Nilotinib: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Nilotinib.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Nisoldipine: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Nisoldipine.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ospemifene: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Ospemifene.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Paricalcitol: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Paricalcitol.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pazopanib: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Pazopanib.  Management: Avoid concurrent use of pazopanib with strong inhibitors of CYP3A4 whenever possible.  If it is not possible to avoid such a combination, reduce pazopanib adult dose to 400 mg.  Further dose reductions may also be required.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Peginterferon Alfa-2b: May decrease the serum concentration of CYP2D6 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     P-glycoprotein/ABCB1 Substrates: P-glycoprotein/ABCB1 Inducers may decrease the serum concentration of P-glycoprotein/ABCB1 Substrates. P-glycoprotein inducers may also further limit the distribution of p-glycoprotein substrates to specific cells/tissues/organs where p-glycoprotein is present in large amounts (e.g., brain, T-lymphocytes, testes, etc.).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pimecrolimus: CYP3A4 Inhibitors (Strong) may decrease the metabolism of Pimecrolimus.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pimozide: Nefazodone may increase the serum concentration of Pimozide.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pomalidomide: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Pomalidomide.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ponatinib: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Ponatinib.  Management: Per ponatinib U.S. prescribing information, the starting dose of ponatinib should be reduced to 30 mg daily during treatment with any strong CYP3A4 inhibitor.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Prasugrel: CYP3A4 Inhibitors (Strong) may decrease serum concentrations of the active metabolite(s) of Prasugrel.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Propafenone: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Propafenone.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Protease Inhibitors: May increase the serum concentration of Nefazodone.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ranolazine: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Ranolazine.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Red Yeast Rice: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Red Yeast Rice. Specifically, concentrations of lovastatin and related compounds found in Red Yeast Rice may be increased.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Regorafenib: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Regorafenib.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Rivaroxaban: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Rivaroxaban.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     RomiDEPsin: CYP3A4 Inhibitors (Strong) may increase the serum concentration of RomiDEPsin.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ruxolitinib: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Ruxolitinib.  Management: Reduce ruxolitinib initial adult dose to 10 mg twice daily in patients receiving strong CYP3A4 inhibitors whose platelet count is 100*10^9/L or greater.  Avoid in patients with lower platelet count.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Salmeterol: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Salmeterol.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Saxagliptin: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Saxagliptin.  Management: Saxagliptin U.S. product labeling recommends limiting saxagliptin adult dose to 2.5 mg/day when used with a strong CYP3A4 inhibitor. Monitor for increased saxagliptin levels/effects. A similar recommendation is not made in the Canadian product labeling.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Selective Serotonin Reuptake Inhibitors: May enhance the serotonergic effect of Antidepressants (Serotonin Reuptake Inhibitor/Antagonist). This may cause serotonin syndrome.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Serotonin Modulators: May enhance the adverse/toxic effect of other Serotonin Modulators. The development of serotonin syndrome may occur.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sildenafil: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Sildenafil.  Management: When used for treatment of pulmonary arterial hypertension, use of sildenafil with strong CYP3A4 inhibitors should be avoided.  When used for erectile dysfunction, starting dose should be reduced to 25 mg.  Max dose with ritonavir is 25 mg per 48 hours.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Silodosin: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Silodosin.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Simvastatin: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Simvastatin.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     SORAfenib: CYP3A4 Inhibitors (Strong) may increase the serum concentration of SORAfenib.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tacrolimus (Systemic): Antidepressants (Serotonin Reuptake Inhibitor/Antagonist) may decrease the metabolism of Tacrolimus (Systemic).",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tacrolimus (Topical): Antidepressants (Serotonin Reuptake Inhibitor/Antagonist) may decrease the metabolism of Tacrolimus (Topical).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tadalafil: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Tadalafil.  Management: Recommendations regarding use of tadalafil in patients also receiving strong CYP3A4 inhibitors may vary based on indication and/or international labeling. Consult appropriate product labeling.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tamsulosin: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Tamsulosin.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ticagrelor: CYP3A4 Inhibitors (Strong) may decrease serum concentrations of the active metabolite(s) of Ticagrelor. CYP3A4 Inhibitors (Strong) may increase the serum concentration of Ticagrelor.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tocilizumab: May decrease the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tofacitinib: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Tofacitinib.  Management: Reduce the adult dose of tofacitinib to 5 mg daily in patients receiving strong CYP3A4 inhibitors.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tolterodine: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Tolterodine.  Management: The maximum recommended dose of long-acting tolterodine is 2 mg/day when used together with a strong CYP3A4 inhibitor.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tolvaptan: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Tolvaptan.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Toremifene: CYP3A4 Inhibitors (Strong) may enhance the adverse/toxic effect of Toremifene. CYP3A4 Inhibitors (Strong) may increase the serum concentration of Toremifene.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vardenafil: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Vardenafil.  Management: Recommendations regarding concomitant use of vardenafil with strong CYP3A4 inhibitors may vary depending on brand name (e.g., Levitra, Staxyn) or by international labeling. Consult appropriate product labeling for specific recommendations.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vemurafenib: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Vemurafenib.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vilazodone: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Vilazodone.  Management: Limit maximum adult vilazodone dose to 20 mg/day in patients receiving strong CYP3A4 inhibitors.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     VinCRIStine (Liposomal): CYP3A4 Inhibitors (Strong) may increase the serum concentration of VinCRIStine (Liposomal).",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Zuclopenthixol: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Zuclopenthixol.  Management: Consider zuclopenthixol dosage reduction with concomitant use of a strong CYP3A4 inhibitor (eg, ketoconazole) in poor CYP2D6 metabolizers or with strong CYP2D6 inhibitors (eg, paroxetine). Monitor for increased zuclopenthixol levels/toxicity.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block foi drugH1Div\" id=\"F1027109\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Food Interactions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Food delays absorption and decreases bioavailability by ~20%",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F200279\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F5722223\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Adverse effects were observed in some animal reproduction studies. When nefazodone is taken during pregnancy, an increased risk of major malformations has not been observed in the limited number of pregnancies studied (Einarson, 2003; Einarson, 2009). The long-term effects of",
"     <i>",
"      in utero",
"     </i>",
"     exposure to nefazodone on infant development and behavior are not known.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     The ACOG recommends that therapy with antidepressants during pregnancy be individualized; treatment of depression during pregnancy should incorporate the clinical expertise of the mental health clinician, obstetrician, primary healthcare provider, and pediatrician. According to the American Psychiatric Association (APA), the risks of medication treatment should be weighed against other treatment options and untreated depression. Consideration should be given to using agents with safety data in pregnancy. For women who discontinue antidepressant medications during pregnancy and who may be at high risk for postpartum depression, the medications can be restarted following delivery. Treatment algorithms have been developed by the ACOG and the APA for the management of depression in women prior to conception and during pregnancy (ACOG, 2008; APA, 2010; Yonkers, 2009).",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F7825537\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Blood pressure, mental status, liver enzymes, clinical signs and symptoms of liver failure (discontinue nefazodone if clinical signs or symptoms suggestive of liver failure occur or if serum AST or ALT levels increase to &ge;3 times the upper limit of normal; do not reinitiate nefazodone in these patients). Monitor patient periodically for symptom resolution; monitor for worsening depression, suicidality, and associated behaviors (especially at the beginning of therapy or when doses are increased or decreased).",
"    </p>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F1027112\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Inhibits neuronal reuptake of serotonin and norepinephrine; also blocks 5-HT",
"     <sub>",
"      2",
"     </sub>",
"     and alpha",
"     <sub>",
"      1",
"     </sub>",
"     receptors; has no significant affinity for alpha",
"     <sub>",
"      2",
"     </sub>",
"     , beta-adrenergic, 5-HT",
"     <sub>",
"      1A",
"     </sub>",
"     , cholinergic, dopaminergic, or benzodiazepine receptors",
"    </p>",
"   </div>",
"   <div class=\"block phd drugH1Div\" id=\"F7710965\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Maximum antidepressant effect: Adults: 4-6 weeks",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F1027115\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacokinetics (Adult data unless noted)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Absorption: Oral: Rapid and complete",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Distribution: Distributes into CNS; V",
"     <sub>",
"      d",
"     </sub>",
"     : 0.22-0.87 L/kg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Protein binding: &gt;99%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Metabolism: Hepatic, via N-dealkylation and aliphatic and aromatic hydroxylation, to three active metabolites: A triazoledione metabolite, hydroxynefazodone, and m-chlorophenylpiperazine (mCPP); other metabolites have also been identified but not tested for activity",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Bioavailability: Oral: Absolute: 20% (variable); AUC increased by 25% in patients with cirrhosis of the liver",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life elimination:",
"     <b>",
"      Note:",
"     </b>",
"     Active metabolites persist longer in all populations.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Children: 4.1 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Adolescents: 3.9 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Adults: 2-4 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Time to peak serum concentration:",
"     <b>",
"      Note:",
"     </b>",
"     Prolonged in presence of food",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Children and Adolescents: 0.5 -1 hour",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Adults: 1 hour",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Elimination: Primarily urine, as metabolites (&lt;1% is eliminated as unchanged drug in urine); feces",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Dialysis: Not likely to be of benefit",
"    </p>",
"   </div>",
"   <div class=\"block pai drugH1Div\" id=\"F7715543\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Patient Information",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?41/61/42965?source=see_link\">",
"      see \"Nefazodone: Patient drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Read the patient Medication Guide that you receive with each prescription and refill of citalopram. An increased risk of suicidal thinking and behavior has been reported with the use of antidepressants in children, adolescents, and young adults (18-24 years of age). Notify physician if you feel more depressed, have thoughts of suicide, or become more agitated or irritable. Avoid alcohol, caffeine, CNS stimulants, tryptophan supplements, and the herbal medicine St John's wort. May cause dizziness or drowsiness and impair ability to perform activities requiring mental alertness or physical coordination; may cause dry mouth. Nefazodone may cause liver abnormalities ranging from increased liver enzymes to cases of liver failure resulting in death or liver transplantation; notify physician if you have yellowing of skin or the whites of eyes, lack of appetite for several days or longer, unusually dark urine, severe nausea, abdominal pain, or general weakness. Notify physician if you have any changes in vision or eye pain; hives, rash, or other allergic reactions. Discontinue use and consult physician immediately if prolonged or inappropriate erections occur. Some medicines should not be taken with nefazodone or should not be taken for a while after nefazodone has been discontinued; report the use of other medications, nonprescription medications, and herbal or natural products to your physician and pharmacist. It may take up to 4-6 weeks to see the full therapeutic effects from this medication. Take as directed; do not alter dose or frequency without consulting prescriber; avoid abrupt discontinuation.",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      ACOG Committee on Practice Bulletins--Obstetrics, \"ACOG Practice Bulletin: Clinical Management Guidelines for Obstetrician-Gynecologists Number 92, April 2008 (Replaces Practice Bulletin Number 87, November 2007). Use of Psychiatric Medications During Pregnancy and Lactation,\"",
"      <i>",
"       Obstet Gynecol",
"      </i>",
"      , 2008, 111(4):1001-20.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?1/7/1145/abstract-text/18378767/pubmed\" id=\"18378767\" target=\"_blank\">",
"        18378767",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      American Psychiatric Association, \"Treatment Recommendations for Patients With Major Depressive Disorder,\" 3rd ed, May 2010. Available at file://www.psychiatryonline.com/pracGuide/pracGuideTopic_7.aspx",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Dodd S, Maguire KP, Burrows GD, et al, \"Nefazodone in the Breast Milk of Nursing Mothers: A Report of Two Patients,\"",
"      <i>",
"       J Clin Psychopharmacol",
"      </i>",
"      , 2000, 20(6):717-8.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?1/7/1145/abstract-text/11106156/pubmed\" id=\"11106156\" target=\"_blank\">",
"        11106156",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Dopheide JA, \"Recognizing and Treating Depression in Children and Adolescents,\"",
"      <i>",
"       Am J Health Syst Pharm",
"      </i>",
"      , 2006, 63(3):233-43.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?1/7/1145/abstract-text/16434782/pubmed\" id=\"16434782\" target=\"_blank\">",
"        16434782",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Dubitsky GM, \"Review and Evaluation of Clinical Data: Placebo-Controlled Antidepressant Studies in Pediatric Patients. Available at www.fda.gov/ohrms/dockets/ac/04/briefing/20044065b1-08-TAB06-Dubitsky-Review.pdf. Accessed on April 21, 2009.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Einarson A, Bonari L, Voyer-Lavigne S, et al, \"A Multicentre Prospective Controlled Study to Determine the Safety of Trazodone and Nefazodone Use During Pregnancy,\"",
"      <i>",
"       Can J Psychiatry",
"      </i>",
"      , 2003, 48(2):106-10.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?1/7/1145/abstract-text/12655908/pubmed\" id=\"12655908\" target=\"_blank\">",
"        12655908",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Einarson A, Choi J, Einarson TR, et al, \"Incidence of Major Malformations in Infants Following Antidepressant Exposure in Pregnancy: Results of a Large Prospective Cohort Study,\"",
"      <i>",
"       Can J Psychiatry",
"      </i>",
"      , 2009, 54(4):242-6.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?1/7/1145/abstract-text/19321030/pubmed\" id=\"19321030\" target=\"_blank\">",
"        19321030",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Emslie GJ, Findling RL, Rynn MA, et al, \"Efficacy and Safety of Nefazodone in the Treatment of Adolescents with Major Depressive Disorder,\"",
"      <i>",
"       J Child Adolesc Psychopharmacol",
"      </i>",
"      , 2000, 12(4):299.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Findling RL, McNamara NK, Stansbrey RJ, et al, \"The Relevance of Pharmacokinetic Studies in Designing Efficacy Trials in Juvenile Major Depression,\"",
"      <i>",
"       J Child Adolesc Psychopharmacol",
"      </i>",
"      , 2006, 16(1-2):131-45.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?1/7/1145/abstract-text/16553534/pubmed\" id=\"16553534\" target=\"_blank\">",
"        16553534",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Findling RL, Preskorn SH, Marcus RN, et al, \"Nefazodone Pharmacokinetics in Depressed Children and Adolescents,\"",
"      <i>",
"       J Am Acad Child Adolesc Psychiatry",
"      </i>",
"      , 2000, 39(8):1008-16.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?1/7/1145/abstract-text/10939229/pubmed\" id=\"10939229\" target=\"_blank\">",
"        10939229",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Goodnick PJ, Jorge CA, Hunter T, et al, \"Nefazodone Treatment of Adolescent Depression: An Open-Label Study of Response and Biochemistry,\"",
"      <i>",
"       Ann Clin Psychiatry",
"      </i>",
"      , 2000, 12(2):97-100.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?1/7/1145/abstract-text/10907801/pubmed\" id=\"10907801\" target=\"_blank\">",
"        10907801",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Laughren TP, \"Memorandum to Members of PDAC and Peds AC: Background Comments for February 2, 2004 Meeting of Psychopharmacological Advisory Committee (PDAC) and Pediatric Subcommittee of the Anti-Infective Drugs Advisory Committee (Peds AC).\" Available at www.fda.gov/ohrms/dockets/ac/04/briefing/2004&ndash;4065b1&ndash;04-Tab02-Laughren-Jan5.pdf. Accessed on April 21, 2009.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Wagner KD, \"Pharmacotherapy for Major Depression in Children and Adolescents,\"",
"      <i>",
"       Prog Neuropsychopharmacol Biol Psychiatry",
"      </i>",
"      , 2005, 29(5):819-26.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?1/7/1145/abstract-text/15908090/pubmed\" id=\"15908090\" target=\"_blank\">",
"        15908090",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Wilens TE, Spencer TJ, Biederman J, et al, &ldquo;Case Study: Nefazodone for Juvenile Mood Disorders,&rdquo;",
"      <i>",
"       J Am Acad Child Adolesc Psychiatry",
"      </i>",
"      , 1997, 36(4):481-5.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Yapp P, Ilett KF, Kristensen JH, et al, \"Drowsiness and Poor Feeding in a Breast-Fed Infant: Association With Nefazodone and Its Metabolites,\"",
"      <i>",
"       Ann Pharmacother",
"      </i>",
"      , 2000, 34(11):1269-72.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?1/7/1145/abstract-text/11098340/pubmed\" id=\"11098340\" target=\"_blank\">",
"        11098340",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Yonkers KA, Wisner KL, Stewart DE, et al, &ldquo;The Management of Depression During Pregnancy: A Report From the American Psychiatric Association and the American College of Obstetricians and Gynecologists,&rdquo;",
"      <i>",
"       Obstet Gynecol",
"      </i>",
"      , 2009, 114(3):703-13.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?1/7/1145/abstract-text/19701065/pubmed\" id=\"19701065\" target=\"_blank\">",
"        19701065",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 13049 Version 47.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0503-218.28.111.102-3C51B1EE61-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f1_7_1145=[""].join("\n");
var outline_f1_7_1145=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5709167\">",
"      ALERT: U.S. Boxed Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1027088\">",
"      Therapeutic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1027122\">",
"      Dosing: Usual",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F200284\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F200268\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7874745\">",
"      Medication Guide",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1027126\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1027110\">",
"      Stability",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1027089\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F200348\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F200345\">",
"      Adverse Reactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1027094\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7710964\">",
"      Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1027095\">",
"      Warnings",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F200333\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F200277\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1027109\">",
"      Food Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F200279\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5722223\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7825537\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1027112\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7710965\">",
"      Pharmacodynamics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1027115\">",
"      Pharmacokinetics (Adult data unless noted)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7715543\">",
"      Patient Information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_PED/13049\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_PED/13049|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?2/0/2057?source=related_link\">",
"      Nefazodone: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?41/61/42965?source=related_link\">",
"      Nefazodone: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f1_7_1146="Platelet biology";
var content_f1_7_1146=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Platelet biology",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?1/7/1146/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?1/7/1146/contributors\">",
"     Charles S Abrams, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?1/7/1146/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?1/7/1146/contributors\">",
"     Lawrence LK Leung, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?1/7/1146/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?1/7/1146/contributors\">",
"     Jennifer S Tirnauer, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?1/7/1146/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Feb 22, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The platelet is a circulating anucleate disc-shaped cell, responsible for initiation of the hemostatic mechanisms that repair injury to the vascular endothelium. The four major platelet functions include the following (",
"    <a class=\"graphic graphic_figure graphicRef81908 \" href=\"UTD.htm?7/17/7446\">",
"     figure 1",
"    </a>",
"    ):",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Platelet adherence",
"     </li>",
"     <li>",
"      Platelet activation and secretion",
"     </li>",
"     <li>",
"      Platelet aggregation [",
"      <a class=\"abstract\" href=\"UTD.htm?1/7/1146/abstract/1\">",
"       1",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Interaction with coagulation factors",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The biology underlying these platelet functions will be discussed here. Discussions of platelet function testing as well as congenital and acquired disorders of platelet function and an overview of hemostasis are presented separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/59/23482?source=see_link\">",
"     \"Platelet function testing\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/9/29850?source=see_link\">",
"     \"Congenital and acquired disorders of platelet function\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/35/27194?source=see_link\">",
"     \"Overview of hemostasis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The biology of the platelet precursor cells (megakaryocytes) and platelet formation are discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/22/4458?source=see_link\">",
"     \"Megakaryocyte biology and the production of platelets\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Platelet functions other than those enumerated above (eg, the role of platelets in inflammatory and immune responses, as well as specific disorders characterized by local or systemic platelet activation) have been reviewed elsewhere [",
"    <a class=\"abstract\" href=\"UTD.htm?1/7/1146/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14905808\">",
"    <span class=\"h1\">",
"     NORMAL VALUES",
"    </span>",
"    &nbsp;&mdash;&nbsp;The normal range for platelet counts in the adult is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/19/15674?source=see_link&amp;anchor=H2#H2\">",
"     \"Approach to the adult patient with thrombocytopenia\", section on 'Definitions and normal values'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/6/24681?source=see_link&amp;anchor=H2#H2\">",
"     \"Approach to the patient with thrombocytosis\", section on 'Definitions'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     OVERVIEW OF PLATELET FUNCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Circulating platelets do not normally encounter the connective tissue matrix that lies beneath vascular endothelial cells. Once a break within the integrity of this vascular lining occurs, platelets are exposed to, and interact with, collagen fibrils. Platelet interactions with collagen not only provide a surface for platelet adhesion, but also serve as a strong stimulus for platelet activation. This results in signaling pathways that induce platelets to change their shape, spreading along the collagen fibrils and to secrete thromboxane A2 and ADP into the circulation. The released thromboxane A2 and ADP stimulate neighboring platelets, causing them to become activated and in turn to secrete additional thromboxane A2 and ADP.",
"   </p>",
"   <p>",
"    Activated platelets not only secrete thromboxane A2 and ADP, they also directly bind to the circulating coagulation protein fibrinogen, via the abundant platelet integrin glycoprotein",
"    <span class=\"nowrap\">",
"     (GP)IIb/IIIa",
"    </span>",
"    (also known as",
"    <span class=\"nowrap\">",
"     alphaIIb/beta3)",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?1/7/1146/abstract/3,4\">",
"     3,4",
"    </a>",
"    ]. Fibrinogen can simultaneously bind two",
"    <span class=\"nowrap\">",
"     GPIIb/IIIa",
"    </span>",
"    receptors and can therefore function as a link between two platelets (",
"    <a class=\"graphic graphic_figure graphicRef81908 \" href=\"UTD.htm?7/17/7446\">",
"     figure 1",
"    </a>",
"    ). This platelet-fibrinogen-platelet connection initiates the process of platelet aggregation [",
"    <a class=\"abstract\" href=\"UTD.htm?1/7/1146/abstract/1\">",
"     1",
"    </a>",
"    ]. Since each platelet has 40,000 to 80,000 copies of",
"    <span class=\"nowrap\">",
"     GPIIb/IIIa",
"    </span>",
"    on its surface, very large clumps (or aggregates) of platelets can assemble at the site of platelet activation [",
"    <a class=\"abstract\" href=\"UTD.htm?1/7/1146/abstract/5,6\">",
"     5,6",
"    </a>",
"    ]. A cross-linked fibrin clot ultimately stabilizes the growing platelet aggregate. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/1/8218?source=see_link&amp;anchor=H3#H3\">",
"     \"Disorders of fibrinogen\", section on 'Fibrinogen structure and function'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In addition to collagen, ADP, and thromboxane A2, other agonists can activate platelets at sites of vascular injury. Tissue factor, which is expressed on all non-vascular cells, is exposed to circulating blood upon disruption of the protective endothelial layer of the vasculature. Tissue factor can interact with factor VIIa to promote local coagulation, and ultimately the generation of thrombin, the most potent of the platelet agonists. Platelets facilitate this process by providing procoagulant phospholipids that accelerate thrombin generation (",
"    <a class=\"graphic graphic_figure graphicRef57152 \" href=\"UTD.htm?22/40/23170\">",
"     figure 2",
"    </a>",
"    ). Consequently, platelet activation and fibrin deposition are intimately linked, maximizing the growth and strength of the hemostatic plug. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/35/27194?source=see_link&amp;anchor=H11#H11\">",
"     \"Overview of hemostasis\", section on 'Clotting cascade and propagation of the clot'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Drugs with antiplatelet actions",
"    </span>",
"    &nbsp;&mdash;&nbsp;A number of drugs are used specifically for their ability to interfere with platelet function, especially in cardiology and vascular medicine. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/49/35610?source=see_link&amp;anchor=H3#H3\">",
"     \"Antiplatelet agents in acute ST elevation myocardial infarction\", section on 'Classification of antiplatelet agents'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/9/29850?source=see_link&amp;anchor=H14#H14\">",
"     \"Congenital and acquired disorders of platelet function\", section on 'Therapeutic antiplatelet agents'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The following four mechanisms are discussed in the relevant sections of this review:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Interference with prostaglandin synthesis (eg,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"       aspirin",
"      </a>",
"      ) (see",
"      <a class=\"local\" href=\"#H21\">",
"       'Eicosanoids and arachidonate'",
"      </a>",
"      below)",
"     </li>",
"     <li>",
"      Interference with cyclic AMP (eg,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?40/25/41366?source=see_link\">",
"       dipyridamole",
"      </a>",
"      ) (see",
"      <a class=\"local\" href=\"#H24\">",
"       'Cyclic AMP and cyclic GMP'",
"      </a>",
"      below)",
"     </li>",
"     <li>",
"      Interference with ADP binding (eg,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?34/9/34969?source=see_link\">",
"       clopidogrel",
"      </a>",
"      ) (see",
"      <a class=\"local\" href=\"#H10\">",
"       'P2Y1 and P2Y12 (ADP receptors)'",
"      </a>",
"      below)",
"     </li>",
"     <li>",
"      Inhibition of the",
"      <span class=\"nowrap\">",
"       GPIIb/IIIa",
"      </span>",
"      receptor (eg,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?6/15/6392?source=see_link\">",
"       abciximab",
"      </a>",
"      ) (see",
"      <a class=\"local\" href=\"#H30\">",
"       'GPIIb/IIIa activation'",
"      </a>",
"      below)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Other drugs used in cardiovascular medicine",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    as antithrombotic agents (eg, nitrates,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    , thrombolytic agents), may also have a direct or indirect effect on platelet function. These agents are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/32/3594?source=see_link\">",
"     \"Effect of cardiac drugs on platelet function\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Certain classes of drugs, including some of those listed above, may also have toxic effects on the bone marrow, the developing megakaryocyte,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    the mature platelet through a number of different mechanisms, including, but not limited to, antibody formation (eg,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?6/15/6392?source=see_link\">",
"     abciximab",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/9/34969?source=see_link\">",
"     clopidogrel",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    ). These are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/40/1673?source=see_link&amp;anchor=H2#H2\">",
"     \"Drug-induced thrombocytopenia\", section on 'Mechanisms'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/59/40890?source=see_link\">",
"     \"Heparin-induced thrombocytopenia\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/61/36826?source=see_link&amp;anchor=H112796005#H112796005\">",
"     \"Causes of thrombotic thrombocytopenic purpura-hemolytic uremic syndrome in adults\", section on 'Antiplatelet agents'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     PLATELET AGONISTS AND THEIR RECEPTORS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most platelet agonists, including thrombin, ADP, epinephrine, and thromboxane A2, stimulate cell surface receptors that span the platelet membrane. The cytoplasmic surface of these receptors interacts with heterotrimeric G-proteins. These G proteins consist of a GTP-binding alpha subunit and beta-gamma heterodimers (",
"    <a class=\"graphic graphic_figure graphicRef70545 \" href=\"UTD.htm?27/54/28527\">",
"     figure 3",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?1/7/1146/abstract/7\">",
"     7",
"    </a>",
"    ]. When GDP is bound to the alpha subunit, the G-proteins are inactive. Agonist-stimulated receptors promote the replacement of GDP with GTP, switching on the G protein. G protein-coupled receptors typically have a limited duration of activity, after which they are turned off by phosphorylation and, in some cases, cleared from the cell surface by endocytosis.",
"   </p>",
"   <p>",
"    The subclass of their alpha subunit characterizes the function of different G-protein heterotrimers, and consequently the role of the receptors that associate with them. Receptors that associate with G-proteins containing a G alpha-q subunit stimulate phosphoinositide hydrolysis by phospholipase Cbeta (PLCbeta) [",
"    <a class=\"abstract\" href=\"UTD.htm?1/7/1146/abstract/8\">",
"     8",
"    </a>",
"    ]. Receptors coupled with G alpha-subclass s stimulate cyclic AMP (cAMP) formation, while those associated with G alpha-subclass i inhibit the production of cAMP [",
"    <a class=\"abstract\" href=\"UTD.htm?1/7/1146/abstract/9\">",
"     9",
"    </a>",
"    ]. G alpha-subclass i-coupled receptors also stimulate phosphatidylinositol 3-kinase (PI3Kgamma) and phospholipase Cbeta. Finally, G alpha-subclass",
"    <span class=\"nowrap\">",
"     12/13-coupled",
"    </span>",
"    receptors stimulate signaling pathways leading to platelet shape-change and phosphoinositide hydrolysis [",
"    <a class=\"abstract\" href=\"UTD.htm?1/7/1146/abstract/10\">",
"     10",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Platelet agonists are sometimes classified as strong or weak, presumably reflecting differences in the sets of intracellular signals they evoke. Strong agonists (eg, thrombin, collagen) potently stimulate phosphoinositide hydrolysis and are relatively unaffected by inhibitors of cyclooxygenase (eg,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    ). The weaker agonists (eg, ADP, epinephrine) have little or no ability to cause phosphoinositide hydrolysis and are more dependent on thromboxane A2 formation for their effects.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     PAR1 (thrombin receptor)",
"    </span>",
"    &nbsp;&mdash;&nbsp;Thrombin is arguably the most potent activator of platelets. When added at picomolar (ie, 10",
"    <sup>",
"     -12",
"    </sup>",
"    Molar) concentrations to platelets in vitro, it causes phosphoinositide hydrolysis, thromboxane A2 formation, protein phosphorylation, and an increase in the cytosolic free Ca",
"    <sup>",
"     ++",
"    </sup>",
"    concentration. These pathways lead to platelet shape change, aggregation, and granule secretion [",
"    <a class=\"abstract\" href=\"UTD.htm?1/7/1146/abstract/8\">",
"     8",
"    </a>",
"    ]. Thrombin receptors are activated by cleavage at a specific site, exposing a new N-terminus (the \"tethered ligand\") that interacts with residues in the second extracellular loop of the receptor [",
"    <a class=\"abstract\" href=\"UTD.htm?1/7/1146/abstract/11\">",
"     11",
"    </a>",
"    ]. This interaction results in the activation of the G-proteins on the cytoplasmic surface of the receptor, and consequently additional signaling events.",
"   </p>",
"   <p>",
"    The primary thrombin receptor in human platelets is known as the Protease-Activated Receptor-1, or PAR-1, to distinguish it from three closely related receptors, PAR-2, PAR-3, and PAR-4. There are approximately 2000 copies of the G alpha-subclass q-, or G alpha-subclass",
"    <span class=\"nowrap\">",
"     12/13-,",
"    </span>",
"    coupled PAR-1 on the surface of human platelets [",
"    <a class=\"abstract\" href=\"UTD.htm?1/7/1146/abstract/12\">",
"     12",
"    </a>",
"    ]. Since platelets synthesize very little protein, they have no real ability to replace cleaved receptors with new ones. Therefore, human platelets usually respond to thrombin only once.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h3\">",
"     PAR-1 antagonists",
"    </span>",
"    &nbsp;&mdash;&nbsp;Vorapaxar and Atopaxar are orally active selective PAR-1 antagonists that block thrombin-mediated platelet activation without interfering with thrombin-mediated cleavage of fibrinogen [",
"    <a class=\"abstract\" href=\"UTD.htm?1/7/1146/abstract/13\">",
"     13",
"    </a>",
"    ]. A number of trials have demonstrated their efficacy in preventing thrombosis in patients undergoing percutaneous coronary intervention as well as in patients with atherothrombotic disease, although at the cost of increased bleeding. These studies are discussed in depth separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/37/41562?source=see_link&amp;anchor=H17#H17\">",
"     \"Antithrombotic therapy for intracoronary stent implantation: Clinical trials\", section on 'PAR-1 antagonists'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/60/40906?source=see_link&amp;anchor=H870616861#H870616861\">",
"     \"Secondary prevention of cardiovascular disease\", section on 'Vorapaxar'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     GP1a/IIa and GPVI (collagen receptors)",
"    </span>",
"    &nbsp;&mdash;&nbsp;Subendothelial collagen has been long recognized as an important initiator of platelet responses, serving both a substrate for platelet adhesion and as a potent platelet agonist. The interaction between platelets and collagen is complex. The collagen responses are accompanied by phosphoinositide hydrolysis, thromboxane A2 formation, protein phosphorylation, and an increase in cytosolic Ca",
"    <sup>",
"     ++",
"    </sup>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?1/7/1146/abstract/14\">",
"     14",
"    </a>",
"    ]. As with thrombin, cyclooxygenase inhibitors retard, but do not eliminate, platelet responses to collagen, suggesting that thromboxane A2 formation is not essential for this response.",
"   </p>",
"   <p>",
"    Platelets possess two different types of collagen receptors [",
"    <a class=\"abstract\" href=\"UTD.htm?1/7/1146/abstract/14\">",
"     14",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Glycoprotein",
"      <span class=\"nowrap\">",
"       Ia/IIa",
"      </span>",
"     </li>",
"     <li>",
"      Glycoprotein VI",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    These are discussed in more detail below.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h3\">",
"     Glycoprotein Ia/IIa",
"    </span>",
"    &nbsp;&mdash;&nbsp;The first collagen receptor, alpha2beta1 (also known as VLA-2, platelet",
"    <span class=\"nowrap\">",
"     GPIa/IIa),",
"    </span>",
"    is a member of the integrin family of adhesion receptors and primarily serves as an anchor for platelets to attach to collagen exposed after disruptions in the vascular endothelial layer (",
"    <a class=\"graphic graphic_figure graphicRef81908 \" href=\"UTD.htm?7/17/7446\">",
"     figure 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?1/7/1146/abstract/15\">",
"     15",
"    </a>",
"    ]. A patient with an acquired deficiency of this integrin",
"    <span class=\"nowrap\">",
"     (GPIa/IIa)",
"    </span>",
"    exhibited a mild bleeding diathesis [",
"    <a class=\"abstract\" href=\"UTD.htm?1/7/1146/abstract/16\">",
"     16",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h3\">",
"     Glycoprotein VI",
"    </span>",
"    &nbsp;&mdash;&nbsp;The identification of a patient with a mild bleeding diathesis who had normal amounts of",
"    <span class=\"nowrap\">",
"     GPIa/IIa,",
"    </span>",
"    but markedly reduced amounts of platelet glycoprotein VI (GPVI), suggested that GPVI also served as an important collagen receptor [",
"    <a class=\"abstract\" href=\"UTD.htm?1/7/1146/abstract/17\">",
"     17",
"    </a>",
"    ]. Experiments using receptor-blocking antibodies, heterologously expressed receptors, and genetically altered mice have elucidated the relative roles of each of these proteins [",
"    <a class=\"abstract\" href=\"UTD.htm?1/7/1146/abstract/15,18\">",
"     15,18",
"    </a>",
"    ]. GPVI serves as the primary collagen agonist receptor and is responsible for collagen-induced platelet aggregation and secretion. It also can serve as a collagen-adhesion receptor, at least under low shear conditions.",
"   </p>",
"   <p>",
"    One patient with a mild bleeding disorder, a moderately reduced platelet count, and an autoantibody that bound to GPVI-positive platelets has been described [",
"    <a class=\"abstract\" href=\"UTD.htm?1/7/1146/abstract/19\">",
"     19",
"    </a>",
"    ]. This patient's platelets failed to become activated in response to collagen and inefficiently adhered to immobilized collagen under conditions of arterial shear. Other patients with a more severe bleeding disorder, often associated with immune dysfunction or autoimmune disease have been described [",
"    <a class=\"abstract\" href=\"UTD.htm?1/7/1146/abstract/20\">",
"     20",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     P2Y1 and P2Y12 (ADP receptors)",
"    </span>",
"    &nbsp;&mdash;&nbsp;Adenosine diphosphate (ADP) is stored in platelet dense granules and released upon platelet activation. ADP interacts with two G-protein-coupled platelet receptors, P2Y",
"    <sub>",
"     1",
"    </sub>",
"    and P2Y",
"    <sub>",
"     12",
"    </sub>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?1/7/1146/abstract/21,22\">",
"     21,22",
"    </a>",
"    ]. These receptors display activity to a range of pyrimidine and purine agonists [",
"    <a class=\"abstract\" href=\"UTD.htm?1/7/1146/abstract/23\">",
"     23",
"    </a>",
"    ]. When ADP stimulates the platelet G alpha-subclass q-coupled P2Y",
"    <sub>",
"     1",
"    </sub>",
"    receptor, it causes phosphoinositide hydrolysis, thromboxane A2 formation, protein phosphorylation, and an increase in cytosolic Ca",
"    <sup>",
"     ++",
"    </sup>",
"    . ADP also stimulates the G alpha-subclass i-coupled P2Y",
"    <sub>",
"     12",
"    </sub>",
"    receptor that inhibits cAMP formation. Studies using platelets derived from knockout mice, or several different ADP receptor antagonists, have demonstrated that simultaneous stimulation of both P2Y",
"    <sub>",
"     1",
"    </sub>",
"    and P2Y",
"    <sub>",
"     12",
"    </sub>",
"    is required for the full ADP-response in platelets [",
"    <a class=\"abstract\" href=\"UTD.htm?1/7/1146/abstract/21\">",
"     21",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12878572\">",
"    <span class=\"h3\">",
"     Abnormalities of the platelet P2Y12 receptor",
"    </span>",
"    &nbsp;&mdash;&nbsp;Congenital deficiency of the P2Y",
"    <sub>",
"     12",
"    </sub>",
"    receptor is an autosomal recessive disorder associated with excessive bleeding, prolonged bleeding time, reversible platelet aggregation in response to weak agonists, impaired aggregation in response to low concentrations of collagen or thrombin, and, most typically, failure to achieve full and irreversible platelet aggregation to ADP, even at very high concentrations [",
"    <a class=\"abstract\" href=\"UTD.htm?1/7/1146/abstract/24\">",
"     24",
"    </a>",
"    ]. A variety of different mutations in the P2Y",
"    <sub>",
"     12",
"    </sub>",
"    receptor have been described, although they are all extremely rare [",
"    <a class=\"abstract\" href=\"UTD.htm?1/7/1146/abstract/23\">",
"     23",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The platelet P2Y",
"    <sub>",
"     12",
"    </sub>",
"    receptor can be inhibited by several drugs, which include the following:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?34/9/34969?source=see_link\">",
"       Clopidogrel",
"      </a>",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?34/27/35255?source=see_link\">",
"       Ticlopidine",
"      </a>",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?26/63/27639?source=see_link\">",
"       Prasugrel",
"      </a>",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?38/0/38919?source=see_link\">",
"       Ticagrelor",
"      </a>",
"     </li>",
"     <li>",
"      Cangrelor",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    These are discussed in more detail below.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h3\">",
"     Clopidogrel and ticlopidine",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several patients with bleeding defects have been described whose platelets show greatly diminished responsiveness to ADP [",
"    <a class=\"abstract\" href=\"UTD.htm?1/7/1146/abstract/25\">",
"     25",
"    </a>",
"    ]. This phenotype is not dissimilar from that produced by the thienopyridine antiplatelet agents",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/27/35255?source=see_link\">",
"     ticlopidine",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/9/34969?source=see_link\">",
"     clopidogrel",
"    </a>",
"    . Both are prodrugs that depend on metabolism by cytochrome P450 isoenzymes for their anti-platelet effects. Both ticlopidine and clopidogrel have been shown to inhibit platelet aggregation ex vivo and to prolong the bleeding time in humans. The degree of prolongation of the bleeding time is equivalent to or greater than that of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    , and the effect of thienopyridines and aspirin appears additive. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/20/39242?source=see_link&amp;anchor=H15#H15\">",
"     \"Antiplatelet agents in acute non-ST elevation acute coronary syndromes\", section on 'Platelet P2Y12 receptor blockers'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Effects of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/27/35255?source=see_link\">",
"     ticlopidine",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/9/34969?source=see_link\">",
"     clopidogrel",
"    </a>",
"    on platelet aggregation and the bleeding time may be seen within 24 to 48 hours of the first dose, but are not maximal for four to six days. Moreover, the effects may last for 4 to 10 days after the drugs have been discontinued. This may be explained by their extended half-life after multiple dosing or by irreversible effects on platelets.",
"   </p>",
"   <p>",
"    Although the target of these two drugs was initially elusive, it was ultimately proven that their metabolites block the platelet P2Y",
"    <sub>",
"     12",
"    </sub>",
"    receptor. Ex vivo studies indicate that",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/27/35255?source=see_link\">",
"     ticlopidine",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/9/34969?source=see_link\">",
"     clopidogrel",
"    </a>",
"    inhibit ADP-mediated signaling, and thereby indirectly impair fibrinogen binding to its platelet receptor,",
"    <span class=\"nowrap\">",
"     GPIIb/IIIa,",
"    </span>",
"    and inhibit platelet aggregation in response to many agonists, particularly ADP. The effect on ADP-induced platelet aggregation seems to account for the observed decrease in responses to low concentrations of other agonists, since ADP released from dense granules plays a role in those responses. Consistent with this hypothesis, aggregation in response to high concentrations of thrombin or collagen are normal.",
"   </p>",
"   <p>",
"    Polymorphisms within the P2Y",
"    <sub>",
"     12",
"    </sub>",
"    gene or the cytochrome P450 system may be responsible for reduced effectiveness of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/9/34969?source=see_link\">",
"     clopidogrel",
"    </a>",
"    in patients with cardiovascular disease, with a resultant increased risk for vascular events [",
"    <a class=\"abstract\" href=\"UTD.htm?1/7/1146/abstract/26\">",
"     26",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/34/37418?source=see_link&amp;anchor=H2#H2\">",
"     \"Nonresponse and resistance to clopidogrel\", section on 'Definitions'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h3\">",
"     Prasugrel",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?26/63/27639?source=see_link\">",
"     Prasugrel",
"    </a>",
"    is a third-generation orally active thienopyridine that also must be converted to an active metabolite by the cytochrome P450 (CYP) system. However, its activation is not adversely affected by the common CYP polymorphisms that can inhibit the effectiveness of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/9/34969?source=see_link\">",
"     clopidogrel",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?1/7/1146/abstract/27-29\">",
"     27-29",
"    </a>",
"    ]. The use of prasugrel to reduce the risk of thrombotic cardiovascular events in patients with acute coronary syndrome being managed with coronary artery stents is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/20/39242?source=see_link&amp;anchor=H22#H22\">",
"     \"Antiplatelet agents in acute non-ST elevation acute coronary syndromes\", section on 'Prasugrel'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2477744\">",
"    <span class=\"h3\">",
"     Ticagrelor",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/0/38919?source=see_link\">",
"     Ticagrelor",
"    </a>",
"    is an orally active P2Y",
"    <sub>",
"     12",
"    </sub>",
"    receptor blocker that does not require metabolic conversion to an active form [",
"    <a class=\"abstract\" href=\"UTD.htm?1/7/1146/abstract/22\">",
"     22",
"    </a>",
"    ]. Ticagrelor binds directly to the P2Y",
"    <sub>",
"     12",
"    </sub>",
"    receptor and can more completely inhibit the sustained platelet aggregation response to ADP than",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/9/34969?source=see_link\">",
"     clopidogrel",
"    </a>",
"    . The use of ticagrelor for reducing thrombotic cardiovascular events in patients with acute coronary syndromes is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/20/39242?source=see_link&amp;anchor=H26#H26\">",
"     \"Antiplatelet agents in acute non-ST elevation acute coronary syndromes\", section on 'Ticagrelor'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/49/35610?source=see_link&amp;anchor=H13#H13\">",
"     \"Antiplatelet agents in acute ST elevation myocardial infarction\", section on 'P2Y12 receptor blockers'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h3\">",
"     Other P2Y12 inhibitors",
"    </span>",
"    &nbsp;&mdash;&nbsp;Other agents capable of blocking the platelet P2Y",
"    <sub>",
"     12",
"    </sub>",
"    receptor have either been approved or are in clinical trials [",
"    <a class=\"abstract\" href=\"UTD.htm?1/7/1146/abstract/30\">",
"     30",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1417150\">",
"    <span class=\"h4\">",
"     Cangrelor",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cangrelor is a nonthienopyridine adenosine triphosphate analogue that blocks the P2Y",
"    <sub>",
"     12",
"    </sub>",
"    receptor. Potential advantages of this intravenously administered agent are its rapid onset of action and rapid return of platelet function after cessation. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/37/41562?source=see_link&amp;anchor=H9#H9\">",
"     \"Antithrombotic therapy for intracoronary stent implantation: Clinical trials\", section on 'Cangrelor'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Adrenergic receptors",
"    </span>",
"    &nbsp;&mdash;&nbsp;Platelet responses to epinephrine are mediated by G alpha-subclass i-, or G alpha-subclass z-, coupled alpha(2)-adrenergic receptors [",
"    <a class=\"abstract\" href=\"UTD.htm?1/7/1146/abstract/31\">",
"     31",
"    </a>",
"    ]. Although high doses of epinephrine induce platelet activation in vitro, platelets do not aggregate when stimulated with physiologic doses of epinephrine alone. In this respect, epinephrine is unique among platelet agonists. It is thought that stress-induced epinephrine in vivo increases the ability of platelets to respond to low doses of other platelet agonists.",
"   </p>",
"   <p>",
"    Epinephrine is a potent inhibitor of cyclic AMP (cAMP) formation, but this alone is not sufficient to trigger platelet activation. High doses of epinephrine cause phospholipase C activation. However, this can be suppressed by",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    , suggesting that it is dependent upon thromboxane A2 formation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Thromboxane receptor",
"    </span>",
"    &nbsp;&mdash;&nbsp;Thromboxane A2 is produced from arachidonate in platelets by the",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    -sensitive cyclooxygenase pathway (",
"    <a class=\"graphic graphic_figure graphicRef66146 \" href=\"UTD.htm?33/29/34269\">",
"     figure 4",
"    </a>",
"    ). Once formed, thromboxane A2 can diffuse across the plasma membrane and activate other platelets via a G alpha-subclass q-coupled receptor known as the thromboxane receptor (also called thromboxane A2 receptor or prostanoid TP receptor). Thromboxane A2, like ADP, amplifies the initial signal for platelet activation, thereby helping to stimulate additional platelets. This process is effective locally, and is limited by the brief half-life of thromboxane A2. This helps to confine the spread of platelet activation to the original area of injury.",
"   </p>",
"   <p>",
"    A number of stable",
"    <span class=\"nowrap\">",
"     endoperoxide/thromboxane",
"    </span>",
"    analogs have been synthesized, including U46619. When added to platelets in vitro, U46619 causes platelet shape change, aggregation, secretion, phosphoinositide hydrolysis, protein phosphorylation, and an increase in cytosolic Ca",
"    <sup>",
"     ++",
"    </sup>",
"    , while having little effect on cAMP formation [",
"    <a class=\"abstract\" href=\"UTD.htm?1/7/1146/abstract/32\">",
"     32",
"    </a>",
"    ]. Similar responses are seen when platelets are incubated with exogenous arachidonic acid. Since the effects of arachidonate can be inhibited with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    , they are thought to be largely due to thromboxane A2 formation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h3\">",
"     Thromboxane receptor antagonist",
"    </span>",
"    &nbsp;&mdash;&nbsp;Terutroban is an orally active inhibitor of the thromboxane A2 receptor.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h1\">",
"     SECOND MESSENGERS AND BEYOND",
"    </span>",
"    &nbsp;&mdash;&nbsp;After platelet activation by an agonist, intracellular signaling is needed for cytoskeletal reorganization, fibrinogen receptor exposure, and granule secretion. Two pathways that are central to platelet activation are the phosphoinositide hydrolysis pathway and the eicosanoid synthesis pathway.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The phosphoinositide hydrolysis pathway begins when phospholipase C cleaves membrane phosphatidylinositol 4,5-bisphosphate (PIP2) to form inositol 1,4,5-trisphosphate (IP3) and diacylglycerol, both of which serve as second messengers (",
"      <a class=\"graphic graphic_figure graphicRef71705 \" href=\"UTD.htm?36/21/37215\">",
"       figure 5",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      The eicosanoid pathway begins when phospholipase A2 releases arachidonate from membrane phospholipids to form thromboxane A2. As mentioned above, most of the agonists that activate platelets do so via G protein coupled receptors, and it is the activation of G-proteins that is the first step in the intracellular signaling pathway leading to platelet second messenger formation.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Inositol signaling: phospholipase C and PI 3-kinases",
"    </span>",
"    &nbsp;&mdash;&nbsp;One of the earliest responses of platelets to most agonists is the activation of phospholipase C (PLC) (",
"    <a class=\"graphic graphic_figure graphicRef70545 \" href=\"UTD.htm?27/54/28527\">",
"     figure 3",
"    </a>",
"    ). Platelets contain beta and gamma forms of this enzyme. The beta forms are activated by G proteins, while the gamma forms (predominantly PLC gamma2) are regulated by tyrosine phosphorylation [",
"    <a class=\"abstract\" href=\"UTD.htm?1/7/1146/abstract/33,34\">",
"     33,34",
"    </a>",
"    ]. PLC beta is thought to be primarily responsible for the rapid burst of phosphoinositide hydrolysis that occurs during platelet activation by agonists such as thrombin and thromboxane A2.",
"   </p>",
"   <p>",
"    In general, PLC(beta1) and PLC(beta3) respond best to G alpha, particularly members of the G alpha-subclass q family, while PLC(beta2) responds best to G beta-gamma. Based upon studies with pertussis toxin and genetically modified mice, PAR-1 in platelets is thought to be coupled to PLCbeta by G alpha derived from Gq or",
"    <span class=\"nowrap\">",
"     G12/13,",
"    </span>",
"    and perhaps Gbeta-gamma derived from G-subclass i [",
"    <a class=\"abstract\" href=\"UTD.htm?1/7/1146/abstract/8,35\">",
"     8,35",
"    </a>",
"    ]. Thromboxane A2 receptors are coupled to",
"    <span class=\"nowrap\">",
"     PLC(beta1/3)",
"    </span>",
"    by Galpha derived from Gq or",
"    <span class=\"nowrap\">",
"     G12/13",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?1/7/1146/abstract/8\">",
"     8",
"    </a>",
"    ]. Once activated, phospholipase C hydrolyzes PI-4,5-P(2) to DAG plus IP(3) (",
"    <a class=\"graphic graphic_figure graphicRef71705 \" href=\"UTD.htm?36/21/37215\">",
"     figure 5",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?1/7/1146/abstract/36,37\">",
"     36,37",
"    </a>",
"    ]. DAG activates PKC, which in turn phosphorylates pleckstrin (a protein critical for granule secretion) [",
"    <a class=\"abstract\" href=\"UTD.htm?1/7/1146/abstract/38\">",
"     38",
"    </a>",
"    ]. IP(3) binds to receptors in the dense tubular system and releases sequestered Ca",
"    <sup>",
"     ++",
"    </sup>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?1/7/1146/abstract/39,40\">",
"     39,40",
"    </a>",
"    ]. Additional discussion of these events is presented below.",
"   </p>",
"   <p>",
"    Phosphatidylinositol 3-kinases (PI3K) are a group of enzymes that phosphorylate the D-3 position of the inositol ring of phosphatidylinositol to produce phosphatidylinositol 3-phosphate (PI 3-P), phosphatidylinositol 3,4-bisphosphates (PI 3,4-P2), and phosphatidylinositol 3,4,5-triphosphates (PI 3,4,5-P2 or PIP3) (",
"    <a class=\"graphic graphic_figure graphicRef71705 \" href=\"UTD.htm?36/21/37215\">",
"     figure 5",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?1/7/1146/abstract/41\">",
"     41",
"    </a>",
"    ]. Four isoforms of PI3K that phosphorylate PI, PI 4-P and PIP2 have been described in humans, and are classified according to their catalytic subunit: p110alpha, p110beta, p110gamma, and p110delta.",
"   </p>",
"   <p>",
"    Using pharmacologic inhibitors, and platelets obtained from genetically modified mice, investigators have begun to understand the role of different PI3K isoforms in platelets and their downstream effectors [",
"    <a class=\"abstract\" href=\"UTD.htm?1/7/1146/abstract/42\">",
"     42",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Mice lacking the p110gamma catalytic subunit of PI3K have a defect in ADP-mediated platelet aggregation [",
"      <a class=\"abstract\" href=\"UTD.htm?1/7/1146/abstract/43\">",
"       43",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Mice lacking the p85alpha regulatory subunit of PI3K have a defect in signaling events initiated by the platelet collagen receptor, GPVI, whereas there is no defect in platelet activation following stimulation by other platelet agonists such as ADP or thrombin [",
"      <a class=\"abstract\" href=\"UTD.htm?1/7/1146/abstract/44\">",
"       44",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Together, the literature suggests that PI3K is involved in both the initial activation of",
"    <span class=\"nowrap\">",
"     GPIIb/IIIa",
"    </span>",
"    and the subsequent stabilization of the",
"    <span class=\"nowrap\">",
"     GPIIb/IIIa/fibrinogen",
"    </span>",
"    interaction that leads to irreversible platelet aggregation [",
"    <a class=\"abstract\" href=\"UTD.htm?1/7/1146/abstract/45\">",
"     45",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Cytosolic calcium ions",
"    </span>",
"    &nbsp;&mdash;&nbsp;Ca",
"    <sup>",
"     ++",
"    </sup>",
"    ions serve as intracellular second messengers, and like protein kinases, affect enzyme activity and protein- protein interactions. Based upon studies with intracellular probes such as Fura-2, the cytosolic free Ca",
"    <sup>",
"     ++",
"    </sup>",
"    concentration in resting platelets is approximately 0.1 microM. Strong agonists, such as thrombin or collagen cause an increase to &ge;1.0 microM. Weaker agonists, particularly epinephrine, may have little or no effect on cytosolic Ca",
"    <sup>",
"     ++",
"    </sup>",
"    .",
"   </p>",
"   <p>",
"    When platelets are activated, the cytosolic Ca",
"    <sup>",
"     ++",
"    </sup>",
"    concentration increases because of a combination of Ca",
"    <sup>",
"     ++",
"    </sup>",
"    release from the dense tubular system and Ca",
"    <sup>",
"     ++",
"    </sup>",
"    influx across the plasma membrane [",
"    <a class=\"abstract\" href=\"UTD.htm?1/7/1146/abstract/46\">",
"     46",
"    </a>",
"    ]. The trigger for Ca",
"    <sup>",
"     ++",
"    </sup>",
"    release from the dense tubular system is 1,4,5-IP3, and the trigger for the Ca",
"    <sup>",
"     ++",
"    </sup>",
"    influx may be secreted ATP binding to a gated ion-channel, the P(2X) purinergic receptor. The rise in cytosolic Ca",
"    <sup>",
"     ++",
"    </sup>",
"    contributes to platelet activation by stimulating enzymes that are not optimally active at low Ca",
"    <sup>",
"     ++",
"    </sup>",
"    concentrations. Examples of these include cPLA(2), phospholipase C, phosphorylase kinase, gelsolin, calpain, and myosin light chain kinase.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Protein kinase C",
"    </span>",
"    &nbsp;&mdash;&nbsp;Protein kinase C (PKC) isozymes are a family of",
"    <span class=\"nowrap\">",
"     serine/threonine",
"    </span>",
"    kinases that play an essential role in the signal transduction mechanisms after activation of receptors [",
"    <a class=\"abstract\" href=\"UTD.htm?1/7/1146/abstract/47\">",
"     47",
"    </a>",
"    ]. PKC has been identified as the cellular receptor for the lipid second messenger diacylglycerol (DAG), and it is therefore a key enzyme in the signaling events that follow activation of receptors coupled to phospholipase C (PLC). PKC isozymes phosphorylate multiple cellular proteins on serine and threonine residues. Although some discrepancies between different studies on PKC isozyme expression exist, platelets probably express PKC alpha, beta, delta, epsilon, eta, theta, and perhaps zeta and lambda [",
"    <a class=\"abstract\" href=\"UTD.htm?1/7/1146/abstract/48\">",
"     48",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Because of the limitations of platelets as a system for genetic studies, pharmacological tools have been widely used in platelets. Consequently, both activation of PKC with phorbol esters (such as PMA or phorbol 12-myristate 13-acetate), and pharmacologic inhibition with PKC, have been the preferred approaches used to understand the involvement of PKC isozymes in platelet biology. PKC isozymes control a variety of functions, including aggregation, release of granular contents, mobilization of intracellular calcium, and regulation of cell shape. PKC isozymes also play an important role in megakaryocyte differentiation. A prominent PKC substrate is pleckstrin. Mice lacking pleckstrin have a complete loss of PKC-mediated granule secretion [",
"    <a class=\"abstract\" href=\"UTD.htm?1/7/1146/abstract/38\">",
"     38",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     Eicosanoids and arachidonate",
"    </span>",
"    &nbsp;&mdash;&nbsp;The passive release of thromboxane A2 from platelets is another mechanism to amplify platelet activation. Eicosanoids are formed from the arachidonate released from membrane phospholipids by phospholipase A2 during platelet activation [",
"    <a class=\"abstract\" href=\"UTD.htm?1/7/1146/abstract/49\">",
"     49",
"    </a>",
"    ]. Platelet phospholipase A2 is stimulated by the rise in the cytosolic Ca",
"    <sup>",
"     ++",
"    </sup>",
"    that accompanies platelet activation. Once released from membrane phospholipids, arachidonate can be metabolized to thromboxane A2 by cyclooxygenase&ndash;1 (COX-1) [",
"    <a class=\"abstract\" href=\"UTD.htm?1/7/1146/abstract/49\">",
"     49",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Once formed, thromboxane A2 can diffuse across the plasma membrane and activate other platelets through signaling pathways. This leads to platelet shape change, aggregation, secretion, phosphoinositide hydrolysis, protein phosphorylation and an increase in cytosolic Ca",
"    <sup>",
"     ++",
"    </sup>",
"    , while having little effect on cAMP formation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h3\">",
"     Aspirin",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"     Aspirin",
"    </a>",
"    acetylates COX-1, causing it to be irreversibly inactivated (",
"    <a class=\"graphic graphic_figure graphicRef56707 \" href=\"UTD.htm?30/7/30847\">",
"     figure 6",
"    </a>",
"    ). Since platelets lack the ability to synthesize significant amounts of protein, inactivation of COX-1 by aspirin blocks thromboxane A2 synthesis for the life of the platelet (ie, approximately seven days). Platelets that do not synthesize thromboxane A2 normally have impaired stimulation by ADP, epinephrine, arachidonic acid, and low doses of collagen and thrombin, but normal responses to the major platelet agonists, collagen and thrombin. Hence, aspirin is the most commonly used drug for antithrombotic therapy. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/12/37066?source=see_link&amp;anchor=H2#H2\">",
"     \"Benefits and risks of aspirin in secondary and primary prevention of cardiovascular disease\", section on 'Mechanisms of action'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Platelet prostaglandin synthesis in an adult is nearly completely inhibited by a single 100 mg oral dose of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    or by 30 mg taken daily for 7 to 10 days. Aspirin is one of the few drugs that prolongs the bleeding time in humans, and appears to do so by blocking platelet aggregation rather than adhesion. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/59/23482?source=see_link&amp;anchor=H13#H13\">",
"     \"Platelet function testing\", section on 'The in vivo bleeding time'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In normal individuals, the effect of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    on the bleeding time is slight (generally no more than 1.2 to 2.0 times the pre-aspirin bleeding time). The bleeding time may remain prolonged for one to four days after aspirin has been discontinued; platelet aggregation tests may remain abnormal for up to a week, until the affected platelets are replaced by unaffected ones. Nonsteroidal anti-inflammatory agents also inactivate COX-1, but without irreversibly modifying the enzyme [",
"    <a class=\"abstract\" href=\"UTD.htm?1/7/1146/abstract/50\">",
"     50",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/49/17177?source=see_link&amp;anchor=H15#H15\">",
"     \"Nonselective NSAIDs: Overview of adverse effects\", section on 'Antiplatelet effects'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/48/13066?source=see_link&amp;anchor=H7#H7\">",
"     \"Overview of selective COX-2 inhibitors\", section on 'Lack of effect upon platelets'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h2\">",
"     Other protein kinases",
"    </span>",
"    &nbsp;&mdash;&nbsp;In addition to",
"    <span class=\"nowrap\">",
"     serine/threonine",
"    </span>",
"    kinases such as PKC, platelets contain a large number of tyrosine kinases, some of which become active during platelet activation. Human platelets contain tyrosine kinases that are receptors for extracellular ligands, as well as large number of nonreceptor (cytoplasmic) tyrosine kinases, including Src, Fyn, Lyn, Hck, and Syk. Some broadly specific inhibitors of tyrosine kinases, such as genistein or the tyrphostins, can inhibit platelet activation.",
"   </p>",
"   <p>",
"    Inhibitors of phosphotyrosine phosphatases, such as vanadate, promote platelet activation. In general, tyrosine phosphorylation can serve two roles. It can have a regulatory effect on the phosphorylated protein, perhaps by causing a conformational change, or it can provide a binding site for modular domains located in other proteins, such as SH2 domains. Although studies of knockout mice have identified the role of some of these proteins in signaling pathways downstream of the GPVI collagen receptor, the function of most tyrosine kinases in platelets is still incompletely understood [",
"    <a class=\"abstract\" href=\"UTD.htm?1/7/1146/abstract/51\">",
"     51",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h2\">",
"     Cyclic AMP and cyclic GMP",
"    </span>",
"    &nbsp;&mdash;&nbsp;Agents that raise the cyclic AMP (cAMP) concentration in platelets inhibit platelet activation, but the mechanism by which this occurs is unclear. In general, the effects of cAMP are thought to be mediated by cAMP-dependent protein kinase, also known as protein kinase A [",
"    <a class=\"abstract\" href=\"UTD.htm?1/7/1146/abstract/52\">",
"     52",
"    </a>",
"    ]. Platelet substrates for this enzyme include the 24 kDa beta chain of glycoprotein Ib, actin-binding protein and myosin light chain, VASP and Rap1B. Raising cAMP levels causes a number of specific changes in platelet function, including impaired phosphoinositide hydrolysis, a smaller increase in the cytosolic free Ca",
"    <sup>",
"     ++",
"    </sup>",
"    concentration in response to agonists, and an accelerated uptake of Ca",
"    <sup>",
"     ++",
"    </sup>",
"    into the dense tubular system.",
"   </p>",
"   <p>",
"    PGI2 released from activated endothelial cells elevates platelet cAMP levels by stimulating receptors on the platelet surface that are coupled to adenylyl cyclase via G proteins. This results in an inhibition of platelet activation. Consequently mice lacking the PGI2 receptor show an increased risk of thrombosis [",
"    <a class=\"abstract\" href=\"UTD.htm?1/7/1146/abstract/53\">",
"     53",
"    </a>",
"    ]. Most platelet agonists suppress cAMP formation by inhibiting adenylyl cyclase via one or more of the G-subclass i family members that are expressed in platelets.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h3\">",
"     Dipyridamole",
"    </span>",
"    &nbsp;&mdash;&nbsp;The drug",
"    <a class=\"drug drug_general\" href=\"UTD.htm?40/25/41366?source=see_link\">",
"     dipyridamole",
"    </a>",
"    (Persantine) exerts antiplatelet effects by inhibiting cAMP phosphodiesterase, thus raising cAMP levels within platelets [",
"    <a class=\"abstract\" href=\"UTD.htm?1/7/1146/abstract/52\">",
"     52",
"    </a>",
"    ]. However, its efficacy as an antiplatelet agent has been debated. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/9/29850?source=see_link&amp;anchor=H17#H17\">",
"     \"Congenital and acquired disorders of platelet function\", section on 'Dipyridamole'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h3\">",
"     Sildenafil",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/19/33080?source=see_link\">",
"     Sildenafil",
"    </a>",
"    , an agent used for erectile dysfunction in men, is a phosphodiesterase-5 inhibitor, and potentiates the ability of nitric oxide (NO) to inhibit platelet aggregation in vitro by preventing platelet cGMP catabolism [",
"    <a class=\"abstract\" href=\"UTD.htm?1/7/1146/abstract/54-56\">",
"     54-56",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/36/30282?source=see_link&amp;anchor=H3#H3\">",
"     \"Treatment of male sexual dysfunction\", section on 'Pharmacotherapy'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/15/8442?source=see_link&amp;anchor=H18#H18\">",
"     \"Sexual activity in patients with heart disease\", section on 'Sildenafil'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h3\">",
"     Cilostazol",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/38/38502?source=see_link\">",
"     Cilostazol",
"    </a>",
"    , a specific inhibitor of cAMP phosphodiesterase in platelets and vascular smooth-muscle cells, is a potent antiplatelet agent and vasodilator. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/37/41562?source=see_link&amp;anchor=H10#H10\">",
"     \"Antithrombotic therapy for intracoronary stent implantation: Clinical trials\", section on 'Cilostazol'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/21/32090?source=see_link&amp;anchor=H451547835#H451547835\">",
"     \"Medical management of claudication\", section on 'Cilostazol'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28\">",
"    <span class=\"h1\">",
"     PLATELET ACTIVATION",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29\">",
"    <span class=\"h2\">",
"     Shape change",
"    </span>",
"    &nbsp;&mdash;&nbsp;One of the more dramatic events during platelet activation is the metamorphosis that occurs when platelets adhere and spread on exposed collagen fibrils or become activated in the circulation by soluble factors such as thrombin or ADP [",
"    <a class=\"abstract\" href=\"UTD.htm?1/7/1146/abstract/57\">",
"     57",
"    </a>",
"    ]. In either case, platelets lose their distinct discoid shape and acquire an irregular morphology with multiple filopodial projections. This transformation is associated with, and largely due to, cytoskeletal rearrangements within the platelet.",
"   </p>",
"   <p>",
"    Platelet cytoskeletal proteins are arranged in three major structures: a cytoplasmic actin network, a rim of membrane-associated cytoskeleton, and a marginal band consisting of a microtubule coil. Together, these lend support to the platelet plasma membrane and give shape to both resting and activated platelets.",
"   </p>",
"   <p>",
"    The cytoplasmic actin network is composed of actin filaments and associated proteins. Actin is a 42 kDa protein which accounts for as much as 20 percent of total platelet protein [",
"    <a class=\"abstract\" href=\"UTD.htm?1/7/1146/abstract/58\">",
"     58",
"    </a>",
"    ]. In resting platelets, 40 to 50 percent of the actin is present as filamentous F-actin, and the remainder is present as globular monomeric G-actin. The shift to increase the proportion of F-actin to 70 to 80 percent during platelet activation involves a coordinated sequence of events in which the actin filaments present in resting platelets are severed and the resultant smaller fragments used as the nidus for new, longer actin filaments.",
"   </p>",
"   <p>",
"    This process is thought to be regulated in part by the increase in levels of a phosphatidylinositol (PI-4,5-P2) that accompanies platelet activation [",
"    <a class=\"abstract\" href=\"UTD.htm?1/7/1146/abstract/59\">",
"     59",
"    </a>",
"    ]. At the same time, myosin is phosphorylated by myosin light chain kinase and becomes associated with F-actin, forming filaments that are anchored to the platelet plasma membrane by attachment, via actin-binding protein, to the GP",
"    <span class=\"nowrap\">",
"     Ib/IX",
"    </span>",
"    complex.",
"   </p>",
"   <p>",
"    The cytoskeletal rim is composed of actin, filamin, P235 (talin), vinculin, spectrin, alpha-actinin and several membrane glycoproteins. Filamin is an elongated 280 kDa protein that is present in platelets and functions as an actin binding protein. In resting platelets, filamin is part of a semi-rigid array that helps to maintain the platelet's discoid shape and limits the lateral movement of GPIb. This role is analogous to that performed by spectrin in erythrocytes.",
"   </p>",
"   <p>",
"    When platelets are activated, actin filaments form and attach to actin-binding protein. Later, the rising cytosolic Ca",
"    <sup>",
"     ++",
"    </sup>",
"    concentration activates calpain that cleaves actin-binding protein, severing the link to GPIb.",
"   </p>",
"   <p>",
"    The third major structural element in platelets is the marginal band [",
"    <a class=\"abstract\" href=\"UTD.htm?1/7/1146/abstract/60\">",
"     60",
"    </a>",
"    ]. This microtubule coil is a single tightly-wound polymer of tubulin that encircles the platelet perimeter and helps to maintain its discoid shape. During platelet activation, the microtubule coil contracts. Initially it was thought contraction of the marginal band was required for stable adhesion of platelets under arterial shear pressures. However, newer evidence has challenged the nature of this marginal band and its function during both resting and activated platelet states [",
"    <a class=\"abstract\" href=\"UTD.htm?1/7/1146/abstract/60,61\">",
"     60,61",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H30\">",
"    <span class=\"h2\">",
"     GPIIb/IIIa activation",
"    </span>",
"    &nbsp;&mdash;&nbsp;The process of transforming",
"    <span class=\"nowrap\">",
"     GPIIb/IIIa",
"    </span>",
"    (alphaIIb-beta3) on the platelet surface into a competent receptor for fibrinogen was one of the most elusive aspects of platelet signaling. It is the final common pathway in platelet responses to most agonists, making it a frequent target for drug development. Circulating platelets do not normally bind fibrinogen or stick to each other unless they have been activated. The reasons for this are multiple, but are ultimately due to the inability of fibrinogen or fibrin to bind to the resting conformation of",
"    <span class=\"nowrap\">",
"     GPIIb/IIIa.",
"    </span>",
"   </p>",
"   <p>",
"    Platelet",
"    activation alters the conformation, or competency, of",
"    <span class=\"nowrap\">",
"     GPIIb/IIIa,",
"    </span>",
"    allowing fibrinogen binding. The process whereby intracellular events alter",
"    <span class=\"nowrap\">",
"     GPIIb/IIIa",
"    </span>",
"    on the cell surface is referred to as \"inside-out\" signaling (",
"    <a class=\"graphic graphic_figure graphicRef81908 \" href=\"UTD.htm?7/17/7446\">",
"     figure 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?1/7/1146/abstract/3,62\">",
"     3,62",
"    </a>",
"    ]. The process requires the binding of talin and kindling-3 to the cytoplasmic tail of GPIIIa. The binding of these two proteins to the cytoplasmic side of the receptor opens the extracellular side and thereby allows it to bind fibrinogen. Normally, this should occur only at sites of vascular injury. Additionally, a series of intracellular signaling events are initiated and propagated, including tyrosine and",
"    <span class=\"nowrap\">",
"     serine/threonine",
"    </span>",
"    kinase and phosphatase activation, as a consequence of fibrinogen binding and platelet aggregation (so called \"outside-in\" signaling) [",
"    <a class=\"abstract\" href=\"UTD.htm?1/7/1146/abstract/63\">",
"     63",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Working against this tendency to platelet activation are a number of internal and external controls that dampen the intracellular signals that would otherwise allow inappropriate platelet activation, thereby contributing to such complications as myocardial infarction or stroke. These controls include tight regulation of the cytosolic Ca",
"    <sup>",
"     ++",
"    </sup>",
"    concentration, intracellular phosphatases that limit signaling through kinase-dependent pathways, extracellular ADPases that hydrolyze released ADP, and the inhibitory effects of PGI2 and nitric oxide (NO) released from endothelial cells. Collectively, these provide a threshold that helps to prevent platelet activation at inappropriate times and",
"    <span class=\"nowrap\">",
"     places.",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H31\">",
"    <span class=\"h3\">",
"     GPIIb/IIIa inhibitors",
"    </span>",
"    &nbsp;&mdash;&nbsp;GPIIb/IIIa",
"    antibodies and receptor antagonists (eg,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?6/15/6392?source=see_link\">",
"     abciximab",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?13/2/13351?source=see_link\">",
"     tirofiban",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/24/32135?source=see_link\">",
"     eptifibatide",
"    </a>",
"    ) inhibit the final common pathway of platelet aggregation, the crossbridging of platelets secondary to fibrinogen binding to the activated GP",
"    <span class=\"nowrap\">",
"     IIb/IIIa",
"    </span>",
"    receptor (",
"    <a class=\"graphic graphic_figure graphicRef81908 \" href=\"UTD.htm?7/17/7446\">",
"     figure 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    These agents may also prevent initial adhesion of platelets to the vessel wall. Their use in coronary heart disease is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/31/19961?source=see_link&amp;anchor=H2#H2\">",
"     \"Early trials of platelet glycoprotein IIb/IIIa receptor inhibitors in coronary heart disease\", section on 'The platelet GP IIb/IIIa receptor'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/20/39242?source=see_link&amp;anchor=H29#H29\">",
"     \"Antiplatelet agents in acute non-ST elevation acute coronary syndromes\", section on 'GP IIb/IIIa inhibitors'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H32\">",
"    <span class=\"h2\">",
"     Secretion (granule exocytosis)",
"    </span>",
"    &nbsp;&mdash;&nbsp;Another important function of platelets is the release of a variety of substances that stimulate or inhibit platelets or other blood and vascular cells, a process that can be modified in the presence of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?1/7/1146/abstract/64\">",
"     64",
"    </a>",
"    ]. These can covalently modify the thrombus to affect its mechanical properties, as well as regulate coagulation, contribute to cell adhesive events, and modulate the growth of cells of the vessel wall. Platelets contain three types of granules:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Dense granules &mdash; Platelet agonists (eg, ADP, ATP, serotonin) which serve to amplify platelet activation",
"     </li>",
"     <li>",
"      Alpha granules &mdash; Proteins which enhance the adhesive process (eg, fibrinogen, fibronectin, vitronectin, von Willebrand factor)",
"     </li>",
"     <li>",
"      Lysosomal granules &mdash;Glycosidases and proteases which have an unclear function in platelet biology [",
"      <a class=\"abstract\" href=\"UTD.htm?1/7/1146/abstract/65\">",
"       65",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Building upon lessons learned about the role of the SNARE complex (",
"    <strong>",
"     s",
"    </strong>",
"    oluble",
"    <strong>",
"     N",
"    </strong>",
"    -ethylmaleimide-sensitive factor",
"    <strong>",
"     a",
"    </strong>",
"    ttachment protein",
"    <strong>",
"     re",
"    </strong>",
"    ceptors) in neuronal cell exocytosis, there has been a substantial increase in our understanding of platelet secretion. Platelets do have the three basic components of the SNARE machinery: t-SNAREs (target receptors), v-SNAREs (vesicle-associated membrane receptors), and soluble components (including NSF and NSF-attachment proteins) [",
"    <a class=\"abstract\" href=\"UTD.htm?1/7/1146/abstract/65\">",
"     65",
"    </a>",
"    ]. The SNARE machinery regulates the association and subsequent fusion of vesicles with membranes.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16734635\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Platelets are responsible for initiating the hemostatic mechanisms that repair injury to the vascular endothelium. This is accomplished via the following major platelet functions (",
"      <a class=\"graphic graphic_figure graphicRef81908 \" href=\"UTD.htm?7/17/7446\">",
"       figure 1",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Overview of platelet function'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Platelet interactions with collagen and other agonists. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Platelet agonists and their receptors'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Intracellular signalling. (See",
"      <a class=\"local\" href=\"#H17\">",
"       'Second messengers and beyond'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Platelet activation and shape change. (See",
"      <a class=\"local\" href=\"#H28\">",
"       'Platelet activation'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H29\">",
"       'Shape change'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Secretion of granule contents. (See",
"      <a class=\"local\" href=\"#H32\">",
"       'Secretion (granule exocytosis)'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A number of drugs (ie, antiplatelet agents) are used specifically for their ability to interfere with various aspects of platelet function, and have greatest uses in cardiology and vascular medicine. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Drugs with antiplatelet actions'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/7/1146/abstract/1\">",
"      Jackson SP. The growing complexity of platelet aggregation. Blood 2007; 109:5087.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/7/1146/abstract/2\">",
"      Smyth SS, McEver RP, Weyrich AS, et al. Platelet functions beyond hemostasis. J Thromb Haemost 2009; 7:1759.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/7/1146/abstract/3\">",
"      Shattil SJ, Newman PJ. Integrins: dynamic scaffolds for adhesion and signaling in platelets. Blood 2004; 104:1606.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/7/1146/abstract/4\">",
"      Coller BS, Shattil SJ. The GPIIb/IIIa (integrin alphaIIbbeta3) odyssey: a technology-driven saga of a receptor with twists, turns, and even a bend. Blood 2008; 112:3011.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/7/1146/abstract/5\">",
"      Bennett JS, Vilaire G. Exposure of platelet fibrinogen receptors by ADP and epinephrine. J Clin Invest 1979; 64:1393.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/7/1146/abstract/6\">",
"      Wagner CL, Mascelli MA, Neblock DS, et al. Analysis of GPIIb/IIIa receptor number by quantification of 7E3 binding to human platelets. Blood 1996; 88:907.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/7/1146/abstract/7\">",
"      Offermanns S. The role of heterotrimeric G proteins in platelet activation. Biol Chem 2000; 381:389.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/7/1146/abstract/8\">",
"      Offermanns S, Toombs CF, Hu YH, Simon MI. Defective platelet activation in G alpha(q)-deficient mice. Nature 1997; 389:183.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/7/1146/abstract/9\">",
"      Yang J, Wu J, Jiang H, et al. Signaling through Gi family members in platelets. Redundancy and specificity in the regulation of adenylyl cyclase and other effectors. J Biol Chem 2002; 277:46035.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/7/1146/abstract/10\">",
"      Moers A, Nieswandt B, Massberg S, et al. G13 is an essential mediator of platelet activation in hemostasis and thrombosis. Nat Med 2003; 9:1418.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/7/1146/abstract/11\">",
"      Vu TK, Hung DT, Wheaton VI, Coughlin SR. Molecular cloning of a functional thrombin receptor reveals a novel proteolytic mechanism of receptor activation. Cell 1991; 64:1057.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/7/1146/abstract/12\">",
"      Brass LF, Vassallo RR Jr, Belmonte E, et al. Structure and function of the human platelet thrombin receptor. Studies using monoclonal antibodies directed against a defined domain within the receptor N terminus. J Biol Chem 1992; 267:13795.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/7/1146/abstract/13\">",
"      Derian CK, Damiano BP, Addo MF, et al. Blockade of the thrombin receptor protease-activated receptor-1 with a small-molecule antagonist prevents thrombus formation and vascular occlusion in nonhuman primates. J Pharmacol Exp Ther 2003; 304:855.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/7/1146/abstract/14\">",
"      Clemetson KJ, Clemetson JM. Platelet collagen receptors. Thromb Haemost 2001; 86:189.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/7/1146/abstract/15\">",
"      Holtk&ouml;tter O, Nieswandt B, Smyth N, et al. Integrin alpha 2-deficient mice develop normally, are fertile, but display partially defective platelet interaction with collagen. J Biol Chem 2002; 277:10789.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/7/1146/abstract/16\">",
"      Nieuwenhuis HK, Akkerman JW, Houdijk WP, Sixma JJ. Human blood platelets showing no response to collagen fail to express surface glycoprotein Ia. Nature 1985; 318:470.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/7/1146/abstract/17\">",
"      Moroi M, Jung SM, Okuma M, Shinmyozu K. A patient with platelets deficient in glycoprotein VI that lack both collagen-induced aggregation and adhesion. J Clin Invest 1989; 84:1440.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/7/1146/abstract/18\">",
"      Poole A, Gibbins JM, Turner M, et al. The Fc receptor gamma-chain and the tyrosine kinase Syk are essential for activation of mouse platelets by collagen. EMBO J 1997; 16:2333.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/7/1146/abstract/19\">",
"      Boylan B, Chen H, Rathore V, et al. Anti-GPVI-associated ITP: an acquired platelet disorder caused by autoantibody-mediated clearance of the GPVI/FcRgamma-chain complex from the human platelet surface. Blood 2004; 104:1350.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/7/1146/abstract/20\">",
"      Arthur JF, Dunkley S, Andrews RK. Platelet glycoprotein VI-related clinical defects. Br J Haematol 2007; 139:363.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/7/1146/abstract/21\">",
"      Kunapuli SP, Dorsam RT, Kim S, Quinton TM. Platelet purinergic receptors. Curr Opin Pharmacol 2003; 3:175.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/7/1146/abstract/22\">",
"      Cattaneo M. New P2Y(12) inhibitors. Circulation 2010; 121:171.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/7/1146/abstract/23\">",
"      Cunningham MR, Nisar SP, Mundell SJ. Molecular mechanisms of platelet P2Y(12) receptor regulation. Biochem Soc Trans 2013; 41:225.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/7/1146/abstract/24\">",
"      Cattaneo M. The platelet P2Y receptor for adenosine diphosphate: congenital and drug-induced defects. Blood 2011; 117:2102.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/7/1146/abstract/25\">",
"      Hollopeter G, Jantzen HM, Vincent D, et al. Identification of the platelet ADP receptor targeted by antithrombotic drugs. Nature 2001; 409:202.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/7/1146/abstract/26\">",
"      Ziegler S, Schillinger M, Funk M, et al. Association of a functional polymorphism in the clopidogrel target receptor gene, P2Y12, and the risk for ischemic cerebrovascular events in patients with peripheral artery disease. Stroke 2005; 36:1394.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/7/1146/abstract/27\">",
"      Brandt JT, Close SL, Iturria SJ, et al. Common polymorphisms of CYP2C19 and CYP2C9 affect the pharmacokinetic and pharmacodynamic response to clopidogrel but not prasugrel. J Thromb Haemost 2007; 5:2429.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/7/1146/abstract/28\">",
"      Mega JL, Close SL, Wiviott SD, et al. Cytochrome P450 genetic polymorphisms and the response to prasugrel: relationship to pharmacokinetic, pharmacodynamic, and clinical outcomes. Circulation 2009; 119:2553.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/7/1146/abstract/29\">",
"      Angiolillo DJ, Bates ER, Bass TA. Clinical profile of prasugrel, a novel thienopyridine. Am Heart J 2008; 156:S16.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/7/1146/abstract/30\">",
"      Angiolillo DJ, Capranzano P. Pharmacology of emerging novel platelet inhibitors. Am Heart J 2008; 156:S10.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/7/1146/abstract/31\">",
"      Yang J, Wu J, Kowalska MA, et al. Loss of signaling through the G protein, Gz, results in abnormal platelet activation and altered responses to psychoactive drugs. Proc Natl Acad Sci U S A 2000; 97:9984.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/7/1146/abstract/32\">",
"      Siess W, Siegel FL, Lapetina EG. Arachidonic acid stimulates the formation of 1,2-diacylglycerol and phosphatidic acid in human platelets. Degree of phospholipase C activation correlates with protein phosphorylation, platelet shape change, serotonin release, and aggregation. J Biol Chem 1983; 258:11236.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/7/1146/abstract/33\">",
"      Cockcroft S, Thomas GM. Inositol-lipid-specific phospholipase C isoenzymes and their differential regulation by receptors. Biochem J 1992; 288 ( Pt 1):1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/7/1146/abstract/34\">",
"      Berridge MJ. Inositol trisphosphate and calcium signalling. Nature 1993; 361:315.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/7/1146/abstract/35\">",
"      Brass LF, Manning DR, Williams AG, et al. Receptor and G protein-mediated responses to thrombin in HEL cells. J Biol Chem 1991; 266:958.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/7/1146/abstract/36\">",
"      Lapetina EG, Billah MM, Cuatrecasas P. Lysophosphatidic acid potentiates the thrombin-induced production of arachidonate metabolites in platelets. J Biol Chem 1981; 256:11984.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/7/1146/abstract/37\">",
"      Rittenhouse SE, Sasson JP. Mass changes in myoinositol trisphosphate in human platelets stimulated by thrombin. Inhibitory effects of phorbol ester. J Biol Chem 1985; 260:8657.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/7/1146/abstract/38\">",
"      Lian L, Wang Y, Flick M, et al. Loss of pleckstrin defines a novel pathway for PKC-mediated exocytosis. Blood 2009; 113:3577.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/7/1146/abstract/39\">",
"      Kaibuchi K, Takai Y, Sawamura M, et al. Synergistic functions of protein phosphorylation and calcium mobilization in platelet activation. J Biol Chem 1983; 258:6701.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/7/1146/abstract/40\">",
"      Brass LF, Joseph SK. A role for inositol triphosphate in intracellular Ca2+ mobilization and granule secretion in platelets. J Biol Chem 1985; 260:15172.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/7/1146/abstract/41\">",
"      Cantley LC. The phosphoinositide 3-kinase pathway. Science 2002; 296:1655.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/7/1146/abstract/42\">",
"      Chen J, De S, Damron DS, et al. Impaired platelet responses to thrombin and collagen in AKT-1-deficient mice. Blood 2004; 104:1703.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/7/1146/abstract/43\">",
"      Hirsch E, Bosco O, Tropel P, et al. Resistance to thromboembolism in PI3Kgamma-deficient mice. FASEB J 2001; 15:2019.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/7/1146/abstract/44\">",
"      Watanabe N, Nakajima H, Suzuki H, et al. Functional phenotype of phosphoinositide 3-kinase p85alpha-null platelets characterized by an impaired response to GP VI stimulation. Blood 2003; 102:541.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/7/1146/abstract/45\">",
"      Lian L, Wang Y, Draznin J, et al. The relative role of PLCbeta and PI3Kgamma in platelet activation. Blood 2005; 106:110.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/7/1146/abstract/46\">",
"      Varga-Szabo D, Braun A, Nieswandt B. Calcium signaling in platelets. J Thromb Haemost 2009; 7:1057.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/7/1146/abstract/47\">",
"      Harper MT, Poole AW. Diverse functions of protein kinase C isoforms in platelet activation and thrombus formation. J Thromb Haemost 2010; 8:454.",
"     </a>",
"    </li>",
"    <li>",
"     Abrams CS, Kazanietz MG. Cambridge University Press. In: Platelets in Thrombotic and Non-Thrombotic Disorders, Gresele P, Page C, Fuster V, Vermylen J (Eds), Cambridge, UK 2002. p.272.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/7/1146/abstract/49\">",
"      Vane JR. Biomedicine. Back to an aspirin a day? Science 2002; 296:474.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/7/1146/abstract/50\">",
"      Stanford N, Roth GJ, Shen TY, Majerus PW. Lack of covalent modification of prostaglandin synthetase (cyclo-oxygenase) by indomethacin. Prostaglandins 1977; 13:669.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/7/1146/abstract/51\">",
"      Nieswandt B, Watson SP. Platelet-collagen interaction: is GPVI the central receptor? Blood 2003; 102:449.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/7/1146/abstract/52\">",
"      Schwarz UR, Walter U, Eigenthaler M. Taming platelets with cyclic nucleotides. Biochem Pharmacol 2001; 62:1153.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/7/1146/abstract/53\">",
"      Murata T, Ushikubi F, Matsuoka T, et al. Altered pain perception and inflammatory response in mice lacking prostacyclin receptor. Nature 1997; 388:678.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/7/1146/abstract/54\">",
"      Li Z, Xi X, Gu M, et al. A stimulatory role for cGMP-dependent protein kinase in platelet activation. Cell 2003; 112:77.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/7/1146/abstract/55\">",
"      Lewis GD, Witzke C, Colon-Hernandez P, et al. Sildenafil improves coronary artery patency in a canine model of platelet-mediated cyclic coronary occlusion after thrombolysis. J Am Coll Cardiol 2006; 47:1471.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/7/1146/abstract/56\">",
"      Schmidt U, Han RO, DiSalvo TG, et al. Cessation of platelet-mediated cyclic canine coronary occlusion after thrombolysis by combining nitric oxide inhalation with phosphodiesterase-5 inhibition. J Am Coll Cardiol 2001; 37:1981.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/7/1146/abstract/57\">",
"      Ma AD, Abrams CS. Pleckstrin homology domains and phospholipid-induced cytoskeletal reorganization. Thromb Haemost 1999; 82:399.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/7/1146/abstract/58\">",
"      Nachmias VT, Yoshida K. The cytoskeleton of the blood platelet; a dynamic structure. Adv Cell Biol 1988; 2:181.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/7/1146/abstract/59\">",
"      Hartwig JH, Bokoch GM, Carpenter CL, et al. Thrombin receptor ligation and activated Rac uncap actin filament barbed ends through phosphoinositide synthesis in permeabilized human platelets. Cell 1995; 82:643.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/7/1146/abstract/60\">",
"      Italiano JE Jr, Bergmeier W, Tiwari S, et al. Mechanisms and implications of platelet discoid shape. Blood 2003; 101:4789.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/7/1146/abstract/61\">",
"      Patel-Hett S, Richardson JL, Schulze H, et al. Visualization of microtubule growth in living platelets reveals a dynamic marginal band with multiple microtubules. Blood 2008; 111:4605.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/7/1146/abstract/62\">",
"      Li R, Mitra N, Gratkowski H, et al. Activation of integrin alphaIIbbeta3 by modulation of transmembrane helix associations. Science 2003; 300:795.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/7/1146/abstract/63\">",
"      Shattil SJ, Ginsberg MH, Brugge JS. Adhesive signaling in platelets. Curr Opin Cell Biol 1994; 6:695.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/7/1146/abstract/64\">",
"      Coppinger JA, O'Connor R, Wynne K, et al. Moderation of the platelet releasate response by aspirin. Blood 2007; 109:4786.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/7/1146/abstract/65\">",
"      Reed GL, Fitzgerald ML, Polg&aacute;r J. Molecular mechanisms of platelet exocytosis: insights into the \"secrete\" life of thrombocytes. Blood 2000; 96:3334.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 6683 Version 15.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1104-202.43.93.2-04D01F2D42-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f1_7_1146=[""].join("\n");
var outline_f1_7_1146=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H16734635\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14905808\">",
"      NORMAL VALUES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      OVERVIEW OF PLATELET FUNCTION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Drugs with antiplatelet actions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      PLATELET AGONISTS AND THEIR RECEPTORS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      PAR1 (thrombin receptor)",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      - PAR-1 antagonists",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      GP1a/IIa and GPVI (collagen receptors)",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      - Glycoprotein Ia/IIa",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      - Glycoprotein VI",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      P2Y1 and P2Y12 (ADP receptors)",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12878572\">",
"      - Abnormalities of the platelet P2Y12 receptor",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      - Clopidogrel and ticlopidine",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      - Prasugrel",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H2477744\">",
"      - Ticagrelor",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      - Other P2Y12 inhibitors",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H1417150\">",
"      Cangrelor",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Adrenergic receptors",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Thromboxane receptor",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      - Thromboxane receptor antagonist",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      SECOND MESSENGERS AND BEYOND",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Inositol signaling: phospholipase C and PI 3-kinases",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Cytosolic calcium ions",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Protein kinase C",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      Eicosanoids and arachidonate",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      - Aspirin",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      Other protein kinases",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      Cyclic AMP and cyclic GMP",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      - Dipyridamole",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      - Sildenafil",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      - Cilostazol",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H28\">",
"      PLATELET ACTIVATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H29\">",
"      Shape change",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H30\">",
"      GPIIb/IIIa activation",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H31\">",
"      - GPIIb/IIIa inhibitors",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H32\">",
"      Secretion (granule exocytosis)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H16734635\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"HEME/6683\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"HEME/6683|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?7/17/7446\" title=\"figure 1\">",
"      Platelet interactions",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?22/40/23170\" title=\"figure 2\">",
"      Pathways of platelet activation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?27/54/28527\" title=\"figure 3\">",
"      Platelet G proteins",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?33/29/34269\" title=\"figure 4\">",
"      Prostaglandin synthesis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?36/21/37215\" title=\"figure 5\">",
"      Plat 2nd messenger production",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?30/7/30847\" title=\"figure 6\">",
"      PG functions and inhibition",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/49/35610?source=related_link\">",
"      Antiplatelet agents in acute ST elevation myocardial infarction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/20/39242?source=related_link\">",
"      Antiplatelet agents in acute non-ST elevation acute coronary syndromes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/37/41562?source=related_link\">",
"      Antithrombotic therapy for intracoronary stent implantation: Clinical trials",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/19/15674?source=related_link\">",
"      Approach to the adult patient with thrombocytopenia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/6/24681?source=related_link\">",
"      Approach to the patient with thrombocytosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/12/37066?source=related_link\">",
"      Benefits and risks of aspirin in secondary and primary prevention of cardiovascular disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/61/36826?source=related_link\">",
"      Causes of thrombotic thrombocytopenic purpura-hemolytic uremic syndrome in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/9/29850?source=related_link\">",
"      Congenital and acquired disorders of platelet function",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?8/1/8218?source=related_link\">",
"      Disorders of fibrinogen",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/40/1673?source=related_link\">",
"      Drug-induced thrombocytopenia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/31/19961?source=related_link\">",
"      Early trials of platelet glycoprotein IIb/IIIa receptor inhibitors in coronary heart disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/32/3594?source=related_link\">",
"      Effect of cardiac drugs on platelet function",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/59/40890?source=related_link\">",
"      Heparin-induced thrombocytopenia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/21/32090?source=related_link\">",
"      Medical management of claudication",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/22/4458?source=related_link\">",
"      Megakaryocyte biology and the production of platelets",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/34/37418?source=related_link\">",
"      Nonresponse and resistance to clopidogrel",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/49/17177?source=related_link\">",
"      Nonselective NSAIDs: Overview of adverse effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/35/27194?source=related_link\">",
"      Overview of hemostasis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/48/13066?source=related_link\">",
"      Overview of selective COX-2 inhibitors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/59/23482?source=related_link\">",
"      Platelet function testing",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/60/40906?source=related_link\">",
"      Secondary prevention of cardiovascular disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?8/15/8442?source=related_link\">",
"      Sexual activity in patients with heart disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/36/30282?source=related_link\">",
"      Treatment of male sexual dysfunction",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f1_7_1147="Clinical conditions UIP";
var content_f1_7_1147=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F57228&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F57228&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Clinical conditions associated with usual interstitial pneumonia pattern",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tr>",
"      <td>",
"       Idiopathic pulmonary fibrosis/cryptogenic fibrosing alveolitis",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Collagen vascular disease",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Drug toxicity",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Chronic hypersensitivity pneumonitis",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Asbestosis",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Familial idiopathic pulmonary fibrosis",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Hermansky-Pudlak syndrome",
"      </td>",
"     </tr>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f1_7_1147=[""].join("\n");
var outline_f1_7_1147=null;
var title_f1_7_1148="SCN versus SN";
var content_f1_7_1148=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F70556&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=8\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F70556&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=8\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Subcutaneous fat necrosis of the newborn versus sclerema neonatorum",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Clinical features",
"       </td>",
"       <td class=\"subtitle1\">",
"        Subcutaneous fat necrosis of the newborn",
"       </td>",
"       <td class=\"subtitle1\">",
"        Sclerema neonatorum",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Onset",
"       </td>",
"       <td>",
"        0 to 4 weeks of age",
"       </td>",
"       <td>",
"        0 to 7 days of age",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Gestational age",
"       </td>",
"       <td>",
"        Usually term",
"       </td>",
"       <td>",
"        Usually preterm",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Associated conditions",
"       </td>",
"       <td>",
"        Birth trauma, including asphyxia, mechanical trauma, thermal trauma",
"       </td>",
"       <td>",
"        Serious underlying disease, including congenital malformations, sepsis, respiratory and gastrointestinal disease",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Site and spread",
"       </td>",
"       <td>",
"        Bony prominences; remains localized",
"       </td>",
"       <td>",
"        Begins on trunk or lower limb and may become generalized; spares palms and soles",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Morphology",
"       </td>",
"       <td>",
"        Circumscribed subcutaneous nodules",
"       </td>",
"       <td>",
"        Hard, wax-like skin and subcutaneous tissue; does not pit",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Mobility",
"       </td>",
"       <td>",
"        Move freely over muscles and bone",
"       </td>",
"       <td>",
"        Bound to underlying muscle and bone",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Histopathology",
"       </td>",
"       <td>",
"        Fat necrosis; extensive granulomatous inflammatory infiltrate; needle-shaped clefts within adipocytes",
"       </td>",
"       <td>",
"        Thickened fibrous septae; sparse non-granulomatous inflammatory infiltrate; needle-shaped clefts within adipocytes",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Adapted from: Zeb, A, Darmstadt, GL. Sclerema neonatorum: a review of nomenclature, clinical presentation, histological features, differential diagnoses and management. J Perinatol 2008; 28:453.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f1_7_1148=[""].join("\n");
var outline_f1_7_1148=null;
var title_f1_7_1149="Anticoagulant herbs";
var content_f1_7_1149=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PC%2F76808&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PC%2F76808&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Anticoagulant herbal ingredients",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Drug",
"       </td>",
"       <td class=\"subtitle1\">",
"        Effect",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"2\">",
"        Anticoagulants",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Alfalfa",
"       </td>",
"       <td>",
"        Coumarin constituents",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Angelica",
"       </td>",
"       <td>",
"        Coumarin constituents",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Aniseed",
"       </td>",
"       <td>",
"        Coumarin constituents",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Arnica",
"       </td>",
"       <td>",
"        Coumarin constituents",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Asafoetida",
"       </td>",
"       <td>",
"        Coumarin constituents, anticoagulant in vivo",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Celery",
"       </td>",
"       <td>",
"        Coumarin constituents",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Chamomile, German",
"       </td>",
"       <td>",
"        Coumarin constituents",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Chamomile, Roman",
"       </td>",
"       <td>",
"        Coumarin constituents",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Clove",
"       </td>",
"       <td>",
"        Eugenol powerful inhibitor of platelet activity",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Fenugreek",
"       </td>",
"       <td>",
"        Coumarin constituents",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Feverfew",
"       </td>",
"       <td>",
"        Inhibits platelet aggregation",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Fucus",
"       </td>",
"       <td>",
"        Anticoagulant action",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Garlic",
"       </td>",
"       <td>",
"        Interaction with warfarin reported",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Ginger",
"       </td>",
"       <td>",
"        Inhibition of platelet activity",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Ginkgo",
"       </td>",
"       <td>",
"        Inhibition of platelet activity",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Ginseng, Panax",
"       </td>",
"       <td>",
"        Reduction of blood coagulation",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Horse-chestnut",
"       </td>",
"       <td>",
"        Coumarin constituents",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Horseradish",
"       </td>",
"       <td>",
"        Peroxidase stimulates synthesis of arachidonic acid metabolites",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Liquorice",
"       </td>",
"       <td>",
"        Inhibition of platelet activity",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Meadowsweet",
"       </td>",
"       <td>",
"        Salicylate constituents",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Poplar",
"       </td>",
"       <td>",
"        Salicylate constituents",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Prickly ash, northern",
"       </td>",
"       <td>",
"        Coumarin constituents",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Prickly ash, southern",
"       </td>",
"       <td>",
"        Coumarin constituents",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Quassia",
"       </td>",
"       <td>",
"        Coumarin constituents",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Red clover",
"       </td>",
"       <td>",
"        Coumarin constituents",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Willow",
"       </td>",
"       <td>",
"        Salicylate constituents",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Adapted with permission from Newall, CA, Anderson, LA, Phillipson, JD. Herbal Medicines: A Guide for Health-Care Professionals, The Pharmaceutical Press, London 1996, p.282.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f1_7_1149=[""].join("\n");
var outline_f1_7_1149=null;
var title_f1_7_1150="Pathog acute infect diarrhea";
var content_f1_7_1150=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F78393&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F78393&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    The pathogenesis of acute infectious diarrhea",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 395px; height: 367px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f1_7_1150=[""].join("\n");
var outline_f1_7_1150=null;
var title_f1_7_1151="Tracheobronchial lymph nodes CT";
var content_f1_7_1151=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F59386&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F59386&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    N3 lymph nodes in lung cancer",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 292px; height: 238px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    CT scan shows slightly enlarged lymph nodes located anterior to the tracheal bifurcation (arrow).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Paul Stark, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f1_7_1151=[""].join("\n");
var outline_f1_7_1151=null;
